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Abstract in English
Verbal suggestions are strong modulators of one’s expectations and they can
be used to induce placebo and nocebo responses. Research so far has investigated
the magnitude (i.e. stronger or weaker) and the direction (i.e. increase or decrease
of pain) of verbal suggestions, while no attention has been given to the dimension
of time. Relying on three main experiments, which investigated the influence of
temporal verbal suggestions in modulating the onset of action of placebo analgesia
and nocebo hyperalgesia, this thesis seeks to address this shortcoming.
In Study 1, pain was induced experimentally on healthy participants via short-
lasting, medium-to-low intensity electrical stimuli. After each noxious stimulus
participants rated their pain from 0 (no pain) to 10 (unbearable pain). Partic-
ipants were assigned to one of three placebo groups, three nocebo groups, a no
expectancy (NE) group, or a natural history (NH) group. An inert cream was ad-
ministered to all participants, except from those in the NH group, while different
verbal suggestions were given according to group allocation. Participants in the
placebo groups were told that the cream had analgesic properties setting in after
5 (Placebo Group 5, P5), 15 (Placebo Group 15, P15) and 30 (Placebo Group 30,
P30) minutes from cream application. Participants in the nocebo groups were
told that the cream had hyperalgesic properties setting in after 5 (Nocebo Group
5, N5), 15 (Nocebo Group 15, N15) and 30 (Nocebo Group 30, N30) minutes from
cream application. Participants in the NE group were told that the cream only
had hydrating properties and that would not influence pain perception, while
those in the NH group did not receive the cream and served to control for pain
natural fluctuations over time. Participants repeated the pain test at baseline,
after 10, 20 and 35 minutes after the cream application. Mixed-method analysis
of variance showed a significant interaction between group and time, indicating
that pain ratings varied between time-points and between groups. As expected,
post hoc comparisons revealed that placebo and nocebo groups began to show a
significant change in pain ratings than the NE group at the expected time point
but not earlier. Interestingly, once triggered, the analgesic effect remained stable
over time, while the hyperalgesic effect increased over time.
In Study 2 and 3, the influence of temporal suggestions on placebo analge-
sia (Study 2) and nocebo hyperalgesia (Study 3) onset was investigated using
a long lasting, high-intensity, tonic pain model, induced with the Cold Pressor
Test (CPT). Heart Rate (HR) was measured to assess whether it correlated with
placebo analgesia and nocebo hyperalgesia. In Study 2, participants were as-
signed to one of two placebo groups, or to the No Expectations (NE) group.
In Study 3, participants were allocated to one of two nocebo groups, while the
control group (NE) was taken from the previous study (Study 2). In this case
participants also received an inert cream and those in the placebo groups were
told that the cream had analgesic properties that would set in after 5 (placebo 5,
P5) and 30 (placebo 30, P30) minutes from its application. Participants in the
nocebo groups were told that the cream had hyperalgesic properties setting in
after 5 (nocebo 5, P5) and 30 (nocebo 30, N30) minutes from application, while
those in the NE group were told that the cream only had hydrating properties.
All the participants repeated the CPT at baseline and after 10 and 35 minutes
from cream application. Percentage change in exposure time (pain tolerance)
from baseline to Test 10 (∆10) and to test 35 (∆35) and changes in HR during
CPT were compared between the three groups. In both studies, data were non-
parametric and non-parametric statistics were used accordingly. In Study 2, ∆10
was greater in P5 than in NE and P30, indicating analgesia only in the group
expecting cream early onset effect. ∆35 was greater in P5 and P30 compared
to NE, showing a delayed onset of analgesia in P30 and maintained analgesia in
P5. The same results, but in the opposite direction, were reported in Study 3,
where hyperalgesia onset followed the temporal verbal suggestions that partici-
pants received. HR differences between groups were not significant in Study 2
nor 3.
In conclusion, the experiments demonstrated that both placebo analgesia and
nocebo hyperalgesia follow the temporal information provided. In addition, it
was shown that once triggered, both placebo analgesia and nocebo hyperalgesia
endure over time (at least for the duration of the experimental session). These
data apply to experimentally induced pain both of a phasic nature with medium-
low intensity and of a tonic nature, reaching high intensities. The important
role of verbal suggestions in modulating the onset of action of a given (inert-)
intervention could not only aid the clinical use of placebo treatment (e.g., in
open-label placebo), but also support the efficacy of active drugs. Indeed, further
research is needed to extend these results from healthy participants to patients
and from placebos to active interventions.
Abstract in Italian
I suggerimenti verbali sono forti modulatori delle aspettative e possono essere
utilizzati per indurre risposte placebo e nocebo. Finora sono state indagate le
dimensioni della grandezza (es. suggerimenti più o meno forti) e della direzione
(es. aumento o diminuzione del sintomo clinico) delle suggestioni verbali, mentre
ancora non ha ricevuto attenzione la dimensione del tempo. Il dottorato è stato
quindi mirato ad indagare l’influenza delle suggestioni verbali, caratterizzate tem-
poralmente, nel modulare l’insorgenza dell’analgesia da placebo e dell’iperalgesia
da nocebo. A questo fine sono stati condotti tre esperimenti.
Nello Studio 1, il dolore è stato indotto sperimentalmente su partecipanti sani
tramite stimoli elettrici di breve durata e di intensità medio-bassa. Dopo ogni sti-
molo nocicettivo i partecipanti hanno valutato il loro dolore da 0 (nessun dolore)
a 10 (dolore insopportabile). I partecipanti sono stati distribuiti in 8 gruppi: tre
gruppi placebo, tre gruppi nocebo, un gruppo no aspettativa (NE) o un gruppo
di storia naturale (NH). Una crema inerte è stata somministrata a tutti i parteci-
panti, ad eccezione di quelli del gruppo NH che aveva il solo scopo di controllare le
fluttuazioni naturali del dolore nel tempo. A seconda del gruppo di appartenenza
sono state date specifiche informazioni verbali . A coloro che sono stati assegnati
ai gruppi placebo è stato detto che la crema aveva una azione analgesica che si
sarebbe manifestata dopo 5 (Gruppo Placebo 5, P5), 15 (Gruppo Placebo 15,
P15) e 30 (Gruppo Placebo 30, P30) minuti dall’applicazione. Ai partecipanti
dei gruppi nocebo è stato detto che la crema aveva una azione iperalgesizzante
che si sarebbe manifestata dopo 5 (Nocebo Gruppo 5, N5), 15 (Nocebo Gruppo
15, N15) e 30 (Nocebo Gruppo 30, N30) minuti. A coloro che sono stati assegnati
al gruppo NE è stato detto che la crema aveva solo proprietà idratanti e che non
avrebbe influenzato la percezione del dolore. Tutti i partecipanti hanno ripetuto
il test del dolore prima dell’applicazione della crema (test basale) e dopo 10, 20 e
35 minuti. L’analisi della varianza con metodo misto ha mostrato un’interazione
significativa tra gruppo e tempo, indicando che le valutazioni del dolore variavano
tra i test in diversi punti temporali e tra i gruppi. Come ipotizzato, i confronti
post hoc hanno rivelato che i gruppi placebo e nocebo hanno iniziato a mostrare
un cambiamento significativo nelle valutazioni del dolore rispetto al gruppo NE
al momento coincidente con l’aspettativa temporale di ciascun gruppo ma non
prima. È interessante notare che, una volta attivato l’effetto iperalgesico è pro-
gressivamente aumentato, mentre l’effetto analgesico è rimasto stabile nel tempo.
Nello Studio 2 e 3, è stata studiata l’influenza delle suggestioni temporali
sull’insorgenza dell’analgesia da placebo (Studio 2) e dell’iperalgesia da nocebo
(Studio 3) utilizzando un modello di dolore tonico di lunga durata, ad alta in-
tensità, indotto con il Cold Pressor Test (CPT). La frequenza cardiaca (FC) è
stata misurata per valutare se fosse correlata con le risposte placebo e nocebo.
Nello Studio 2, i partecipanti sono stati assegnati a uno di due gruppi placebo o
al gruppo No Aspettativa (NA). Nello Studio 3, i partecipanti sono stati asseg-
nati a uno di due gruppi nocebo, mentre per il gruppo di controllo (NE) è stato
utilizzato quello dello studio precedente (Studio 2). Anche in questo caso, i parte-
cipanti hanno ricevuto una crema inerte. Ai partecipanti dei gruppi placebo è
stato detto che la crema aveva proprietà analgesiche che si sarebbero manifestate
dopo 5 (placebo 5, P5) e 30 (placebo 30, P30) minuti dalla sua applicazione. Ai
partecipanti dei gruppi nocebo è stato detto che la crema aveva proprietà iperal-
gesiche che si sarebbero instaurate dopo 5 (nocebo 5, P5) e 30 (nocebo 30, N30)
minuti dall’applicazione, mentre ai partecipanti del gruppo NE è stato detto che
la crema aveva solo proprietà idratanti . Tutti i partecipanti hanno ripetuto il
CPT prima dell’applicazione della crema (test basale) e dopo 10 e 35 minuti.
La variazione percentuale del tempo di esposizione (tolleranza al dolore) dal test
basale al test 10 (∆10) e al test 35 (∆35) e le variazioni della FC durante il
CPT sono stati confrontati tra i tre gruppi. In entrambi gli studi, i dati sono
risultati non parametrici e di conseguenza sono state adottate analisi statistiche
non parametriche. Nello studio 2, il ∆10 era maggiore in P5 rispetto a NE e
P30, indicando analgesia solo nel gruppo che si aspettava un effetto di insorgenza
precoce della crema. ∆35 era maggiore in P5 e P30 rispetto a NE, mostrando
un’insorgenza ritardata dell’analgesia in P30 e un’analgesia mantenuta in P5. Gli
stessi risultati, ma nella direzione opposta, sono stati conseguiti nello Studio 3, in
cui l’insorgenza dell’iperalgesia appariva essere in linea con i suggerimenti tem-
porali riferiti ai partecipanti. Non sono state riportate differenze significative in
termini di FC, né nello Studio 2 né nello Studio 3.
In conclusione, è stato dimostrato che sia l’analgesia da placebo che l’iperalgesia
da nocebo seguono le informazioni temporali fornite. È inoltre stato dimostrato
che una volta innescate, sia l’analgesia da placebo che l’iperalgesia da nocebo
persistono nel tempo (almeno per la durata della sessione sperimentale). Questo
fenomeno sembra essere presente sia nel dolore indotto sperimentalmente di natura
fasica con intensità medio-bassa che in quello tonico, con intensità elevata. L’importante
ruolo dei suggerimenti verbali nel modulare l’inizio dell’efficacia del trattamento,
in questo caso una sostanza inerte, potrebbe non solo potenziare l’uso clinico del
trattamento con placebo (ad esempio, somministrazione ‘open-label’ placebo), ma
soprattutto supportare e ottimizzare l’efficacia dei farmaci attivi. Sarebbero a tal
scopo necessarie ulteriori ricerche, per validare questi risultati su pazienti e su
interventi attivi.
Abstract in Dutch
Het gebruik van suggestieve taal kan iemands verwachtingen sterk regelen.
Suggestief taalgebruik wekt placebo- en nocebo reacties op. De omvang en richt-
ing van suggestief taalgebruik op deze reacties werd reeds onderzocht, terwijl er
geen aandacht werd besteed aan het tijdsaspect. Deze tekortkoming wordt in
dit proefschrift aangepakt. Het doel van dit proefschrift is het onderzoeken van
de invloed van tijdsafhankelijk suggestief taalgebruik op de start van pijnstilling
(placebo) en pijnopwekking (nocebo). Hiervoor zijn drie experimenten uitgevo-
erd.
In het eerste onderzoek werd pijn experimenteel opgewekt bij gezonde deelne-
mers via kortdurende elektrische prikkels van gemiddelde tot lage intensiteit. Na
elke schadelijke prikkel beoordeelden de deelnemers hun pijn op een schaal van
0 (geen pijn) tot 10 (ondraaglijke pijn). Deelnemers werden toegewezen aan een
van de drie placebogroepen, aan een van de drie nocebo-groepen, aan een groep
zonder verwachting of een groep met natuurlijk beloop. Een niet-werkzame zalf
werd toegediend aan alle deelnemers, behalve aan de deelnemers in de groep met
natuurlijk beloop, terwijl verschillende verbale suggesties werden gegeven volgens
de groepstoewijzing. Deelnemers in de placebogroepen werd verteld dat de zalf
pijnstillende zou werken na 5, na 15 en na 30 minuten na het aanbrengen van de
zalf. Deelnemers in de nocebo-groepen werd verteld dat de zalf pijn zou opwekken
na 5, na 15 en na 30 minuten na het aanbrengen van de zalf. Deelnemers in de
groep zonder verwachting werd verteld dat de zalf enkel hydrateerde en dat dit
de pijnbeleving niet zou bëınvloeden. De deelnemers in de groep met natuurlijk
beloop kregen de zalf niet en dienden om natuurlijke pijnschommelingen in de
loop van de tijd te bestuderen. Deelnemers beoordeeelden hun pijn bij de start
van het experiment, na 10, na 20 en na 35 minuten na het aanbrengen van de
zalf. Variantieanalyse toonde een significante interactie aan tussen groep en tijd,
wat aangeeft dat pijnscores veranderden in de tijd en tussen de groepen. Zoals
verwacht lieten post-hoc vergelijkingen zien dat de placebo- en nocebo groepen
een significante verandering in pijn vertoonden ten opzichte van de groep zon-
der verwachting op het verwachte tijdstip, maar niet eerder. Interessant is dat
het pijnstillende effect, eenmaal geactiveerd, stabiel bleef in de tijd, terwijl het
pijnopwekkende effect in de loop van de tijd toenam.
In het tweede en derde onderzoek werd de invloed van tijdsafhankelijke ver-
bale suggesties op placebo-pijnstilling (onderzoek 2) en nocebo-pijnopwekking
(onderzoek 3) onderzocht met behulp van een langdurige, zeer intense koudwa-
ter proef. De hartslag werd gemeten om te beoordelen of deze samenhing met
placebo-pijnstilling en nocebo-pijnopwekking. In het tweede onderzoek werden
deelnemers toegewezen aan een van de twee placebogroepen of aan een groep zon-
der verwachtingen (controlegroep). In het derde onderzoek werden deelnemers
toegewezen aan een van de twee nocebo-groepen, met als controlegroep de groep
zonder verwachtingen uit het tweede onderzoek. Ook in dit geval kregen de deel-
nemers een niet-werkzame zalf. De proefpersonen in de placebogroepen vernamen
dat de zalf de pijn zou verminderen na 5 en na 30 minuten na het aanbrengen.
Degenen in de nocebo-groepen werd verteld dat de zalf pijn zou opwekken na 5 en
na 30 minuten na het aanbrengen. Degenen in de controlegroep kregen te horen
dat de zalf enkel hydrateerde. Alle deelnemers herhaalden de koudwaterproef bij
aanvang, na 10 en na 35 minuten na het aanbrengen van de zalf. Procentuele
veranderingen in pijntolerantie na 10 en na 35 minuten en veranderingen in de
hartslag tijdens de koudwaterproef werden vergeleken tussen de drie groepen. In
het tweede onderzoek was de pijnstilling na 10 minuten groter in vergelijking met
de controlegroep en zij die pijnstilling verwachtten na 30 minuten. Dit wijst op
pijnstilling die enkel optreedt in de groep die een vroeg begineffect van de zalf
verwacht. Bij alle deelnemers was de pijnstilling na 35 minuten groter in vergeli-
jking met de controlegroep. Dit wijst op een een vertraagd begin van pijnstilling
bij wie pijnstilling na 30 minuten verwacht. Het laat ook zien dat pijnstilling zich
handhaaft in de tijd bij wie vroege pijnstilling verwacht. Dezelfde resultaten,
maar in de tegenovergestelde richting, werden gevonden in het derde onderzoek.
De start van pijnopwekking volgde de tijdsafhankelijke verbale suggesties die de
deelnemers ontvingen. In beide onderzoeken werden geen verschillen in hartslag
tussen de groepen gevonden.
Samengevat werd er aangetoond dat bij gezonde deelnemers zowel placebo-
pijnstilling als nocebo-pijnopwekking de verstrekte tijdsafhankelijke informatie
volgen. Dit gold zowel voor pijn van gemiddelde tot lage intensiteit als voor pijn
met hoge intensiteit. Bovendien werd aangetoond dat eenmaal geactiveerd, zowel
pijnstilling als pijnopwekking in de loop van de tijd aanhouden (tenminste voor
de duur van de experimentele proef). De belangrijke rol van suggestief taalge-
bruik bij het regelen van het begin van de actie van een bepaalde (niet-actieve)
interventie zou niet alleen het klinische gebruik van placebobehandelingen kunnen
helpen, maar ook de werkzaamheid van actieve geneesmiddelen kunnen onders-
teunen. Er is inderdaad meer onderzoek nodig om deze resultaten uit te breiden
naar patiënten en actieve interventies.
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1.1 Placebo and nocebo effects: A brief overview
The term placebo (Latin word for ‘I shall please’) refers to an intervention that
resembles an active medical treatment but is not. The classical sugar pill without
active agent, a sham surgical procedure or a sham injection, are all good examples
of placebos [1]. The placebo effect is a phenomenon in which amelioration of
symptoms follows the administration of the inert (placebo) treatment [2]. The
term nocebo (Latin word for ‘I shall harm’) was introduced to describe the case
in which negative effects follow the administration of these sham interventions.
Accordingly, the nocebo effect is a phenomenon in which the administration of an
inert substance is followed by negative side effects [3].
The positive and negative outcomes that may follow the administration of
placebos and nocebos are not to be attributed to the substances themselves but
to the psychosocial context in which these are given. Such psychosocial context
includes verbal suggestions delivered to the patient, social cues, medical setting
characteristics, the features of the treatment (e.g. whether the treatment is more
or less invasive) and specific features of the patient (e.g. previous experience,
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mindset, pre-existing expectations, age and cognitive impairments) [4; 5] and of
the doctor (i.e., professionalism and appearance) (See Figure 1.1) [6]. A placebo
effect is likely to occur if the active compound of the treatment is replaced by
a sham intervention while the psychosocial factors remain the same influencing
one’s mind and body as if the active treatment had been given [7]. The contextual
factors are internalised by the patient, eliciting specific emotions and contributing
to the formation of either positive or negative expectations of therapeutic outcome
which then result in placebo and nocebo responses, respectively [6].
Figure 1.1: The psychosocial context in the clinical setting.
Expectations have been extensively studied and are, arguably, the main factor
influencing placebo and nocebo phenomena, playing such a crucial role that the
term ‘expectation effect’ is often used interchangeably with ‘placebo effect’ or
‘placebo response’ [7; 8]. Expectations are at the core of this doctoral thesis and
will be discussed in more detail in Section 1.2.2. Factors within the psychoso-
2
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cial context, such as verbal suggestions, directly trigger expectation formation,
whereas learning mechanisms, namely classical conditioning 1 and social obser-
vational learning, are more complex processes and their effect can either trigger
or bypass expectation formation [10; 11; 12; 13] (See Figure 1.2).
In 2003, Benedetti and colleagues demonstrated that placebo response fol-
lowing classical conditioning is mediated by expectation [11]. Here, participants
were assessed on pain perception after heat pain stimulation and they were pre-
conditioned for two consecutive days with ketorolac, an antiinflammatory drug
that produces pain reduction. On the third day, participants received a placebo
instead of ketorolac, along with suggestions of pain reduction (analgesia) in one
group and of pain increase (hyperalgesia) in the other. Those who received sug-
gestions of analgesia reported pain reduction as if they had received the active in-
tervention. Interestingly, those who received suggestions of hyperalgesia reported
pain increase, despite analgesia pharmacological preconditioning. The nocebo
response after ketorolac preconditioning shows that both placebo and nocebo ef-
fects following conditioning are meditated by expectations rather than being the
mere consequence of pharmacological preconditioning per se [11]. Further stud-
ies have shown that conditioning can be used as an ‘expectation enhancer’. For
instance, expectations of analgesia can be reinforced by the administration of an
active painkiller in the conditioning phase, providing evidence for the truthful-
ness of verbal suggestions of analgesia. Such boosted expectations are maintained
even when, in the post-conditioning phase, the analgesic intervention is replaced
with a placebo, supporting the enhanced placebo response. Accordingly, placebo
1Classical conditioning, or Pavlovian conditioning, is a learning mechanism in which the
repeated association between one stimulus, the conditioned stimulus, and another stimulus, the
unconditioned stimulus, leads to a learnt conditioned response that occurs even in the absence of
the unconditioned stimulus [9]. Accordingly, placebo and nocebo responses are the conditioned
responses resulting from the learnt association between theconditioned stimulus(i.e. swallowing
of the pill) and the unconditioned stimulus (i.e. active agent inside the pill) [2]
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responses preceded by conditioning are stronger compared to placebo responses
preceded by expectation modulation alone [14; 15]. It is noteworthy that, in the
same aforementioned study, Benedetti et al. (2003) [11], showed a different role of
expectations when investigating hormonal secretion, both growth hormone (GH)
and cortisol. For two consecutive days, participants were preconditioned with
sumatriptan, a 5-HT1B/1D agonist that stimulates GH and inhibits cortisol se-
cretion. On the third day, placebo was administered instead of sumatriptan, and
opposite verbal suggestions were given. Some participants were told they were
receiving the same drug that would increase GH and reduce cortisol secretion,
while others were told they were receiving a different compound that would lead
to the opposite effect, decrease of GH and increase of cortisol. In both groups,
GH and cortisol secretion occurred as if sumatripan was administered. Thus,
hormonal secretion was in line with verbal suggestions in one case, and in oppo-
sition to verbal suggestions in the other, indicating that the occurring placebo
response was the consequence of pharmacological preconditioning per se rather
than being mediated by expectations [11]. In line with these findings it would
appear that expectations play a greater role on cognitive mediated processes, like
pain, while these become less influential on unconscious and automatic processes
such as hormonal secretion [11].
Social observational learning has also been shown to directly influence expec-
tations, acting as an ‘expectations enhancer’ [12]. Social learning refers to the
learning process by which the observer modifies their behaviour or belief on the
basis of the behaviour or belief of the demonstrator [16].
Although it has been demonstrated that social learning leads to stronger
placebo responses compared to when expectation are triggered by verbal sug-
gestions alone [13; 17], the extent to which expectations are responsible for such
stronger responses is yet to be clarified [13]. In fact, social observational learning
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is likely to have a unique role, interacting and working alongside other cognitive
and emotional components such as empathy [18]. Accordingly, individual degree
of empathy has been shown to positively correlate with the magnitude of the
placebo response following social observational learning [13].
Figure 1.2: Mechanisms of placebo and nocebo effects
When we talk about placebo, we are referring to the administration of an in-
ert intervention. However, research has shown that the influence of expectations
on therapeutic outcome works similarly when delivering an active treatment. In-
deed, shaping expectations can enhance or reduce treatment effectiveness above
and below the biological effect that the treatment would have if delivered in iso-
lation from the psychosocial context. Placebo-related effect refers to the positive
therapeutic outcome that has to be attributed, not to the active compound, but
to the positive psychosocial context in which the active treatment is delivered.
Nocebo-related effect refers to the negative therapeutic outcome arising from a
negative psychosocial context [2; 19]. Placebo and nocebo-related effects have
been repeatedly demonstrated using the open-hidden paradigm [20; 21; 22]. In
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the open condition, the patient is informed of being administered a painkiller (pa-
tient is aware of active treatment), whereas in the hidden condition the patient
is not informed of being administered a painkiller (patient is unaware of active
treatment). However, in both cases a constant dose of painkiller is delivered.
Open-hidden paradigm has been used to test at least five different analgesics
(morphine, buprenorphine, tramadol, ketorolac, metamizole) [20; 21; 22]. Find-
ings are consistent across studies, showing that the analgesic effect of the drug is
significantly greater in the open compared to the hidden condition. For example,
in a study comparing the analgesic effectiveness of open administered ketorolac
with hidden administered ketorolac, it was demonstrated that tolerance to the
painful stimulus was significantly higher (p < 0.05) in the former case (toler-
ance, 21.5 +/- 5.11 min) than in the latter (tolerance 17.23 +/- 2.4 min) [20].
This shows that by simply informing the patient of drug administration we can
significantly enhance treatment efficacy. Placebo-related effects are particularly
important because the final goal of placebo research is not to treat patients with
inert treatments, but instead to use what we know about the influence of the
psychosocial context to maximise the effect of active treatments.
Placebo and nocebo effects have been identified and studied across a variety
of conditions (See Table 1.1). However, pain remains the most studied and,
arguably, the most informative model when investigating these phenomena [2].
Pain is a subjective experience which undergoes psychological modulation more
than other conditions and is therefore particularly susceptible to the influence of
placebo and nocebo interventions (See Section 1.2).
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Table 1.1: Placebo and nocebo effects across diseases/systems
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Pain [30; 31; 32; 33; 34; 35]
Throughout my PhD I was actively involved in data collection, data analysis
and manuscript writing for research projects investigating placebo-related effects
in Parkinson’s disease (see Section 6.1), Myastenia gravis (see Section 6.2) and
high altitude headache (see Section 6.3). However, my core doctoral research
focuses on the model of pain.
1.2 The model of pain: Placebo analgesia and
nocebo hyperalgesia
1.2.1 Pain and nociception are not synonyms
Pain experience is a complex process that goes beyond mere nociception. Noci-
ception can be defined as the system that encodes and processes noxious stimuli
(i.e. tissue damage, excessive pressure, heat or cold)[36]. In nociception, sensory
neurons, namely nociceptors, respond to damaging (or potentially damaging)
stimuli, sending a ‘warning signal’ from the periphery to the spinal cord and the
brain; this is referred to as the ascending pathway [36] (See Figure 1.3b). Periph-
eral nociceptors need to reach a specific threshold to activate. If the stimulus is
strong enough, the threshold is reached and a signal is delivered through neurons’
axons into the dorsal horn in the spinal cord and to the central nervous system
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[37]. Peripheral nociceptors include both phasic and tonic receptors, the former
responding to short lasting noxious stimulation (i.e. receptors are activated by
changes in stimulus intensity), and the latter to longer lasting stimulation (i.e.
receptors continuously respond to the lengthy stimulation) [38; 39]. Activation
of phasic receptors results in a sharp, short-lasting and often very localized sen-
sation, referred to as phasic pain [7; 40], whereas the activation of tonic receptors
leads to an enduring sensation of pain which extends over a wider area and en-
gages both superficial skin as well as deeper tissues, referred to as tonic pain
[7; 40; 41].
Figure 1.3: From nociception to pain. a) Schematic representation of the bio-
logical, psychological and social factors that modulate pain perception. b) Brain
regions involved in pain processing, from pain-sensitive regions to the descending
pain pathway. The red arrow going up, represents the nociceptive input coming
from the periphery
Regulation of nociceptive processing occurs via the descending pathway, a
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brainstem subcortical-cortical network that either facilitates or inhibits nocicep-
tive signalling [42]. This network includes higher level brain areas - i.e. ventro-
medial prefrontal cortex (vmPFC), anterior cingulate (ACC), insular cortex (IC),
orbitofrontal cortex (OFC) and the amygdala - that project to the periaqueductal
gray (PAG) [43] from which the signal travels downwards to the dorsal horn of the
spinal cord [43]. Precisely, three inhibitory neurotransmitters are released from
the PAG (i.e. serotonin, noradrenaline and enkephalins), which are responsible
for the inhibition of the nociceptive signalling [44; 45]. In the case of serotonin,
depending on the receptor subtype, this can also have a facilitatory effect on the
transmission of the nociceptive signalling [46]. Note that enkephalins are one of
the three families of opioid peptides of the endogenous opioid system, which is
fundamental in the mechanisms of analgesia and which will be discussed later
on in this thesis [47]. Once adjusted, the nociceptive signal is sent back up via
the ascending pathway (See Figure 1.3b). The loop continues and regulates the
experience of pain [43; 48].
Although nociception is likely to lead to the sensation of pain, this relationship
is not linear and the resulting pain may not correspond to nociception intensity.
Indeed, nociception can occur without pain, and pain without nociception [43].
The International Association of the Study of Pain defines pain as ‘an unpleasant
sensory and emotional experience associated with, or resembling that associated
with, actual or potential tissue damage’ [49]. Pain is in fact a subjective and con-
scious experience that is modulated by biological, psychological and social factors
[43] (See Figure 1.3a). The discrepancy between nociception and pain is under-
stood in light of the interplay between ascending and descending pathways, where
the descending pathway is influenced by higher order regions involved in cogni-
tive and emotional processing and is responsible for the down or up regulation
of nociceptive input. Expectations leading to placebo and nocebo responses have
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been shown to down-and-up regulate pain via the engagement of the descending
pathway (See Section 1.2.2.2).
Functional magnetic resonance imaging (fMRI) is an indirect measure of brain
activity. By looking at the changes in oxygenation concentration (Blood Oxygen
Level Dependent, or BOLD contrast) that occur as a consequence of increased
neural activity it is possible to infer which areas are activated or deactivated in
that given moment [50]. Accordingly, pain research has used this technique to
identify the regions that are the most active during pain, these include the pri-
mary and secondary somatosensory areas (S1, S2), IC, ACC, prefrontal cortices
(PFC) and the thalamus [43; 51; 52]. Activation of these pain-sensitive regions
was also demonstrated during pharmacologically induced analgesia [53; 54; 55].
In addition, Wager and colleagues [52] were able to use an algorithm to predict
the intensity of participants’ subjective pain experience on the basis of the ac-
tivation of these same areas (S1, S2, IC, ACC) (See Figure 1.3b). These areas
are a mixture of somatosensory, limbic and associative regions, attesting for the
complexity of pain experience. While S1 and S2 are involved in sensory encoding,
higher order areas, both limbic and associative, are responsible for cognitive and
emotional appraisal of the nociceptive signal [43]. Other regions such as basal
ganglia, cerebellum, amygdala, hippocampus and others within the parietal and
temporal cortices have also been shown to be involved in pain processing [43].
The engagement of different limbic and affective brain regions is likely to vary
depending on the factors involved in characterising each specific and unique pain
experience (i.e. mood, cognition, context, nociception) [43].
Noteworthy is the influence that age and cognitive impairments can have on
pain processing [56; 57; 58; 59; 60; 61; 62; 63] and on placebo analgesia responsive-
ness [4; 5]. Regarding pain processing, pain tolerance has been shown to decrease
with age [56; 61]. Accordingly, Cole et al., observed a decrease in striatal activity
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during pain in older individuals and the authors suggest this may indicate a dys-
function in inhibitory circuits rendering older individuals more vulnerable to pain
suffering [57]. As for neurocognitive disorders, patients suffering from Alzheimer
Disease (AD) have been shown to have augmented responses to pain compared
to other patients suffering from milder forms of dementia [58; 59; 60; 61]. Ac-
cordingly, a systematic review looking at the insurgence of adverse events in the
placebo arm of donepezil trials, reported that AD patients experienced greater
adverse reactions than patients with mild cognitive impairments [62]. A sub-
sequent review confirmed higher level of adverse events in placebo -treated AD
patients who participated in RCTs, and extended these findings to other neurode-
generative disorders, including Parkinson’s disease [63]. Concerning the influence
of cognitive dysfunction on placebo processes, it has been observed that patients
with neurocognitive disorders have a reduced or absent response to placebo anal-
gesia [4]. In another study, the neural correlates of placebo analgesia in patients
with neurocognitive disorders were elucidated in subjects complaining of various
cognitive deficits (from mild cognitive impairment probably due to Alzheimer’s
disease to mild AD). In particular, the study aimed to assess how and to what
extent executive (dys)functions of the medial prefrontal cortex (mPFC) may be
related to placebo analgesia. Placebo analgesia was studied with the experimental
venipuncture pain paradigm (open versus hidden [O-H] application of lidocaine).
Patients also underwent a comprehensive neuropsychological assessment and a
GO/No-GO fMRI task to elicit selective activation of the mPFC. The results
showed a relationship between lower PA and mPFC dysfunction by neuropsy-
chological assessment and fMRI. A separate voxel-based morphometry analysis
also controlled for the possible influence of reduced grey matter volume on both
fMRI results and placebo analgesia. fMRI results were not directly influenced by,
and thus independent of, disease-specific grey matter atrophy, which was indeed
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located more anteriorly within the rostral anterior cingulate and inversely corre-
lated with placebo analgesia [5]. Altogether, these data indicates that age and
cognitive impairments are important modulators of pain processing, and these
may be associated with a dysfunctionality in the pain inhibitory system. Ac-
cording with the literature, minimal cognitive decline may already start from 25
years old, but a steeper decline is likely to occur from the sixth decade of life
[64]. Therefore, age-related aspects become particularly important when study-
ing pain processing, placebo analgesia and nocebo hyperalgesia in participants
older than 60 years old and over, in which case cognitive deterioration and neu-
rocognitive dysfunctions must be controlled for [63]. Paraphs most importantly,
these findings must be considered when designing the placebo group of RCTs
[5; 62; 63].
1.2.2 The influence of expectations on pain
1.2.2.1 Expectancy effect on pain-related brain regions
Positive and negative expectations change both subjective experience and objec-
tive activity of pain areas in the brain [65]. In a functional magnetic resonance
imaging study conducted by Wager and colleagues in 2004 [32], pain was exper-
imentally induced on healthy participants via electrical stimulation and an inert
cream was applied along with suggestions of analgesia. This resulted in a re-
duction in the subjective perception of pain (Visual Analogue Scale, VAS) and
was mirrored by reduced activity in pain-sensitive regions, including thalamus,
IC and ACC.
The first attempt to summarize the brain areas involved in placebo analgesia
in human experimental pain was done in 2011 by Amanzio and colleagues [66].
Here, the activation likelihood estimation (ALE) meta-analysis, a quantitative
voxel-based method, was used to investigate placebo-related cortical activity as
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a function of time, meaning that the authors divided between anticipatory phase
(i.e., while anticipating pain decrease/increase), noxious stimulation phase (i.e.,
while receiving noxious inputs) and post-stimulation phase (i.e., after having re-
ceived noxious stimulation). During the expectation phase, increased activity was
observed in areas implicated in the descending inhibitory pain pathway, such as
the ACC, the PAG along with the rostral PFC, further attesting for the down
regulatory effects that expectations have on pain perception [67]. During the
noxious stimulation phase, increased activity was revealed in regions involved in
the descending inhibitory pain pathway (i.e., ACC, IC, the thalamus, the hy-
pothalamus, the PAG and the pons) [43; 68], while decreased activity was shown
in pain-sensitive regions (i.e., posterior and mid-cingulate cortex, the IC and the
basal ganglia) [43; 69]. Reduced activity in pain-sensitive regions is likely to reflect
an antinociceptive effect associated with placebo analgesia, along with cognitive
modulation of pain as suggested by the increased activity of the descending pain
pathway [66]. For what concerns the post-stimulation phase, it was not possible
to perform the analysis due to the lack of sufficient data in the literature. A sub-
sequent meta-analysis investigating placebo analgesia during noxious stimulation
reported similar patterns of activation and deactivation, confirming the influence
of placebo-induced changes in pain sensitive brain regions and in the descending
inhibitory pain pathway [70]. Precisely, increased activity was observed in the
OFC, ACC, dorsolateral PFC, ventral striatum, left thalamus and in the mid-
brain surrounding the PAG during noxious stimulation, and decreased activity
was shown in IC, ACC, the thalamus, amygdala and right lateral PFC [70].
Although generally less attention has been given to the nocebo phenomenon,
a recent meta-analysis reported nocebo-induced increases during noxious stimu-
lation in pain-modulating areas, including the dACC, the parietal operculum and
the posterior IC [71]. Similarly to placebo analgesia, but in the opposite direc-
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tion, such increased activity in pain-sensitive region during the noxious stimula-
tion phase suggests a pro-nociceptive effect associated with nocebo hyperalgesia.
Importantly, two pivotal positronemission tomography (PET) studies have fur-
ther demonstrated the strong neurophysiological responses associated with both
placebo analgesia and nocebo hyperalgesia [31; 72]. The first PET study showed
the engagement of the endogenous opioid system in placebo analgesia [31]. In
this study, neurological correlates of placebo-induced and opioid-induced (i.e.
remifentalin administration) analgesia were compared. In both cases, subjec-
tive pain ratings decreased and opioid neurotransmission increased in the OFC
and ACC. Opioid-induced analgesia also activated the vmPFC and IC. It was
therefore demonstrated for the first time that placebo analgesia uses a similar,
but reduced, pathway of opioid-induced analgesia. The second PET study repli-
cated and expanded these findings, suggesting opposite opioid responses between
placebo and nocebo effects [72]. While placebo analgesia led to increased opioid
neurotransmission in pain-related regions, nocebo hyperalgesia decreased opioid
release in these same regions (ACC, OFC, IC, nucleus accumbens, thalamus,
amygdala). Higher opioid neurotransmission corresponded to lower pain ratings,
whereby lower opioid neurotransmission was associated with higher pain ratings
[72].
As mentioned earlier, expectations of pain increase are known to play an
important role in enhancing pain experience and evidence is accumulating that
demonstrates the influence of negative expectations on the activity of pain areas
in the brain [65; 67] (For further details on the neurophysiology of expectations
See Section 1.2.2.2). The first attempt to identify brain regions that consistently
engage in pain anticipation, by looking at multiple studies with pain anticipa-
tion paradigms in a single analysis, was done by Palermo and colleagues [73]
using ALE meta-analysis. Here, increased activation was observed in the dorso-
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lateral PFC, IC, medial and inferior frontal gyri, inferior parietal lobule, middle
and superior temporal gyrus, thalamus, and caudate, while deactivation was re-
ported in the ACC, superior frontal gyrus, parahippocampal gyrus and in the
claustrum. Since the anticipation of a painful event is likely to be underpinned
by multiple processes, Palermo et al. investigated the behavioral domains (BD)
(i.e., interoception, emotion, perception, action, cognition) associated with func-
tional connectivity networks, instead of limiting their analysis to single areas of
activation/deactivation. Network analysis was therefore used to assess FC of
preselected ROIs, the anterior insula (AI) and cingulate cortices, separately. AI
showed higher coactivation with the claustrum, thalamus, inferior/middle and
superior frontal gyri, inferior parietal lobule, precuneus, lentiform nucleus (puta-
men), parahippocampal gyrus, pre-/postcentral gyri, and middle temporal gyrus.
A second cluster of coactivation involved the medial frontal gyrus, anterior and
posterior cingulate. Coactivation with the ACC was observed in the insula, thala-
mus, inferior/middle and superior frontal gyri, inferior parietal lobule, lentiform
nucleus (putamen), pre-postcentral gyri, and transverse temporal gyrus. Such
functional connectivity meta-analytic analysis provides, for the first time, an
overview of the interconnected brain responses triggered by the anticipation of
pain. Importantly, AI and ACC and related clusters were highly correlated with
BD of action (imagination, inhibition, and execution), emotion and perception
(pain and interoception). Accordingly, the authors suggest that pain anticipation
may engage a supramodal system in which AI and ACC regulate emotional, atten-
tional and sensory (pain/interoception) responses, accounting for the complexity
of pain perceptual processes, including pain anticipation.
Overall, this in-depth section outlining the brain areas involved in placebo
analgesia and nocebo hyperalgesia during the anticipation and the noxious stim-
ulation phases suggests that these phenomena engage brain regions involved in the
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pain downregulation pathway and influence pain-sensitive brain areas, decreasing
and increasing their activity for placebo analgesia and nocebo hyperalgesia, re-
spectively. Overall, this neuroimaging evidence adds scientific strength to these
phenomena, indicating that it is unlikely that these are simply the result of a
response bias and of social pressure to comply to instructions.
1.2.2.2 Neurophysiology of expectations
From a neuroscientific perspective, expectations of a future outcome have an im-
portant role in preparing the body for the future event. Positive expectations
indicate the body should prepare for a positive event and trigger biological re-
actions such as activating the reward system and reducing anxiety. Conversely,
negative expectations prepare the body for a negative event by increasing anxiety,
which is essential for reacting to threat [74; 75].
Positive expectations may induce placebo responses through the engagement
of the reward system. The reward circuit is a network that drives our behaviour
towards pleasurable stimuli (i.e.food) and pleasurable emotions (i.e joy), and
drives our behaviour away from unpleasant stimuli (i.e. pain) and unpleasant
emotions (i.e. sadness). The anatomical structures of the reward system are lo-
cated within the cortico-basal ganglia-thalamo-cortical loop [76] and when reward
is experienced, dopamine is released from two main dopaminergic pathways: the
mesolimbic and the mesocortical pathways. The mesolimbic pathway transmits
dopamine from the Ventral Tegmental Area (VTA) in the midbrain to the Nu-
cleus Accumbens (NAc) in the ventral striatum (which also includes the olfactory
tubercle) [77]. Dopamine release from the VTA to the NAc is a core component
of the reward circuit.
Scott et al. (2007) used receptor-binding PET to show that placebo respon-
siveness was related to dopamine activation in the NAc. Here, pain was exper-
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imentally induced and placebo responsiveness was evaluated according to pain
reduction following the administration of a placebo intervention. Additionally,
they compared activation of the dopaminergic pathway during a monetary re-
ward task, a well studied paradigm known to activate the reward system, and
during a placebo analgesia task. It was demonstrated that the larger the NAc
activation for monetary reward, the stronger the NAc activation during placebo
response, suggesting that placebo responsiveness depends on the functioning of
the reward system [78]. In a similar study, dopaminergic activation in the NAc
was observed during the anticipatory phase of placebo analgesia, while opioid
neurotransmission in pain-related brain regions (ACC, OFC, IC, NAc, amygdala,
and periaqueductal gray matter) was shown during placebo analgesia. Greater
placebo analgesia was associated with greater dopaminergic and opioid activ-
ity. Oppositely, nocebo responses were associated with decreased dopaminergic
and opioid activity [72]. This evidence suggests that expectations of therapeutic
amelioration following placebo intake activate the reward system, which in turn
interacts with endogenous opioid release resulting in placebo analgesia.
Placebo analgesia has been also associated with a decrease in perceived anxi-
ety [79] and reduced activation of anxiety-related areas (i.e., emotional network,
including amygdala) [27; 80]. Indeed, the larger the placebo response, the greater
the deactivation of the emotional network [27]. Along with other physiological
parameters of stress, heart rate (HR) has been used as a physiological indicator
of anxiety reduction in placebo research. Since HR has been used in the research
conducted during this Doctoral Degree, greater attention is given to this physio-
logical parameter throughout this chapter, compared to others (i.e galvanic skin
response, heart rate variability). Yet, the reliability of HR is still under debate.
For instance, a recent meta-analysis reported six placebo studies showing HR
reduction in association with analgesia, while eight showed that placebo effects
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did not impact HR [81].
Negative expectations leading to nocebo hyperalgesia have been associated
with two biochemical pathways strongly linked to stress reactions: cholecys-
tokinin (CCK) secretion and hypothalamic-pituitary-adrenal axis (HPA). CCK
is a neuropeptide in the central nervous system, which is secreted in response to
anxiogenic and panicogenic responses [82]. In 1997 [83], it was shown that no-
cebo hyperalgesia was blocked by pre-treatment with proglumide, a non- specific
CCK-A/CCK-B receptor antagonist. While not being a painkiller, proglumide
prevented nocebo hyperalgesia in a dose dependent manner, attesting for the
critical role of CCK secretion in nocebo. The HPA axis is a system formed
by the feedback interactions of the hypothalamus, pituitary gland and adrenal
glands. This neuroendocrine system is responsible for the regulation of multiple
body processes including regulation of stress via cortisol secretion [84]. In 2006,
Benedetti and colleagues [85] demonstrated that nocebo hyperalgesia induced
by verbal suggestions of pain worsening led to an increase in plasma concentra-
tion of adrenocorticotropic hormone (ACTH) and cortisol, attesting for HPA axis
hyperactivity. Interestingly, it was shown that administration of diazepam, an
anti-anxiety benzodiazepine, blocked both nocebo hyperalgesia and the HPA axis
hyperactivity, demonstrating the crucial role of anxiety in nocebo responses. Also
HR is a physiological parameter that has been used as an indicator of anxiety
during the anticipatory phase of threat in nocebo hyperalgesia. Ploghaus et al.
(2001) [86] showed decreased HR during high anxiety anticipatory phase and in-
creased HR during low anxiety anticipatory phase. HR deceleration in response
to high anxiety may seem peculiar, as greater anxiety is usually associated with
HR acceleration [87]. Contrasting evidence is provided by Colloca and Benedetti
(2009) which reported HR increase in high anxiety anticipatory phase and HR
decrease in low anxiety anticipatory phase [13]. Although Ploghaus et al.’s (2001)
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findings are in line with the defence cascade model [88], which suggests that dur-
ing anticipation of pain HR first decreases and then increases, further research is
needed to better understand HR variations in the anticipatory phase of nocebo
hyperalgesia.
Finally yet importantly, neuroimaging evidence has demonstrated that during
the anticipatory phase prior to noxious stimulation, expectations of high and
low pain engage key cortical regions of the descending pain modulatory circuit
(rACC, mPFC, and PAG), and result in enhanced pain perception in the case
of expectations of high pain and reduced pain in the case of expectations of low
pain, attesting for the critical role of expectancy in up-and-down regulating pain
experience [31; 32; 67; 89].
1.2.2.3 Understanding expectations: A predictive coding framework
From an evolutionary perspective, our brain can be seen as a ‘prediction machine’
whose goal is to make sense of our surroundings as efficiently as possible. This
brain function is crucial for survival because we need to predict potential risks
to avoid them and foresee potential rewards to approach them [75]. Perceptual
accuracy depends on the amount of information we gather about the incoming
stimulus yet gathering information takes time [90]. From a survival perspective,
speed is crucial. It is safer to mistake a wood-stick for a snake than to take time
accurately examining the shape of the object and discover it is in fact a deadly
snake. It follows that in perception, there is always a trade-off between accuracy
and speed [75]. Consequently, when we are presented with a clear stimulus, we
easily gather sufficient information to accurately interpret it in a short time.
However, when presented with an ambiguous stimulus we attempt to exploit all
available information to fill in the gaps; taking advantage of sensory inputs on
one side and resourcing from our previous experience and expectations on the
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other [90]. Thus, the more ambiguous the stimulus, the more room there is for
expectancy to influence perception [90; 91].
The key role of expectancy in perception is in line with the Bayesian pre-
dictive coding framework in which computational tools are used to explain how
expectations shape perception. Predictive coding has been applied to some areas
of perception, vision being the most studied [92]. In 2016, Wiech [93] applied the
predictive coding framework to explain pain encoding. Sensory cues trigger pain
related expectations and the model of expected pain is compared with sensory
experience; if there is a match between the expected and experienced pain, the
expectations are confirmed and reinforced. Otherwise, if the mismatch between
the predicted model and the sensory experience is large enough, expectations are
updated accordingly with the newly accumulated evidence; a ‘prediction error
message’ is generated in the brain, which updates the pre-existing model (See
Figure 1.4). This mechanism of learning and updating is essential to maintain a
functional and accurate perception of reality. It has been suggested that disrup-
tion of updating mechanisms, leading to change-resistant mental representation,
is involved in the development and maintenance of chronic pain [94].
The moment of comparison between sensory input and our predicted model
is crucial for the resulting experience. The predictive coding framework acknowl-
edges the bias towards higher weighting of elements that are in agreement with
expectations and down weighting of elements that contradict expectations. This
predisposition of favouring evidence in line with our expectations results in a
perceptual experience that is more coherent with the predicted model. Placebo
analgesia and nocebo hyperagesia are clear examples of this predictive framework
in which pain is either down or up regulated accordingly with one’s expectations.
In line with this, Koyama et al. (2005) and Keltner et al. (2006) [67; 89] inves-
tigated the influence of cues on perception of noxious stimuli and showed that
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noxious stimuli are perceived as more or less intense according to whether these
are preceded by visual cues indicating high or low pain, respectively. Importantly,
not only participants self-reported lower or higher pain according to the cues
that preceded the noxious stimulation, but pain-related regions activity during
the pain phase increased if preceded by high-pain cues, and decreased if preceded
by low-pain cues. Moreover, engagement of descending pain modulatory circuit
regions during the anticipatory phase of placebo and nocebo responses attests for
the role of expectancy in down and up regulation of pain [31; 32; 67; 89]. As
previously explained, in domains of perception such as vision, the influence of ex-
pectancy increases with more ambiguous stimuli [92; 95; 96; 97]. Yet, influence of
the ambiguity of noxious stimuli on pain perception has not been systematically
investigated. However, it is likely that expectations have stronger influence on
more noisy and ambiguous incoming noxious stimuli.
Figure 1.4: Predictive coding framework of pain
21
1.2 The model of pain: Placebo analgesia and nocebo hyperalgesia
1.2.3 Verbal suggestions trigger analgesia and hyperalge-
sia
Verbal suggestions are, arguably, the stronger factor directly influencing expecta-
tion formulation. In the clinical setting, verbal suggestions are constantly present.
These range from the doctor’s specific instructions to the nurse’s reassuring words
and the advice of family members expressing their concerns and beliefs. There-
fore, the patient is exposed to multiple, and at times contrasting, suggestions that
are likely to have a strong influence on the patient’s recovery (See Figure 1.5).
Figure 1.5: Verbal suggestions of various nature characterise the clinical setting
1.2.3.1 Verbal suggestions vary in ‘direction’ and in ‘magnitude’
Generally, research has studied how verbal suggestions shape expectations in
terms of their ‘direction’, either positive (placebo) or negative (nocebo), and of
their ‘magnitude’ , either strong or weak. Let us now consider some examples.
In 2011, Van Laarhoven et al. [34] demonstrated that the same noxious stim-
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uli, induced experimentally via electrical stimulation, were perceived as more or
less painful according to the direction of verbal suggestions. Specifically, when
an inert cream was applied along with suggestions of analgesia, the stimuli were
perceived as less painful, whereas when the cream was given with suggestions
of hyperalgesia, the stimuli were perceived as more painful. Similar effects were
reported by other studies modulating the direction of verbal instructions while
delivering placebo and nocebo interventions [14; 98].
Furthermore, verbal suggestions are potent to the extent of reversing the ac-
tion of active treatments. Bingel and colleagues in 2011 [35] used an open-hidden
paradigm while inducing pain to healthy participants via heat stimulation. Opioid
treatment, remifentanil, was administered intravenously throughout the experi-
ment, at a constant dosage. Positive and negative expectations were induced by
first telling participants that the anaesthetist would ‘start opioid injection’ (pos-
itive expectations of pain reduction) and then by telling them that the anaes-
thetist would ‘stop opioid injection to investigate the possible increase in pain
after ceasing the opioid infusion’ (negative expectations of pain increase). Here,
it was demonstrated that positive verbal suggestions doubled the analgesic ef-
fect of remifentanil, whereas negative suggestions abolished remifentanil analgesia
[35]. In a different study, administration of an active analgesic cream associated
with positive suggestions led to enhanced analgesics effects, while administra-
tion of the same cream with negative suggestions led to pain increase (nocebo
response), despite the analgesic properties of the treatment. This is in line with
a previous study in which the analgesic effect of nitrous oxide, was reversed into
a hyperalgesic response, simply by telling participants that pain might increase
as a consequence of the treatment administration [99]. Taken altogether, these
findings attest for the power of verbal suggestions not only in enhancing, but also
in reversing active treatments effects.
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Suggestions can also vary in terms of their magnitude. Changing the certainty
of delivered information shapes the magnitude of the suggestion. More certain
information increases the magnitude, whilst less certain information decreases the
magnitude. Pollo et al. [100] assessed post-operative pain after informing some
patients they would receive a powerful painkiller (certain information) while in-
forming others they would receive either a placebo or a painkiller (uncertain). Al-
though the information varied across groups, every patient received the same dose
of painkiller. It was demonstrated that post-operative pain was lower (greater
analgesia) in the certain information group compared to the uncertain group.
Interestingly, both certain and uncertain groups reported significant analgesia
compared to the control group, in which patients were unaware that they were
receiving a painkiller. Furthermore, the effects of delivering certain or uncertain
verbal suggestions on analgesia induced by both placebo intervention and active
treatment were investigated in two studies with Irritable Bowel Syndrome (IBS)
patients. The two studies were almost identical, with the main difference lying
within the information delivered. In one case, verbal suggestions were certain:
‘The agent you have just been given is known to significantly reduce pain in some
patients’ [101]. In the other case, patients were told they would receive either
lidocaine or inert treatment (uncertain condition) [102]. Comparison between the
studies demonstrated that certain suggestions [101], compared to uncertain ones
[102], led to stronger analgesic effects, both for the placebo and for the active
treatment. Similar findings were reported in conditions other than pain, includ-
ing physical performance in healthy participants [103] and motor performance in
Parkinson’s patients [25].
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1.2.3.2 The time component of verbal suggestions
Time is an important aspect in the clinical context both to make informed de-
cisions on the basis of patient’s history (i.e. how long has the patient been
experiencing symptoms) [104; 105] and in terms of the prognosis (i.e. how long
before amelioration of symptoms) [106; 107]. Indeed, when a treatment is admin-
istered, temporal features such as the duration required by the treatment before
setting into action, the longevity of the treatment effect and the temporal win-
dow within which side effects may arise, are important for patients, giving them
a better sense of what is ahead, in other words, of what to expect [107].
Temporal expectations refer to one’s ability to extract temporal information
from the environment [108]. On the basis of temporal expectations it is possi-
ble to predict when an event is going to occur, allocating the attention towards
relevant sensory inputs at the correct time, leading to behavioural benefits includ-
ing faster reaction times, increased movement accuracy and improved perception
[109; 110; 111; 112]. In addition, temporal preparation has been associated with
the contingent negative variation (CNV), a cortical potential of negative polarity
that builds up in central cortical regions and peaks just before the onset of the
temporally predicted stimulus [112; 113; 114].
Given the centrality of time when starting a treatment, and given the impor-
tant role of temporal expectations in preparing ourselves to the incoming event,
gaining a better understanding of whether modulating temporal expectations can
influence the onset of action of a given intervention becomes particularly impor-
tant. For example, is it possible to anticipate the onset of action of a treatment
by delivering temporal expectations of anticipated onset of action? If so, does this
effect last over time? On the opposite hand, is it possible to delay the onset of
action of the treatment by giving temporal instructions of delayed effect? Before
this Doctoral project, no research had been conducted to address these questions.
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Placebo and nocebo expectancy modulation procedures are particularly suited
to start addressing these questions because they allow to isolate the effect of
temporal expectations on the onset of a given effect, without biases due to the
effectiveness of an active treatment. The most efficient way to modulate one’s
temporal expectations of treatment onset of action is by delivering temporal sug-
gestions. Although placebo and nocebo research has largely focused on the mod-
ulation of verbal suggestions, no study has so far investigated the consequences
of modulating temporal verbal suggestions on the onset of placebo and nocebo
effects.
In a few placebo experiments temporal details were explicitly given while de-
livering placebo verbal instructions [28; 115; 116], however, temporal indications
were there to give credibility to the placebo treatment, rather than to test the
influence of the temporal information on the onset and duration of the placebo
response. For example, in a study looking at whether placebo coffee would boost
physical performance the following suggestions were given: ‘Caffeine would be-
come effective within 8-10 minutes.’ [115]. In another study, assessing placebo
analgesic cream effectiveness, participants were told it would take 30 seconds for
the cream to begin numbing their hand [116].
Pollo et al. [28] is, to my knowledge, the only exception in which verbal infor-
mation on time was given both in terms of when the treatment would start to be
effective (placebo onset: ‘It takes a couple of minutes to work’ ), and for how long
it would last (placebo extinction: ‘The anesthetic effect takes a couple of minutes
to vanish’ ). In line with the temporal indications, placebo analgesia was present
after few minutes from cream application and vanished soon after. Although the
scope of this study was not to investigate the role of temporal suggestions, this
remains the first experiment showing that the analgesic effect associated with
placebo administration sets in and fades away accordingly with the temporal
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suggestions that were given. Yet, the study lacks the methodological structure to
rigorously evaluate the influence of temporal information on placebo onset and
duration, therefore it is important to consider the results as preliminary, rather
than drawing strong conclusions from them. First, the study does not compare
multiple groups receiving different temporal information. Consequently, it is not
possible to conclude that the onset varies according with temporal instructions.
Second, the time frame is extremely small (i.e. few minutes overall), and this is
problematic for at least two reasons. One is that the occurrence of both onset
and extinction of the effect within minutes is not an accurate representation of
the real time-frame in which painkillers work. Consider that the time of action of
popular painkillers such as paracetamol (acetaminophen) is approximately 10-20
minutes and their effect last for hours [117; 118]. An additional reason why the
short time window is problematic is the reduced likelihood to encounter cognitive
fluctuations such as expectation re-evaluation and update that may arise by leav-
ing a longer interval for the participant to experience and familiarise themselves
with the treatment effect and incoming sensory input [90]. This last point leads
to an important final consideration. Pollo et al. [28] assessed analgesia on one
single fast stimulus, instead of delivering multiple stimuli one after the other and
then calculating the average, as commonly done in other pain studies [14; 34].
A fast stimulus gives us less time to gather information [90], therefore one could
argue that the short-lasting stimulus used by Pollo et al. has high ambiguity. In
addition, participants do not get the opportunity to further explore the noxious
sensation by receiving multiple stimuli one after the other, further increasing the
level of ambiguity of the stimulus. In line with the predictive coding framework
(see Section 1.2.2), delivering one highly ambiguous stimulus limits the possibility
for our brain to collect data to eventually update expectations, while inflating
the influence of expectations [90].
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In conclusion, only few placebo studies have included temporal details in
their instructions, and although Pollo et al. [28] gave some preliminary insight
into the role of temporal suggestions, no study had been purposely designed to
investigate the influence of temporal suggestions on placebo and nocebo onset
modulation. Indeed, a systematic investigation is required to empirically test if
and how temporal information influences the onset and maintenance of placebo
and placebo-related effects. Accordingly, the goal of the present Thesis is to
address this gap in the literature, conducting purposely designed experiments
to investigate the effects of temporal suggestions in modulating the onset and
duration of placebo analgesia and nocebo hyperalgesia.
1.3 General organization of the research project
The main goal of the research conducted during this Doctoral Degree is to in-
vestigate whether temporal suggestions modulate the onset and the duration of
placebo analgesia and nocebo hyperalgesia both on phasic and tonic pain models.
A secondary aim, is to offer a preliminary reflection on whether the degree of am-
biguity of the incoming painful stimulus influences the extent to which temporal
suggestions modulate these effects. Overall, three studies were conducted during
the 3-year doctoral training programme (2017-2020).
The introductory chapter that just ended (Chapter 1) is followed by three
chapters (Chapter 2, 3, 4), each one covering one research project. The fifth
chapter (Chapter 5) summarises the primary findings across the studies, par-
ticularly focusing on their clinical implications and future directions. The last
chapter (Chapter 6), briefly outlines the collateral projects, aside from my pri-
mary investigation, in which I was involved during my PhD.
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1.3.1 Chapter 2 - The effect of temporal information on
placebo analgesia and nocebo hyperalgesia.
This chapter contains the first of three studies conducted during the 3-years of
doctoral training, which will be henceforth referred to as Study 1. Study 1 has
been published in 2021 in The Psychosomatic Medicine Journal [119]. Here, it
was investigated whether the onset of placebo analgesia and nocebo hyperalgesia
can be modulated by varying the information participants received about the on-
set of the expected treatment effect. Pain was induced experimentally on healthy
participants via short-lasting, medium-to-low intensity, phasic electrical stimuli.
No physiological measures were taken. It was hypothesised that both placebo anal-
gesia and nocebo hyperalgesia onsets would follow the temporal information that
participants received along with the inert cream, setting in at the expected time
point, and not earlier, in a phasic pain model. In line with our predictions,
participants who were told that the (inert-)treatment had a fast time of action
reported the (inert-)treatment effect to occur early on, while those who were in-
structed that the (inert-)treatment required a longer time of action, reported a
delayed (inert-)treatment response. This was true for both placebo and nocebo,
indicating that the onset of both placebo analgesia and nocebo hyperalgesia can
be modulated by the given temporal suggestions.
1.3.2 Chapter 3 - ‘External timing’ of placebo analgesia
in an experimental model of sustained pain.
This chapter contains the second of the three studies, which will be henceforth
referred to as Study 2. Study 2 has been published in 2021 in The European
Journal of Pain [120]. Here, the influence of temporal suggestions on placebo
analgesia onset was investigated using a long lasting, high-intensity, tonic pain
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model, induced with the Cold Pressor Test (CPT). Heart Rate (HR) was mea-
sured to assess whether it correlated with placebo analgesia. It was hypothesised
that placebo analgesia onset would follow temporal suggestions, setting in at the
specified time point, in a tonic pain model. In agreement with our predictions
and accordingly with the results from Study 1, placebo analgesia onset shifted
accordingly with the temporal suggestions that participants received. Precisely,
analgesia occurred early when participants were told that the (inert-)treatment
had a fast time of action, while analgesia was delayed when participants were
told that it would have a slow time of action.
1.3.3 Chapter 4 - The temporal modulation of nocebo hy-
peralgesia in a model of sustained pain.
This chapter contains the third of the three studies, which will be henceforth
referred to as Study 3. Study 3 is currently in preparation and will be shortly
submitted for consideration to a peer-reviewed journal. This project relies on the
same experimental design of Study 2, but investigates the influence of temporal
suggestions on nocebo hyperalgesia. It was hypothesised that nocebo analgesia
onset would follow temporal suggestions, setting it at the specified time point, in
a tonic pain model. As expected, hyperalgesia onset followed the temporal verbal
suggestions that participants received.
1.3.4 Chapter 5 - General Discussion
This chapter pulls together the strands of research conducted during this Doctoral
Programme. By considering the primary findings of the three studies altogether,
and comparing them one with the other, it offers a comprehensive discussion of
their clinical implications and future perspectives.
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1.3.5 Chapter 6 - PhD Collateral Projects
This chapter contains the abstracts of the collateral projects in which I was
involved during my PhD. Although these were not part of my main research
investigation, I was involved in data collection, data analysis and manuscript
writing. These projects investigated placebo and nocebo effects in conditions
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[110] K. Lange and B. Röder, “Orienting attention to points in time improves
stimulus processing both within and across modalities,” Journal of cognitive
neuroscience, vol. 18, no. 5, pp. 715–729, 2006. 25
[111] S. Vangkilde, J. T. Coull, and C. Bundesen, “Great expectations: temporal
expectation modulates perceptual processing speed.” Journal of Experi-
mental Psychology: Human Perception and Performance, vol. 38, no. 5, p.
1183, 2012. 25
[112] D. Meijer, E. Te Woerd, and P. Praamstra, “Timing of beta oscillatory syn-
chronization and temporal prediction of upcoming stimuli,” NeuroImage,
vol. 138, pp. 233–241, 2016. 25
[113] P. Praamstra, D. Kourtis, H. F. Kwok, and R. Oostenveld, “Neurophysiol-
ogy of implicit timing in serial choice reaction-time performance,” Journal
of Neuroscience, vol. 26, no. 20, pp. 5448–5455, 2006. 25
[114] A. Breska and L. Y. Deouell, “Automatic bias of temporal expectations
following temporally regular input independently of high-level temporal ex-
pectation,” Journal of cognitive neuroscience, vol. 26, no. 7, pp. 1555–1571,
2014. 25
[115] A. Piedimonte, F. Benedetti, and E. Carlino, “Placebo-induced decrease
in fatigue: evidence for a central action on the preparatory phase of move-
46
REFERENCES
ment,” European Journal of Neuroscience, vol. 41, no. 4, pp. 492–497, 2015.
26
[116] A. L. Geers, J. A. Wellman, S. L. Fowler, S. G. Helfer, and C. R. France,
“Dispositional optimism predicts placebo analgesia,” The Journal of Pain,
vol. 11, no. 11, pp. 1165–1171, 2010. 26
[117] P. L. Møller, S. E. Nørholt, H. E. Ganry, J. H. Insuasty, F. G. Vincent,
L. A. Skoglund, and S. Sindet-Pedersen, “Time to onset of analgesia and
analgesic efficacy of effervescent acetaminophen 1000 mg compared to tablet
acetaminophen 1000 mg in postoperative dental pain: a single-dose, double-
blind, randomized, placebo-controlled study,” The Journal of Clinical Phar-
macology, vol. 40, no. 4, pp. 370–378, 2000. 27
[118] P. Moller, S. Sindet-Pedersen, C. Petersen, G. Juhl, A. Dillenschneider, and
L. Skoglund, “Onset of acetaminophen analgesia: comparison of oral and
intravenous routes after third molar surgery,” British journal of anaesthesia,
vol. 94, no. 5, pp. 642–648, 2005. 27
[119] E. M. Camerone, A. Piedimonte, M. Testa, K. Wiech, L. Vase, D. A. Zam-
fira, F. Benedetti, and E. Carlino, “The effect of temporal information
on placebo analgesia and nocebo hyperalgesia,” Psychosomatic Medicine,
vol. 83, no. 1, pp. 43–50, 2021. 29
[120] E. M. Camerone, K. Wiech, F. Benedetti, E. Carlino, M. Job, A. Scafoglieri,
and M. Testa, ““external timing” of placebo analgesia in an experimental
model of sustained pain,” European Journal of Pain, 2021. 29
47
Chapter 2
The effect of temporal
information on placebo analgesia
and nocebo hyperalgesia
Published as:
Camerone, E. M., Piedimonte, A., Testa, M., Wiech, K., Vase, L.,
Zamfira, D. A., Benedetti, F. & Carlino, E. (2020). Psychosomatic
Medicine.
Eleonora Maria Camerone
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child
Health, University of Genova - Italy
Alessandro Piedimonte
Department of Neuroscience, University of Turin Medical School - Italy
Marco Testa
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child
Health, University of Genova - Italy
48
Katja Wiech
Nuffield Department of Clinical Neurosciences, University of Oxford - UK
Lene Vase
Department of Psychology and Behavioural Sciences, School of Business and Social Sciences,
Aarhus University - Denmark
Denisa Zamfira
Department of Neuroscience, University of Turin Medical School - Italy
Fabrizio Benedetti
Department of Neuroscience, University of Turin Medical School - Italy
Elisa Carlino




Objective. Expectations are known to be key determinants of placebo and
nocebo phenomena. In previous studies, verbal suggestions to induce such expec-
tations have mainly focused on the direction and magnitude of the effect while
little is known about the influence of temporal information. [121]
Methods. Using an experimental placebo and nocebo design, we investigated
whether information about the expected onset of a treatment effect modulates
the start and time-course of analgesic and hyperalgesic responses. Healthy vol-
unteers (N=166) in three placebo and three nocebo groups were informed that
the application of an (inert) cream would reduce (placebo groups) or amplify
pain (nocebo groups) after 5, 15 or 30 minutes. Two control groups were also
included (Natural History and No Expectations). Participants’ pain intensity
rating of electrical stimuli administered before and 10, 20 and 35 minutes after
cream application were obtained.
Results. Mixed-method analysis of variance showed a significant interaction
between group and time F (12, 262) = 18.172, p < 0.001, pη2 = 0.454, suggesting
that pain variations differed across time points and between groups. Post-hoc
comparisons revealed that placebo and nocebo groups began to show a signif-
icantly larger change in perceived pain intensity than a no-expectancy control
group at the expected time-point (p < 0.05) but not earlier (p > 0.05). Once
triggered, the analgesic effect remained constant over the course of the experiment
whereas the hyperalgesic effect increased over time.
Conclusions. Our results indicate that temporal suggestions can shape
expectancy-related treatment effects which – if used systematically - could open




The outcome of analgesic treatment has been shown to considerably de-
pend on an individual’s expectations. The anticipation of pain relief can boost
the treatment effect whereas expectations of increased pain can aggravate pain
[122; 123; 124]. Studies using brain imaging techniques have begun to unravel the
neural basis of expectancy effects on pain perception. They identified a network of
brain regions including the dorsolateral prefrontal cortex, rostral anterior cingu-
late cortex, periaqueductal gray and amygdala which modify pain-related brain
activity in a top-down fashion depending on the expectation of the individual
[125; 126; 127]. In experimental contexts, expectancy effects on the perception
of pain have mainly been studied using placebo or nocebo paradigms where par-
ticipants are led to believe that an inert substance or procedure will have an
analgesic effect (placebo) or a hyperalgesic effect (nocebo) [122; 123; 124; 128].
However, the modulatory influence of expectations has also been demonstrated
in clinical studies on pain [129; 130; 131] and other health conditions [132]. These
observations have recently inspired a new wave of research aiming to harness the
potential of positive expectations and avoid the detrimental effect of negative
expectations in clinical populations [133].
So far, research in this field has mainly focused on two characteristics of expec-
tation, namely its direction (i.e., whether the treatment is expected to improve
or aggravate symptoms) and magnitude (i.e., how strong the expected effect will
be). However, any expectation will also be linked to aspects of time – for in-
stance, when the treatment is going to take effect and for how long it is going to
last. Although some studies include information about the expected onset and
duration of the effect [134; 135; 136; 137], the influence of temporal information
on treatment outcome has not been studied systematically.
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Here, we investigated in healthy volunteers whether the onset of placebo anal-
gesia and nocebo hyperalgesia can be modulated by varying the information par-
ticipants receive about the onset of the expected treatment effect. We hypothesise
that the onset of the treatment effect (i.e., analgesia in placebo groups and hy-
peralgesia in nocebo groups) depends on the information provided and coincides
with the expected onset time.
2.3 Methods
2.3.1 Participants
166 healthy volunteers were recruited from the student population of the
University of Turin. Sample size calculation has been calculated using G*Power
(see Sample size calculation in Supplemental Digital Content Section 2.6.0.1.
Students were recruited during classes and were informed about the possibility
to participate in a study investigating the onset of action of an analgesic or
hyperalgesic cream. Those interested in participating in the study were contacted
by phone. Participants provided written informed consent before starting the
experiment. Signing the consent, all participants agreed that some details of
the experimental procedure would have been omitted during the experiment and
that they would be debriefed via email about the details of the study at the
end of the experiment. Both in the informed consent and in the debriefing email,
participants were told that they could decide to withdraw their consent and data;
no one decided to do so. Participants received neither payment nor credits to
participate in the study.
Data from nine participants were excluded from the analysis because they
met our outlier criteria (See Section 2.3.2.12), leading to a total sample size of
157 participants (for participants’ characteristics see Table 2.1). Data collection
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started in February 2019 and ended in June 2019. Participants had no history
of neurological, psychiatric, or other medical conditions and were instructed to
refrain from consuming alcohol or taking analgesic medication for at least 12 hours
prior to the experiment. Experimental procedures were conducted according to
the policies and ethical principles of the Declaration of Helsinki. The study
was approved by the Ethics Committee of the University of Turin (registration
number: 138875).
Age Sex BMI STAI-I STAI-II
Pain
baseline
Mean SEM Females/Males Mean SEM Mean SEM Mean SEM Mean SEM
NH 25.37 0.83 F=9; M=10 21.13 0.47 32.58 1.69 38.74 1.64 2.59 0.27
NE 24.7 0.63 F=9; M=12 22.14 0.58 30.57 1.21 39.33 1.57 3.01 0.25
P5 22 0.36 F=10; M=11 21.55 0.49 31.19 1.42 37.52 1.84 2.43 0.22
P15 22.1 0.23 F=10; M=10 20.95 0.58 31.7 1.13 38.05 2.27 2.52 0.21
P30 22.7 0.25 F=12; M=8 21.82 0.58 33.55 1.56 38.75 1.42 2.59 0.24
N5 22.16 0.22 F=12; M=7 20.95 0.55 32.32 1.3 41 2.45 2.46 0.22
N15 22.74 0.4 F=10; M=9 21.1 0.46 32.32 1.27 39.84 2.12 2.78 0.23
N30 22.78 0.34 F=12; M=6 21.53 0.53 32.17 1.32 39.44 1.56 3.23 0.27
Table 2.1: Mean and standard deviation (SEM) of age, sex, BMI, STAI-I/II and
pain intensity at baseline.
2.3.2 Experimental design
Participants were assigned to one of three placebo groups, three nocebo
groups, a no expectancy (NE) group or a natural history (NH) group (see be-
low for details; Figure 2.1). The NH group was filled first, as a form of pilot
study. For this reason, this group has been excluded from the primary analysis
and only serves as control for pain perception fluctuations over time. The re-
maining participants were divided into the seven experimental groups (i.e. NE
group, Placebo groups, Nocebo groups) using stratified randomization in order
to control for demographic variables (e.g. age and sex) [138].
2.3.2.1 Placebo groups
Participants in the placebo groups were informed that an analgesic cream
would be applied to reduce the painful sensation induced by an electrical stim-
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Figure 2.1: Experimental Groups: Placebo and nocebo groups received different
temporal information. P5 and N5 expected the effect of the treatment to set in 5
minutes after cream application, P15 and N15 after 15 minutes and P30 and N30
after 30 minutes. The no expectancy and natural history do not receive temporal
instructions.
ulation (See Section 2.6.0.2). They were led to believe that the analgesic would
become effective after 5 minutes (Positive Verbal Suggestion 5 Group, P5 group,
N=21), 15 minutes (Positive Verbal Suggestion 15 Group, P15 group, N=20) or
30 minutes (Positive Verbal suggestion 30 Group, P30group, N=20). The 5 min-
utes interval was chosen to mimic the effect of a fast-acting analgesic, whereas
the 15 and 30 minute interval were intended to resemble the effect of analgesics




Participants in the nocebo groups were informed that a hyperalgesic cream
would be applied to increase the painful sensation induced by the electrical stim-
ulation. Participants were informed that the hyperalgesic effect would set in
after 5 minutes (Negative Verbal Suggestion 5 Group, N5 group, N=19), after
15 minutes (Negative Verbal Suggestion 15 Group, N15 group, N=19) or after
30 minutes (Negative Verbal Suggestion 30 Group, N30 group, N=18). The time
intervals were identical to those used in the placebo groups.
2.3.2.3 No expectancy group
Participants assigned to the No Expectancy Group (NE group, N=21) were
informed that an inert cream would be applied that would have no effect on their
pain perception.
2.3.2.4 Natural history group
A Natural History Group (NH group, N=19) was added to control for the
natural course of pain. In this group, no cream was applied and no verbal sug-
gestions concerning treatment effectiveness were given.
2.3.2.5 Noxious stimulation
Pain was induced using electrical stimuli delivered by a somatosensory stimu-
lator (Neuroscan, Compumedics, Charlotte, NC, USA). See Noxious stimulation
in the Supplemental Digital Content Section 2.6.0.2 for more details.
2.3.2.6 Pain intensity ratings
All participants were instructed to rate the perceived intensity of the ten
noxious electrical stimuli 10 minutes (Test10’), 20 minutes (Test 20’) and 35
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minutes (Test 35’) after the cream had been applied. Ratings were provided
verbally using the same NRS as during the calibration phase (i.e., 0 representing
no pain, 1 the beginning of a painful sensation, 5 moderate and 10 unbearable
pain) and were recorded by the experimenter.
2.3.2.7 Assessment of expectations and anxiety
Participants completed the State-Trait Anxiety Inventory (I-II) [139] prior
to the actual experiment, to assess potential baseline differences in anxiety level
between groups. Moreover, after the experiment, they were asked to rate their
expectations about the efficacy of the cream. The question asked was: “Before the
experiment, what was your expectation about the analgesic action of the cream?”.
Five possible answers were proposed: 1) the cream will completely reduce my
pain; 2) the cream will partially reduce my pain; 3) the cream will slightly reduce
my pain; 4) the cream will not alter my pain; 4) the cream will increase my pain.
Questions were reversed for the nocebo groups, in which the hyperalgesic action
of the nocebo cream was investigated.
2.3.2.8 Experimental procedure
The experimental procedure is summarized in Figure 2.2. Participants sat on
a chair with the right arm placed on a desk in front of them. A customised wall
clock with 5-minute intervals (i.e., 5 to 55) was positioned in front of them. The
clock face also showed an icon of a cream tube at the 12 o’clock position to indicate
the time-point at which the cream had been applied. Participants were informed
that the clock was used to help them keep track of time and to know when the next
test session was imminent. Following calibration of the individual stimulation
intensity, participants were familiarised with the experimental setup in a practice
run. After a 5 minutes break, the actual experiment commenced with the baseline
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session. Subsequently, participants were informed about the group they had been
assigned to and the cream was applied in all groups except the no treatment group
along with the verbal instructions (See Section 2.3.2.11 for details). Immediately
after the cream had been applied, the experimenter adjusted the clock so that
the minute hand pointed at the 12 o’clock position, indicating the time of cream
application (‘Time 0’). Although no cream was applied in the no treatment
group, the same procedure was followed and participants were told that ‘Time 0’
referred to the time at which the cream would have been applied if they had been
allocated to the active condition. Ten minutes after cream administration, the
first test session was run (Test 10’) which was followed by a 10 minute rest period.
The second test session was completed 20 minutes after cream application (Test
20’) and followed by a 15 minute rest period. Participants underwent the third
and final test session 35 minutes after cream application (Test 35’). Note that the
test was performed 10, 20 and 35 minutes after cream application and not after
5, 15 and 30 minutes, which were the specific time points at which participants
expected the cream to set in, depending on group allocation. We allowed a 5-
minute leeway to avoid participants doubting that the effect of a cream could be
so precisely timed (i.e., setting in exactly after 5, 15 and 30 minutes). During the
rest periods between test sessions participants were instructed to relax and were
given the opportunity to read, study or use their phone. Although participants
were able to track time by looking at the watch in front of them, the experimenter
communicated verbally that the next test session was about to start by saying
“Okay, now we will repeat the test again”.
2.3.2.9 Verbal suggestions
Participants in the placebo groups expected to receive a cream that would
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Figure 2.2: Experimental protocol: Diagram showing each experimental step
(A). Firstly, pain threshold assessment. Secondly, familiarization trial followed,
after a 5 minutes break, by the Baseline Session. Thirdly, cream administration
along with verbal instructions which varied accordingly with group allocation.
Lastly, the three Test Sessions occurring after 10, 20 and 35 minutes from cream
application. Stimuli intensity remains stable within and across pain trials. To be
noted that the NH group was not included in the randomization and was part
of a pilot study. The image next to the diagram (B) shows experiment set up,
including the customised wall clock facing the participant.
decrease their pain (analgesic cream), whereas participants in the nocebo groups
expected to receive a cream that would increase their pain (hyperalgesic cream).
The instructions were provided at the time-point of cream application. Below, an
example of the instructions provided to the P5/N5 group is reported. “Studies
have shown that this is an effective analgesic/hyperalgesic cream. Specifically,
they have shown that this cream already takes effect after 5 minutes from its ap-
plication. Therefore, we expect that all the tests we will do after this moment
are under the effect of the cream, for this reason you will feel less/more pain
(compared to the first test) in all three test sessions after 10, 20 and 35 min-
utes [experimenter points at time 10, 20 and 35 minute marks on the clock]”.
Participants in the NE group were told that an inert cream would be applied:
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“The agent you will receive is an inert cream that only has hydrating properties
but no effect on pain perception. The pain at the three test sessions after 10,
20 and 35 minutes [experimenter points at time 10, 20 and 35 minute marks on
the clock] will therefore be similar to the first baseline”. Participants in the NH
group were told that they would receive no treatment and the following instruc-
tions were given: “Your group serves to assess natural variations of pain over
time. Your pain may vary or may remain the same. Simply report your perceived
pain intensity when you are prompted to do so”.
2.3.2.10 Cream
A sham cream was administered in the placebo, nocebo and NE groups.
It consisted of AquaGel Solution (2g) and water (17ml) and was presented to
participants in a clear plastic tube. The experimenter applied the cream within a
radius of 2cm around the electrode and massaged it into the skin to ensure that
it was fully absorbed.
2.3.2.11 Debriefing
Participants were debriefed via email, giving details on the real aim of the
study, a list of readings on the topic, as well as the possibility of discussing doubts
or concerns with their data being used.
2.3.2.12 Statistical analyses
Analyses were performed using Statistica Software (StatSoft, version 9 for
Windows). First, a mean pain intensity rating was calculated for each time-point
(i.e., baseline and T10’, T20’ and T35’) by averaging across the 10 ratings per
time-point, resulting in four mean pain intensity ratings for each participant.
Second, these average measures were tested for normal distribution using the
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Shapiro-Wilk test. The test did not report significance for any of the variables.
Before running further statistical analyses, the data were screened for outliers.
Participants were defined as outliers and discarded from further analysis if any of
their average pain intensity ratings were 2.5 times the standard deviation higher
or lower than their group mean value. Two outliers were removed from the NH
group (N=19), the N15 group (N= 19) and the N30 group (N=19). One outlier
was excluded from the NE group (N=21), the P30 group (N=20), and the N5
group (N=19). The final sample size was therefore 157 participants. To test for
baseline differences in demographic variables, baseline pain intensity scores and
STAI I-II scores, we first compared the eight groups using an analysis of variance
(ANOVA) for continuous variables, or Chi-square test for categorial variables.
Turning to pain intensity ratings, to test whether pain perception changed over
time irrespective of treatment and treatment onset expectations, changes in mean
pain ratings of the NH group for the four different time-points were analyzed
separately using repeated measure ANOVA. Similarly, to investigate whether the
application of the cream in itself (e.g. moisture, sensation of freshness) interacts
with pain perception, repeated measure ANOVA was used to assess pain rating
changes the four different time-points in the NE group. To test whether placebo
and nocebo effects occurred, we conducted 6 repeated measure ANOVAs, one
for each experimental group (P5, P15, P30, N5, N15, N30), to evaluate changes
in mean pain ratings (raw scores) within each group for the four different time-
points.
Subsequentially, we calculated the percentage change in NRS scores from the
Baseline Session to each Test Session (delta%, ∆%) in the placebo and nocebo
groups. Thus, three ∆s were calculated for each group, corresponding to the
percentage change in pain perception at T10’, T20’ and T35’ (∆10, ∆20 and
∆35, respectively). To compare the effect of information regarding the onset of
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the expected treatment effect between groups, ∆10, ∆20 and ∆35 of the placebo,
nocebo and no expectancy group were entered into a 3 x 7 mixed ANOVA with
the within-group factor TIME (3 levels: T10’, T20’ and T35’) and between-group
factor GROUP (7 levels: P5, P15, P30, N5, N15, N30 and NE). Significant effects
were followed up using pairwise Student-Newman-Keuls (SNK) post hoc tests.
To investigate the significant results of the factor GROUP and the interaction
between GROUP and TIME (see Section 4.4), the placebo and the nocebo groups
were compared against the NE group, which served as a reference. To explore the
duration of the induced effects in each group, changes in pain intensity relative
to baseline (i.e., ∆10, ∆20 and ∆35) were compared separately for P5, P15, N5
and N15.
Furthermore, as done in other studies [140], sex, age and BMI were included
as covariates. Since we found no significant effects of these covariates on pain
perception nor interactions between these predictors and results were identical to
the 3 x 7 mixed ANOVA, we have only included the more parsimonious analysis.
To investigate the possible influence of anxiety (scores of STAI I and STAI II)
on pain perception, two correlation analysis were performed: 1) a correlation
analysis between anxiety scores and mean pain intensity ratings at Baseline and
2) a correlation analysis between anxiety scores and the percentage (∆) of pain
decrease (in the placebo groups) and increase (in the nocebo groups) after the
application of the cream (i.e. ∆10 in P5 and N5 groups, ∆20 in P15 and N15
groups, ∆35 in P30 and N30 groups). To investigate the possible influence of
expectations of treatment efficacy on pain perception, a correlation analysis was
performed between expectancy scores and the percentage (∆) of pain decrease
(in the placebo groups) and increase (in the nocebo groups) after the application
of the cream. Note that data from the NH group were not included in further
analyses as participants in this group did not show a significant change in pain
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perception over time (Section 2.4.0.1). Data are presented as mean ± standard
error of the mean (SEM), and the level of significance was set at p < 0.05.
2.4 Results
The groups did not differ with respect to age, Sex, BMI, state (STAI-I) and
trait (STAI-II) anxiety scores nor pain intensity at baseline (p > 0.05 for all
comparisons) (See Table 2.1 in Section 2.6)
2.4.0.1 Effects of no treatment
Repeated measure ANOVA showed no significant changes in mean pain rat-
ings of the NH group for the four different time points [F(3,54)=0.664, p =
0.578, pη2 = 0.181]. This indicates that without cream administration and verbal
instruction regarding expected changes in pain perception, pain remained stable
over the entire course of the experiment. Repeated measure ANOVA showed
a significant main of time on mean pain ratings in the NE group [F (3, 60) =
2.88, p = 0.043, pη2 = 0.660]. SNK post hoc tests reported a tendency to signifi-
cance when comparing baseline with T10 (p = 0.051) and T20 (p = 0.057), and
significant pain increase between baseline and T35 (p = 0.044). This suggests
that pain perception tends to increase with time when the inert cream is applied
with no expectation modulation.
2.4.0.2 Placebo and Nocebo Raw Data Analysis
Three repeated measure ANOVAs for the three placebo groups showed signifi-
cant changes in mean pain rating for P5 [F (3, 60) = 9.77, p < 0.001, pη2 = 0.997],
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P15 [F (3, 57) = 22.86, p < 0.001, pη2 = 1.000], P30 [F (3, 57) = 15.01, p <
0.001, pη2 = 1.000], for the four different time points. In P5 group, SNK post hoc
tests showed a significant reduction in mean pain ratings from baseline to T10,
T20 and T35 (p < 0.001), suggesting that placebo analgesia occurs in all the Test
Sessions occurring 10 minutes after cream application. However, no significant
difference was shown between T10 and T20 (p = 0.254), T10 and T35 (p = 0.334)
and T20 and T35 (p = 0.786), indicating that placebo analgesia remains stable
once triggered. In P15 group, SNK post hoc tests indicated a significant decrease
in pain ratings from baseline to T20 (p < 0.001) and to T35 (p < 0.001). Simi-
larly, a significant decrease was reported from T10 to T20 and from T10 to T35
(p < 0.001). These comparisons show that placebo analgesia arise in the two
test sessions occurring after 20 minutes from cream application. No significant
difference was shown between T20 and T35 (p = 0.839) showing, similarly to P5,
that once analgesia is triggered it remains stable over time. In P30 group, SNK
post hoc tests reported a significant decrease in pain ratings from baseline to T35
(p¡0.001), from T10 (p = 0.001) to T35 and from T20 to T35 (p < 0.001) showing
placebo analgesia to arise in the final test session, after 35 minutes from cream
application.
Three repeated measure ANOVAs for the three nocebo groups showed sig-
nificant changes in mean pain rating for N5 [F (3, 54) = 26.27, p < 0.001, pη2 =
1.000], N15 [F (3, 54) = 33.40, p < 0.001, pη2 = 0.997], N30 [F (3, 51) = 26.44, p <
0.001, pη2 = 1.000], for the four different time points. In N5 group, SNK post
hoc tests showed a significant increase in mean pain ratings scores from baseline
to T10 (p < 0.001), T20 (p < 0.001), and T35 (p < 0.001), suggesting that no-
cebo hyperalgesia occurs in all the test sessions occurring after 10 minutes from
cream application. Additionally, significant increase in pain ratings was reported
between T10 and T20 (p = 0.045) and between T10 and T35 (p = 0.006), suggest-
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ing that once triggered, nocebo hyperalgesia increases over time. In N15 group,
SNK post hoc tests indicated a significant increase in pain rating from baseline
to T20 (p < 0.001) and to T35 (p < 0.001) as well as from T10 to T20 and to T35
(p < 0.001). These comparisons indicate that nocebo hyperalgesia occurs during
the two test sessions after 20 minutes from cream application. In this case also, a
significant increase was shown between T20 and T35 (p=0.011). Therefore, the
N5 and N15 groups agree that once nocebo hyperalgesia is triggered, it increases
over time in this study. In N30 group, SNK post hoc tests displayed a significant
increase in pain ratings from baseline to T35 (p < 0.001), from T10 (p < 0.001)
to T35 and from T20 to T35 (p < 0.001) showing nocebo hyperalgesia to arise in
the final test session, after 35 minutes from cream application.
2.4.0.3 Placebo and Nocebo Percentage Change Analysis
The 3x7 mixed ANOVA revealed a significant main effect of TIME (F (2, 262) =
7.363), p = 0.001, pη2 = 0.053) and a significant main effect of GROUP (F (6, 131) =
31.701, p < 0.001, pη2 = 0.069). See Section 2.6.0.3 for more details. Most impor-
tantly, we found a significant interaction between TIME and GROUP (F (12, 262) =
18.172, p < 0.001, pη2 = 0.454) (Figure 2.3).
Comparisons between placebo groups (P5, P15, P30) and the NE group
showed significantly stronger pain reduction in the P5 group after 10 (p = 0.003),
20 (p < 0.001) and 35 (p < 0.001) minutes. In the P15 group, the analgesic
effect was stronger after 20 (p < 0.001) and 35 minutes (p < 0.001) whereas the
P30 group only showed a significantly stronger decrease in pain after 35 minutes
(p < 0.001). These results indicate that the analgesic effect strictly followed the
verbal information about the expected onset of the analgesic effect. As previ-
ously reported in the raw data analysis, P5 and P15 did not show differences
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in perceived pain after analgesia onset, confirming that once triggered, placebo
analgesia is stable over time.
Figure 2.3: Results are presented as percentage of change (∆%) from Baseline in
each test (Test 10, Test 20, Test 35). Left side: groups where the expected onset
of action of the treatment was 5 minutes (plus no expectancy group). Middle:
groups where the expected onset of action of the treatment was 15 minutes (plus
no expectancy group). Right side: groups where the expected onset of action
of the treatment was 30 minutes (plus no expectancy group). Gray bars depict
the NE group, green bars (light, middle and dark) depict placebo groups and red
bars (light, middle and dark) depict nocebo groups. Asterisks represent significant
differences (∗ = p < 0.05; ∗∗ = p < 0.01; ∗ ∗ ∗ = p < 0.001). Error bars represent
standard errors of the mean (SEMs).
Turning to the nocebo groups (N5, N15, N30), the N5 group showed a signifi-
cantly stronger increase in pain ratings than the NE group after 10 (p = 0.02), 20
(p < 0.001) and 35 (p < 0.001) minutes. In the N15 group, a significantly stronger
pain increase compared to the NE group was found only after 20 (p = 0.006) and
35 (p < 0.001) minutes. In the N30 group, a significant pain increase was only
detected after 35 minutes (p = 0.007).Again, these results suggest that the effect
on pain perception strictly follows the verbal information provided. In contrast
to the placebo effect which remained stable over time, the hyperalgesic effect
became stronger over the course of the experiment. In the N5 group, ∆35 was
significantly larger than ∆10 (p = 0.002). Similarly, an increasing hyperalgesic
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effect was found in the N15 group with a larger ∆35 than ∆20 (p = 0.013). These
results replicate what previously shown in the raw scores analysis, and indicate
that, once the hyperalgesic effect has set in it continues to increase over time. To
further explore this effect, compared to stable placebo analgesic effects, a series of
t-test was performed in order to specifically compare ∆s between the N5 and P5
groups, as well as between the N15 and P15 groups. Results showed significant
differences only between ∆35 of N5 compared to P5 (p = 0.028) and ∆35 of N15
compared to P15 (p = 0.011).
Finally, considering the effect of anxiety scores on pain perception, we found a
positive correlation between STAI II and the percentage (∆) of pain increase after
the application of the cream in the nocebo groups (r(56) = 0.329, p = 0.013), but
not in the placebo group. No significant correlation between expectancy scores
and the percentage (∆) of pain decrease (in the placebo groups) and increase (in
the nocebo groups) after the application of the cream was found.
2.5 Discussion
This study demonstrates for the first time that verbal information regarding the
expected onset of a treatment effect can influence the time-course of placebo and
nocebo effects. Participants who had been informed that the cream would take
effect promptly following application showed an early analgesic (placebo group)
or hyperalgesic effect (nocebo group). Similarly, both effects only set in later in
those who expected their treatment effect to unfold after a longer delay.
Previous studies have shown that verbal information can stir placebo and no-
cebo effects [124; 141; 142]. However, the majority of these studies focused on
information about the direction (e.g., increase or decrease of pain) [131; 143; 144]
or the magnitude of the effect (e.g., strong or weak) [145; 146]. Results of the
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present study demonstrate that expectations also contain a temporal aspect that
determines the onset of placebo analgesia and nocebo hyperalgesia and that can
be modulated through information provided to the individual. Our observation
of a delayed analgesic response could therefore be of interest in clinical contexts
where - due to the pharmacological properties of the treatment - the effect of an
intervention only becomes noticable to the patient after days or even weeks. For
instance, the delayed mechanism of action of certain antidepressants requires pa-
tients to maintain their positive treatment expectations over an extended period
of time until the drug has reached the required blood concentration to take effect.
Informing patients about the delayed onset could prevent (premature) abandon-
ment of positive treatment expectations during the period when no treatment
effect is detectable (yet) and preserve the supportive effect of these expectations
for the time-point when the pharmacological effect sets in. Our findings show that
the positive influence of expectations on pain perception could be withheld for at
least 30 minutes. Whether these encouraging findings translate to longer delays
requires further investigation. Regarding the magnitude of the effects found, we
reported a 25.6% pain decrease in the placebo groups (that is mean pain reduc-
tion from the baseline after the sham analgesic cream took effect) and a 37.5%
pain increase in the nocebo groups (mean pain increase from the baseline after
the sham hyperalgesic cream took effect). Considering the baseline ratings of the
different groups, this result equals an overall mean decrease of 0.6 points in the
NRS in the placebo groups and an overall mean increase of 1 point in the NRS
in the nocebo groups. While these are small changes from the baseline values,
similar ranges of pain ratings have been observed in recent experimental studies
using behavioral paradigms [147; 148] as well as in classic neuroimaging studies
[149]. Here we demonstrated the effect of verbal information following the appli-
cation of an inert substance, but verbal information can also affect the efficacy of
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active treatments. Information leading to expectations of pain relief doubled the
analgesic outcome of an opioid treatment whereas information inducing negative
expectations abolished its beneficial effect [125].It follows that the small effects
of placebo and nocebos interventions become larger when delivered in associa-
tion with active treatments, rendering such phenomena valuable strategies in the
clinical context. However, the impact that temporal information can have on the
clinical setting is yet to be explored. Future studies are needed to investigate
clinical conditions, such as low back pain or neuropathic pain, in order to achieve
more ecological results. The effect of temporal information on analgesia should
be explored when delivered in association with active treatments.
A second important finding of this study relates to the changes in placebo
and nocebo effects once they have been triggered. As shown in Figure 2.3, the
hyperalgesic effect becomes stronger over the course of the experiment while the
analgesic effect remained stable. Given that the stimulation was calibrated to the
same perceived level in all groups, and neither the placebo nor the no treatment
groups showed an increase in pain ratings, it seems unlikely that the hyperal-
gesic effect was the result of peripheral sensitization. Contemporary models of
perception, such as the predictive coding model [150], have offered explanations
for such changes in perception which are rooted in the understanding that any
type of perception is based on an inferential process. In this framework, incoming
sensory information is compared to expectations which the individual holds. If
sensory input is as expected, the expectation is confirmed. However, if expecta-
tions and incoming information are incongruent, the expectation will be updated
following a learning rule that determines the translation of expectancy violation
(formalized as prediction error) into expectation updating. Within this frame-
work, two scenarios could explain the difference between the placebo and nocebo
group we observed. First, the intensity of the noxious input at T10 confirmed
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expectations in the placebo group but was stronger than expected in the nocebo
group. As a result, expectations would be updated (towards a higher intensity)
only in the nocebo group. Alternatively, a similar discrepancy between expec-
tation and incoming information might have been detected in the placebo and
nocebo groups but a different learning rule was applied that led to an upwards
correction of expectations (and subsequently of the perceived stimulus intensity
in subsequent test sessions) in the nocebo group but not the placebo group. A
recent study using a cue probability paradigm suggested a similar asymmetry in
expectation updating [126] which might be driven by the higher biological rele-
vance of an aggravation of aversive sensory experience (as in the nocebo condition)
compared to a turn for the better (as in the placebo condition). Because we did
not acquire trial-by-trial expectancy ratings and are therefore unable to verify
whether expectancy ratings were adapted between test sessions, further studies
are needed to explore the link between the changes in pain perception over time
and expectation updating. This study also confirms the crucial role of anxiety on
nocebo effects and is in line with previous data that highlight how anxiety affect
hyperalgesia [151; 152].
Some limitations of the present study need to be considered. The first source
of limitation to be discussed here is the number of participants. Even though
more than 160 participants were recruited, different shortcomings of the current
experiment could be derived from the smaller number of participants included
in each experimental group (i.e. NE, P5, P15, P30, N5, N15, N30). Firstly,
the use of the SNK post hoc test instead of more strict corrections for multiple
comparisons, such as the Bonferroni correction, could be questioned. However,
we performed a planned-comparison Bonferroni correction which resulted in the
same significant results highlighted by the SNK test, leaving out only the differ-
ence between ∆10 and ∆35 in the N5 group, thus confirming our main results
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and conclusions. In addition, this study is the first to directly investigate the
temporal aspects of placebo/nocebo effects. Therefore, the usage of a less strict
post hoc test can be justified because it allows to discover important albeit small
differences that are present in new and poorly understood phenomena [153; 154].
The second limitation stemming from the low number of participants is the lack
of a full randomization assignment in favor of a stratified randomization due to
the need to balance specific characteristics, such as sex and age between groups.
However, adding sex, age and BMI characteristics as covariates to the main anal-
ysis did not show any significant impact of these factors on pain perception nor
significant differences between groups regarding these variables. Still, future stud-
ies, possibly focusing on one single experimental question (e.g. focusing only on
placebo analgesia or nocebo hyperalgesia), should reach a higher number of par-
ticipants per group to avoid these limitations. The second source of limitation
is that our study focused on rather low pain intensities (NRS below 5) which
may have induced a “floor effect” such that nocebo effects (i.e. changes toward
the higher part of the scale) could have been overestimated, while placebo effects
(i.e. changes toward the lower part of the scale) could have been underestimated.
Nonetheless, the investigation of the magnitude of these effects goes beyond the
purpose of the present study. Further research is needed to explore whether our
findings persist with the use of more intense pain stimuli as well as in clinical con-
texts. The third source of limitation is that verbal instructions used in this study
were directive as they not only described the drug effect (i.e., increases/decreases
pain) but anticipated what the participant is going to feel. Although it could be
argued that these suggestions make it difficult to discriminate between placebo
and nocebo responses and a simple ‘experimental demand’ effect, other studies
have used similar instructions [155; 156]. Future studies should focus on the
description of the drug effect and should involve more objective measure of pain
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perception (neuroimaging or electrophysiological measure) to confirm that partic-
ipants are actually reporting their pain changes rather than following experimen-
tal demand. Indeed, our study results are based on participants’ pain intensity
ratings only. Although these ratings have been shown to correlate with peripheral
(e.g., skin conductance and heart rate [138; 157] and central measures including
activity in brain regions associated with pain processing [126; 127], follow-up
studies should consider simultaneous recording of these measures to investigate
accompanying changes in objective parameters; examples include neuroimaging
studies and electrophysiological measures of pain expectations [124; 136]. Given
the multi facet nature of pain perception and the importance of expectation of
pain, future studies on the temporal aspects of placebo analgesia or nocebo hyper-
algesia should also collect behavioral measures before the experimental sessions
such as “a priori” questionnaires on expectations but also subjective reports on
the unpleasantness of the pain stimuli during the different time frames.
To conclude, our data suggest that the delivery of temporal information in-
fluences the onset of placebo analgesia and of nocebo hyperalgesia. Even if these
findings have been collected in an a strictly experimental context, their potential
implications in a clinical context are remarkable and additional work is required
to explore how our findings relate to the effect of active drugs. Strategic timing
of treatment effects through targeted temporal information may have the po-
tential to substantially enhance desired therapeutic effects and delay or abolish
unwanted side effects.
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2.6.0.1 Sample size calculation
Sample size calculation was performed on the basis of Van Laarhoven et al.
[156] because the design of that study was the most similar to ours. Specifically,
placebo analgesia and nocebo hyperalgesia were induced with verbal suggestions
alone, as well as cream being used to induce deception. Our sample size calcula-
tion was conducted using G*Power and it was based on Van Laarhoven et al.’s
(2011) [156] effect size (η2 = 0.372). Based on this, our recommended sample size
per group is of 21 subjects (level of significance set at 5% and a statistical power
set at 90%).
2.6.0.2 Noxious stimulation
Two silver chloride electrodes were positioned on the ventral side of the right
forearm. The electrodes were placed on the forearm, between the ventral side of
the wrist and of the elbow; at a distance from the wrist equal to half the distance
between the tip of the middle finger and the wrist line. The stimulation intensity
was calibrated using an ascending staircase method [158]. Three series of electrical
stimuli were delivered, starting at an intensity of 0.5 mA, and increasing in steps
of 0.5 mA. Each stimulus was 1 second long and was comprised of a square pulse
of 500 µs duration being delivered at a frequency of 1Hz. Participants had to
rate the perceived intensity of each stimulus on a Numerical Ratings Scale (NRS)
ranging from 0 to 10, where 0 indicated no pain, 1 represented the beginning
of a painful feeling, 5 moderate pain and 10 unbearable pain [122; 141]. The
calibration run was stopped when participants’ ratings reached pain threshold
(i.e., when the intensity of the stimulus was rated as 1). The threshold was
calculated as the average of the three pain threshold intensities. During the
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actual experiment, a total of ten stimuli, with 1.5 times the current used to set
the initial pain threshold, were delivered in the practice run, baseline and each
of the three test time-points.
2.6.0.3 Placebo and Nocebo Percentage Change Analysis
The main effect of TIME indicated that changes in pain rating (relative to
baseline) differed between test time-points across groups. Pairwise SNK tests
found a significant difference between ∆10 and ∆35 (p=0.002), a trend towards
a significant difference between ∆20 and ∆35 (p=0.056), but no significant dif-
ference between ∆10 and ∆20. The significant main effect of GROUP indicated
that changes in pain ratings differed between groups irrespective of the time-point.
SNK post hocs were computed, comparing groups across time-points. The three
placebo groups showed a significantly stronger pain reduction (lower overall ∆s)
compared to the NE group (P5, p < 0.001; P15, p < 0.001; P30, p < 0.001). How-
ever, changes in pain did not differ significantly between P5, P15 and P30 which
indicates that changes in pain intensity were comparable between the placebo
groups if time is not taken into account. For the nocebo groups we found a sig-
nificantly greater increase in pain in N5 and N15 relative to the NE group (N5,
p < 0.001; N15, p = 0.007), whereas no significant difference was found between
N30 and NE. Comparison between nocebo groups showed no difference between
N5 and N15, however significantly higher increase in pain occurred between N5
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Background. Research on placebo analgesia commonly focuses on the im-
pact of information about direction (i.e., increase or decrease of pain) and mag-
nitude of the expected analgesic effect, whereas temporal aspects of expectations
have received little attention so far. In a recent study, using short-lasting, low-
intensity stimuli, we demonstrated that placebo analgesia onset is influenced by
temporal information. Here, we investigate whether the same effect of temporal
suggestions can be found in longer lasting, high-intensity pain in a Cold Pressor
Test (CPT).
Methods. Fifty-three healthy volunteers were allocated to one of three
groups. Participants were informed that the application of an (inert-) cream
would reduce pain after 5 min (P5) or 30 min (P30). The third group was
informed that the cream only had hydrating properties (NE). All participants
completed the CPT at baseline and 10 (Test 10) and 35 min (Test 35) following
cream application. Percentage change in exposure time (pain tolerance) from
baseline to Test 10 (∆10 ) and to Test 35 (∆35 ) and changes in heart rate (HR)
during CPT were compared between the three groups.
Results. ∆10 was greater in P5 than in NE and P30, indicating that analgesia
was only present in the group that was expecting an early onset of analgesia. ∆35
was greater in P5 and P30 compared to NE, reflecting a delayed onset of analgesia
in P30 and maintained analgesia in P5. HR differences between groups were not
significant.
Conclusions. Our data suggest that ‘externally timing’ of placebo analgesia
may be possible for prolonged types of pain.
Significance. Research on placebo effects mainly focuses on the influence
of information about direction (i.e., increase or decrease of pain) and magnitude
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(i.e., strong or weak) of the expected effect but ignores temporal aspects of ex-
pectations. In our study in healthy volunteers, the reported onset of placebo
analgesia followed the temporal information provided. Such ‘external timing’ ef-
fects could not only aid the clinical use of placebo treatment (e.g., in open-label
placebos) but also support the efficacy of active drugs.
3.2 Introduction
Pain is understood to not only be determined by noxious afferent input but
also by the individual’s expectations [159]. Although this influence has been
demonstrated in various experimental paradigms, placebo analgesia remains the
most intriguing of them. The mere information that one has received a potent
painkiller can lead to substantial pain reduction – even though the ‘painkiller’
contains no analgesic properties. Experimental and clinical studies aiming to har-
ness the power of expectations have focused on providing information about the
direction (i.e., whether treatment is expected to ameliorate or aggravate symp-
toms) [160; 161; 162] and magnitude of the expected effect [163] but have so
far ignored that expectations also include a temporal aspect that determines
when the desired effect is expected to set in and how long it lasts. In a re-
cent study we demonstrated that temporal information about the expected onset
of the placebo effect determines the reported start of pain reduction suggesting
that ‘external timing’ of placebo effects is possible [164]. By ‘external timing’
we mean the unfolding of the placebo response in line with externally provided
temporal information. While participants who were told that the placebo effect
would commence after five minutes reported early pain reduction, those who were
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instructed that the analgesic effect would only set in thirty minutes after cream
application showed a delayed onset in their analgesic response. Like many experi-
mental pain studies, we used short-lasting electrical stimuli to probe the influence
of temporal information. While this phasic pain model offers several advantages
in an experimental setting (e.g., more repetitions for a higher number of trials),
it has been criticized for its limited ecological validity [165; 166]. Furthermore,
the short duration and low stimulus intensity might have made it easy for verbal
suggestions to bias perception. According to contemporary models of perception,
verbal suggestions shape expectations which serve as a prior in an inferential pro-
cess that interprets incoming sensory information [167]. Importantly, the relative
impact of sensory information in this process critically depends on its precision.
Expectations are more likely to impact perception when stimuli are weak, noisy
and ambiguous [168; 169], such as the short-lasting, low-intensity electrical stim-
uli we used in the previous study. The temporal shift in the onset of the placebo
response we found might therefore at least partly be explained by these stimulus
features. Here, we investigated whether the modulatory effect of temporal infor-
mation on the onset and duration of placebo analgesia extends to more intense,
longer-lasting (tonic) pain in a Cold Pressor Test (CPT). The test assesses pain
tolerance operationalised as the time participants are able to keep their hand
in ice-cold water before the pain becomes unbearable. This paradigm allowed
us not only to investigate whether tonic pain is equally susceptible to temporal
information as phasic pain, but also to use a behavioural outcome measure (i.e.,






Seventy-seven healthy volunteers were recruited from the student population
of the Vrije Universiteit Brussel (VUB), Belgium. Participants had no history of
neurological, psychiatric, or other chronic medical conditions and were instructed
not to consume alcohol or analgesic medication twelve hours prior to the exper-
iment. 29 participants had to be excluded: one participant developed muscle
cramps in her arm during the experiment, whilst 28 participants did not with-
draw their hand from the ice water within the maximum exposure time that we
set for safety reasons - i.e. maximum exposure time was set at 10 min during the
familiarisation trial and at 15 min during the test sessions [170; 171]. Of these
28, 26 exceeded the maximum exposure time during the familiarisation trial,
i.e., before participants were assigned to the different groups. The remaining 2
out of these 28 participants which were ultimately excluded reached maximum
exposure time during one of the test sessions (baseline, test10, test35). The fi-
nal sample therefore comprised 48 participants. Participants were informed they
would take part in a study investigating the onset of the effect of a newly de-
veloped analgesic cream. All participants provided written informed consent in
which they also agreed to be debriefed about the details of the study at the end
of the experiment. All experimental procedures were conducted in accordance
with the policies and ethical principles of the Declaration of Helsinki. The study





Participants were randomised by blind extraction to one of two placebo groups
or a control group.
3.3.2.1 Placebo groups
In the two placebo groups, participants were informed that the inert cream
(see details below) that was applied contained an analgesic substance that would
reduce the painful sensation induced during the CPT. The two groups differed
in the information they received about the expected onset of the analgesic ef-
fect. The first placebo group was led to believe that the analgesic would become
effective after 5 min (Positive Verbal Suggestion 5 Group, P5 group, N=16),
mimicking a fast-acting analgesic (‘The agent you will receive is known to have
a strong analgesic effect which sets in about 5 min after application. You will
therefore become less sensitive to pain and be able to keep your hand in the cold
water for a longer period of time in the two test sessions after 10 and 35 min
[experimenter points at time 10 and 35 minute marks on a clock] compared to the
first test [CPT baseline].’). The second placebo group was informed that the anal-
gesic would become effective after 30 min (Positive Verbal suggestion 30 Group,
P30 group, N=16), resembling the effect of analgesics with a delayed onset time
(‘The agent you will receive is known to have a strong analgesic effect which sets
in about 30 min after application. You will therefore become less sensitive to pain
and be able to keep your hand in the cold water for a longer period of time in the
test session after 35 min [experimenter points at time 35 min marks on a clock]




Participants assigned to the control group were informed that an inert cream
would be applied that would have no effect on their pain perception (No Ex-
pectancy, NE group, N=16; ‘The agent you will receive is an inert cream that
only has hydrating properties but no effect on pain perception. Because the cream
has no analgesic properties, your test performance after 10 and 35 min [experi-
menter points at time 10 and 35 minute marks on a clock] may be similar to the
performance in the first test [CPT baseline] but it can also be longer or shorter
than before’.).
3.3.3 Experimental protocol
After providing written informed consent, participants were seated in a com-
fortable chair positioned next to the CPT device (Figure 3.1). A stopwatch
displayed on a computer screen in front of the participants and a customised
wall clock were used for participants’ temporal orientation. The wall clock with
5-minute intervals (i.e., 5 to 55) showed an icon of a cream tube at the 12 o’clock
position to indicate the time-point of cream application. A poster depicting the
pain intensity rating scale was positioned on the desk. The experiment started
with a 4-minute heart rate measurement at rest during which the participant was
asked to breath naturally and relax. Participants were then introduced to the
CPT, completed the familiarization run and filled in the psychological question-
naires. Subsequently, all participants underwent the CPT baseline test before
they were allocated to one of the three groups, the cream was applied and par-
ticipants were provided with information about the nature of the cream and the
expected onset of the analgesic effect (placebo groups only). Immediately after
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the cream had been applied, the experimenter adjusted the clock so that the
minute hand pointed at the 12 o’clock position, indicating the time of cream ap-
plication (‘Time 0’). Afterwards, the CPT was repeated 10 min (‘Test 10’) and
35 min (‘Test 35’) after cream application. Note that the test was performed 10
and 35 minutes after cream application and not after 5 and 30 minutes, which
were the specific time points at which participants expected the cream to set in,
depending on group allocation. We allowed a 5-minute leeway to avoid partici-
pants doubting that the effect of a cream could be so precisely timed (i.e., setting
in exactly after 5 and 30 minutes)(Figure 3.2).
Figure 3.1: Experimental Set-up.
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Figure 3.2: Experimental Protocol: After signing the consent form, participants’
heart rate at rest was measured before participants completed the CPT famil-
iarisation run and the psychological questionnaires. Thirteen minutes after the
CPT baseline test, the cream was applied and verbal suggestions were provided
(P5, P30, NE) (approx. 2 min). Placebo groups P5 (green) and P30 (blue) were
informed that the cream has a strong analgesic effect that sets in 5 min (group
P5) or 30 min (group P30) after application. The No Expectation group (NE,
grey) was informed that the cream only had hydrating properties. The CPT was
then repeated after 10 and 35 min after cream application. Placebo analgesia was
expected both at Test 10’ and at Test 35’ for P5, and only at Test 35’ for P30.
No effect was expected for NE.
3.3.4 Cold Pressor Test
During the CPT, participants had to immerse their right hand in seven litres of
circulating cold water (7C°, ±0.2C°; CPT device: Thermo Scientific™ VersaCool™
Refrigerated Circulating Bath, procedure adapted from Mitchell, Macdonald and
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Brodie [172]. To indicate the level to which participants had to lower their hand,
the experimenter drew a red line from the participant’s ulnar styloid process
to the radial styloid process (wrist level). The CPT was repeated a total of
four times (familiarisation, baseline, Test 10’, Test 35’) with approximately 25
min breaks between tests to restore the baseline hand temperature (Figure 3.2).
During the breaks between each CPT session, participants were allowed to read a
book. Each CPT block started with one minute of HR recording at rest, followed
by the actual CPT. Ten seconds before participants had to place their hand into
the CPT device, they were alerted by the experimenter to get ready to immerse
their hand into the water. Upon a verbal prompt from the experimenter (“Go”),
the participant lowered their hand into the CPT device and the experimenter
started the stopwatch to record the time between beginning of exposure and
hand withdrawal. The stopwatch was displayed on a computer screen located in
front of the participant for temporal orientation. Participants were instructed not
to move their fingers or hand while they were immersed in the water and to keep
their fingers spread with the palm parallel to the ground, but without touching it.
The experimenter prompted the participant every 15 seconds to provide a verbal
rating of their current pain intensity (See Section 3.3.5 ) which the experimenter
recorded manually on a spreadsheet. The participants’ task was to keep their
hand in the water basin until the pain reached tolerance level. Participants then
removed their hand from the water basin and rested it on a towel placed on their
knees. The time elapsed between immersion and withdrawal of the hand was
recorded as CPT tolerance.
3.3.5 Pain Intensity Ratings
A poster depicting the rating scale including verbal and numerical anchors
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(0= not painful at all, 25= somewhat painful, 50= moderately painful, 75= very
painful, 100= unbearable pain) was positioned in front of the participant (Figure
3.1). Participants provided numerical pain intensity ratings every 15 seconds
during the CPT. Note that pain intensity ratings are not considered primary
outcome measures because all participants were instructed to maintain their hand
in the water until the pain reached an intensity of 100.
3.3.6 Heart Rate Recording
A decrease in heart rate (HR) has previously been shown to accompany
placebo-induced analgesia [173; 174], thus HR was chosen as potential physio-
logical correlate of this effect. Exposure to cold water triggers vasoconstriction
which leads to changes in blood pressure and HR [175; 176]. However, this ef-
fect which occurs irrespective of pain should on average have been comparable in
all three groups because the same time window of observation was chosen in all
groups (See Section 3.3.10 for details). We therefore expected pain to have an ad-
ditional effect on HR recordings which was hypothesized to vary between groups
depending on the placebo effect induced by the different temporal information.
The ECG signal was measured using a heart rate monitor (Polar V800) which
was connected to two standard surface electrodes positioned on the participant’s
lower end of the sternum. Data was collected at a sampling rate of 700 Hz. The
HR was first recorded for 4 min during a rest period in which the participant
was asked to sit comfortably and breath normally. Subsequently, HR recording
started one minute prior to each CPT and continued until two min after comple-
tion of the test. To limit HR artefacts, participants were instructed to maintain a




Table 3.1: Psychological questionnaires.
Questionnaire Abbreviation Construct/Process Reference







Fear of Pain Questionnaire FPQ Fear of pain [183]
Revised Life Oriented Test RLOT Degree of optimism [184]
3.3.7 Assessment of pain-related psychological traits
Participants completed a set of questionnaires (Table 3.1) to assess psycholog-
ical traits that have previously been linked to placebo responsiveness [177; 178;
179; 180]. Questionnaires were completed between the familiarization with the
CPT and the test sessions. At the end of the experiment, the two placebo groups
were asked to retrospectively rate how they had expected the cream to affect (i)
their pain during the experiment (‘When the cream was applied on your hand,
did you expect it to make you feel less pain during the task?’) and (ii) their abil-
ity to keep their hand in the cold water (‘When the cream was applied to your
hand, did you expect it to make you keep your hand in the water for longer?’).
Furthermore, participants had to retrospectively rate between 0 (= not at all )
to 7 (= very much) to which extent they had believed the information regarding
the onset of the analgesic effect (‘When the cream was applied on your hand,
how much did you agree with the following statement: The cream will start to
become effective after 5 min (P5); The cream will start to become effective after
30 min (P30)’).
3.3.8 Cream
A sham cream was administered in all three groups. It consisted of a water-
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based gel (KY-gel, Johnson & Johnson) which was presented to participants in a
transparent plastic tube. The experimenter applied the cream on the volar and
dorsal side of the hand up to the red line which had previously been drawn onto
the participant’s wrist to indicate how deep the hand had to be submerged into
the water. The cream was massaged into the skin for approximately one minute
to ensure that it was fully absorbed.
3.3.9 Debriefing
To debrief participants they were sent an email that explained in detail the
actual purpose of the study and why deception that had been used. Participants
were offered to contact the experimenter in case they felt the need to discuss their
participation and any concerns related to it. They were also given the opportunity
to withdraw their data. None of the participants decided to do so.
3.3.10 Statistical Analysis
Analyses were performed using the Statistical Package for the Social Sciences
(SPSS, version 9.6). To test for baseline differences in demographic variables
and questionnaire scores, we compared the three groups using an analysis of
variance (ANOVA) for continuous variables, or Chi-square test for categorial
variables. Pain ratings (NRS from 0 to 100) were not included as an outcome
measure but served to check whether participants had kept their hand in the
cold water until tolerance level had been reached. Note that these ratings do not
necessarily represent the level of pain at the moment of hand withdrawal, but the
last rating participants provided before they removed their hand (e.g. if the hand
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was removed after 59 second, the last pain intensity rating was obtained after 45
seconds). Median and interquartile range (IQR) are reported in Section 3.4.
As data for CPT tolerance at baseline, after 10 (Test 10’) and 30 (Test 35’)
minutes did not follow a normal distribution (Shapiro-Wilk tests p < .05), non-
parametric tests were used throughout. First, Kruskal-Wallis H-Test was per-
formed to test for baseline differences in CPT tolerance between groups. Second,
Friedman Tests were performed to detect differences in CPT tolerance between
the three different time points (Baseline, Test 10’ and Test 35’) separately for
each group. Data are presented as median ±interquartile range (IQR) and level
of significance was set at p < .05. Significant results were followed up using
Wilcoxon Signed Rank Tests, Bonferroni-corrected for multiple comparisons. Ef-
fect sizes were calculated as r = z/
√
N [185]. Third, we compared changes in
CPT tolerance between groups using a Kruskal-Wallis H-Test. To this end, we
calculated the percentage change in CPT tolerance from baseline to CPT10’ (∆
10) and baseline to CPT35’ (∆ 35) for each participant as follow:
∆ 10 = (CPT Test 10’*100)/ Baseline CPT-100
∆ 35 = (CPT Test 35’*100)/ Baseline CPT-100.
Because baseline tolerance level varied considerably across participants (see
IQR in Table 3.3; Section 3.4), percentage changes were used as a way to scale
the results with respect to each participant’s baseline tolerance, thus making the
increase or decrease more comparable between participants. Significant results
were followed up using pairwise Mann Whitney U Tests, Bonferroni-corrected for
multiple comparisons. Effect sizes were calculated as r = z/
√
N [185].
To investigate the possible influence of expectations of treatment efficacy on
CPT tolerance, Spearman rank-order correlation analyses were performed in the
placebo groups between retrospective expectancy measures and ∆ 10 and ∆ 35.
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Expectancy measures assessed how participants expected the cream to affect a)
their pain, b) pain tolerance as well as their expectations regarding the onset of
the analgesic effect.
For the analysis of HR data, ECG recordings were first truncated at the
shortest tolerance time recorded (i.e., 15 seconds after hand immersion) to ensure
comparability across participants. The mean HR for each of the three CPTs (i.e.,
baseline, Test 10’ and Test 35’) was calculated for each participant by averaging
the number of heartbeats within this time window, resulting in three mean HR
indices for each participant. As HR data were normally distributed (Shapiro-Wilk
tests p > .05), parametric analysis was used. To compare the HR between groups
and time-points, an ANOVA with the within-subject factor TIME (Baseline, Test
10’ and Test 35’) and between-subject factor GROUP (NE, P5, P30) was used.
Significant results were followed up using Bonferroni-corrected t-tests.
3.4 Results
The groups did not differ with respect to age, sex, BMI and psychological
variables (anxiety, disposition for behavioural inhibition/approach, fear of pain
and degree of optimism) (p > .05 for all comparisons). For participants’ char-
acteristics, see Table 3.2 (demographics) and Table 3.3 (psychological traits).
Participants’ pain intensity ratings served to check whether participants indeed
only removed their hand from the ice water when the pain had become unbear-
able. As shown in Table 3.4, ratings reached on average (median) NRS of 90 or
higher in all test sessions.
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Table 3.2: Participants’ demographics.
Demographics
Groups No Expectations Placebo 5 Placebo 30
N 16 16 16
Age in years
(Mean/SD)
28.14 ±2.13 24.78 ±3.17 26.08 ±5.99
BMI
(Mean/SD)
24.3 ±2.6 22.2 ±4.0 22.1 ±3.0
Sex 9 M ; 7 F 6 M; 10 F 9 M; 7 F
Handedness 12 R ; 4 L 15 R; 1 L 16 R
Note: M, Male; F, Female; R, Right; L, Left.
Table 3.3: Psychological traits
Psychological Traits
Groups No Expectations Placebo 5 Placebo 30
BAI 10.25 ±5.05 9.25 ±6.84 10.31 ±5.62
BAS-Drive 8.81 ±1.84 9.69 ±2.02 8.69 ±2.33
BAS -Fun-Seeking 8.25 ±1.84 8.25 ±2.18 7.88 ±1.67
BAS-Reward 8.50 ±2.1 7.56 ±1.82 8 ±1.67
BIS 14.75 ±2.08 15.13 ±2.63 15.38 ±2.73
FPQ 72.75 ±13.23 78.38 ±14.26 77 ±13.97
RLoT 13.94 ±3.99 14.38 ±6.28 14.75 ±5
Abbreviations: BAI, Beck Anxiety Inventory; BAS, Behavioural Approach Scale;
BIS, Behavioural Inhibition Scale; FPQ, Fear of Pain Questionnaire;
RLoT, Life-Orientation Test-Revisited.
3.4.1 Placebo Effects: Within group comparison
Friedman Tests for within-group comparisons showed that CPT tolerance
changed significantly in both placebo groups (P5, χ2(2) = 18.95, p < .001; P30,
χ2(2) = 21.37, p < .001 ) but not in the NE group, χ2(2) = 3.124, p = .210
(Table 3.5). Post hoc Wilcoxon Signed Rank tests showed that in the P5 group,
CPT tolerance significantly increased from baseline to Test 10’ (z=-3.47, p=.002,
r=.613) and was still higher than at baseline when assessed at Test 35’ (z=-3.34,
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Table 3.4: Median and first (Q1) and third (Q3) quartiles of maximum numerical
rating of pain intensity (0-100).
NE P5 P30
Median Q1 Q3 Median Q1 Q3 Median Q1 Q3
Max Baseline 90 83 99 96 90 100 92 82.5 99.75
Max T10 90 75 99 96 90 99.75 95 90 99.75
Max T35 90 80 98 97 91.25 99.75 96.5 90.5 99.75
Abbreviations: Q1, First quartile ; Q3, Third quartile
Figure 3.3: Within-group Comparison: CPT tolerance at Baseline, Test 10’ and
Test 35’ for each group (NE, P5, P30). Asterisks indicate significant differences
in tolerance time within each group (p < .05). In the P5 group, tolerance was
significantly higher at Test 10’ and at Test 35’ compared to Baseline. In the P30
group, tolerance was significantly higher at Test 35’ compared to both Baseline
and Test 10’. The lowest and highest boundaries of the boxes indicate the 25th
and the 75th percentiles, respectively. The black line within each box indicates
the median. Whiskers above and below the boxes indicate the largest and the
lowest data points (excluding any outliers), respectively.
p=.002, r=.590). No significant difference was found between Test 10’ and Test
35’ (z=-.710, p=1.434, r=.125). These results suggest that placebo analgesia
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occurred at the expected time-point and once analgesia had been triggered, it
remained stable over time, at least up until 35 minutes after cream application
(Figure 3.3). In contrast, the P30 group showed no significant difference in CPT
tolerance between baseline and Test 10’ (z=-.828, p=.224, r=.146). Only at
the later test time-point (Test 35’), CPT tolerance was significantly higher than
baseline (z=-3.46, p=.002, r=.612) and in Test 10’ (z=-3.52, p=.001, r=.622),
indicating that the analgesic effect only set in late in accordance with the instruc-
tions provided (Figure 3.3).
Table 3.5: Median and IQR of CPT pain tolerance (in seconds).
Tolerance Baseline Tolerance Test 10 Tolerance Test 35
Median IQR Median IQR Median IQR
NE 69.50 226 62.50 223 62.50 263
P5 69.50 87 98 149 85.50 138
P35 55 266 51.59 257 72.50 386
Abbreviations: IQR, Interquartile Range.
3.4.2 Placebo Effects: Between group comparison
No significant difference in baseline CPT tolerance level between the three
groups was reported by Kruskal-Wallis H-Tests (p = .988). Kruskal-Wallis H-
Tests showed a significant group difference in ∆ 10, χ2(2) = 23.05, p < .001, with
a mean rank ∆ 10 of 37.81 in P5, 20.72 in P30 and 14.97 in NE. Post hoc Mann-
Whitney U-tests revealed that ∆ 10 was significantly higher in P5 than in both NE
(U =16.5, p < .001 , r = .743) and P30 (U =26.5, p < .001, r=-.676) but did not
differ significantly between the NE group and P30 (U =87, p=.266, r=.274). This
indicates that 10 minutes after cream application, pain reduction was stronger in
P5 than in NE and P30 (Figure 3.4). For ∆ 35, Kruskal-Wallis H-Test also showed
a statistically significant difference between groups, χ2(2) = 18.06, p < .001, with
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a mean rank ∆ 35 of 29.31 in P5, 31.75 in P30 and 12.44 in NE. Post hoc Mann-
Whitney U-tests revealed that ∆ 35 was significantly higher in both P5 (U =38,
p=.002, r= .600) and P30 (U =25, p¡.001, r= .686) compared to the NE group,
indicating that pain reduction after 35 minutes was stronger in the two placebo
groups than in the NE (Figure 3.4). No significant difference in ∆35 was found
between P5 and P30 (U =155, p=1.872, r=.179). Median and IQR of percent
change in CPT pain tolerance (∆10 ,∆35) in the three experimental groups are
reported in Table 3.6.
Figure 3.4: Between-group Comparison: Percent change in CPT pain tolerance
from Baseline to Test 10’ (∆10) and to Test 35’ (∆ 35) for each group (NE, P5,
P30). Asterisks indicate significant differences in ∆ s between groups (p < .05). ∆
10 was significantly higher in P5 than in both NE and P30. ∆ 35 was significantly
higher in both P5 and P30 compared to the NE group. The lowest and highest
boundaries of the boxes indicate the 25th and the 75th percentiles, respectively.
The black line within each box indicates the median. Whiskers above and below




Table 3.6: Median and IQR of percent
change in CPT pain tolerance (∆ 10 ,∆ 35).
∆ 10 ∆ 35
Median IQR Median IQR
NE -7.54 24 -5.18 26
P5 29 35 27.55 50
P35 3.46 26 37.48 35
Abbreviations: IQR, Interquartile Range
3.4.3 Retrospective expectancy
Median and IQR of retrospective expectancy measures for both P5 and P30
are reported in Table 3.7. Spearman rank-order correlations between retrospec-
tive expectations of i) pain, ii) CPT resistance and iii) onset of analgesic effect
and ∆ 10 and ∆ 35 did not reach significance in either of the two placebo groups.
Table 3.7: Median and IQR of retrospective expectancy rat-
ings for pain (1 to 7), CPT resistance (1 to 7) and onset of
analgesic effect (1 to 7).
P5 P30
Median IQR Median IQR
Retrospective Expectancy
Pain 5.50 1.00 5.50 1.00
Resistance 6.00 1.00 6.00 1.00
Onset of analgesic effect 5.00 2.00 5.00 3.00
Abbreviations: IQR, Interquartile Range.
3.4.4 Heart Rate
HR data showed a significant main effect of TIME (F(2,90)=19.39, p < .001)
but no main effect of GROUP or interaction between both factors (both p >
0.05). Bonferroni-corrected post hoc comparisons between the different time-
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Table 3.8: HR mean and standard deviation (SD).
Baseline Test 10’ Test 35’
Heart Rate Mean SD Mean SD Mean SD
Overall 82.60 11.74 79.04 11.28 77.75 12.33
Control 81.26 8.21 76.53 8.94 75.73 8.44
P5 81.95 11.38 80.80 11.00 77.76 13.28
P30 84.59 15.11 79.80 13.68 79.76 14.85
points revealed that the HR decreased significantly between baseline and Test
10’ (p < 0.001) and between baseline and Test 35’ (p < 0.001). Changes in HR
from Test 10’ to Test 35’ did not reach significance (p > 0.05). Overall means and
standard deviations across the three groups as well as for each group separately
are reported in Table 3.8 below.
3.5 Discussion
Previous experimental placebo studies have focused on the effect of infor-
mation about the direction or magnitude of the expected effect on ‘treatment’
outcome. In a recent study, we demonstrated that the outcome of a placebo
manipulation is also influenced by information about the expected time-course of
the effect[164]. Using low-intensity and short-lasting electrical stimuli, we showed
that those who had been informed that the ‘analgesic’ would become effective
shortly after administration displayed immediate (and sustained) pain reduction.
In contrast, those who expected analgesia to set in after 30 minutes reported a
delayed decrease in pain. Here, we extend these findings by demonstrating a sim-
ilar effect in an experimental model of sustained pain (CPT) with pain tolerance
as an independent behavioural outcome measure.
Our results confirm two key findings of our previous study. First, the on-
set of analgesia was determined by the temporal information that participants
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received at the beginning of the experiment (Figure 3.4). Only those who had
been instructed that the analgesic effect would commence shortly after cream
application showed increased pain tolerance at the first test after baseline. The
group that was informed that the pain alleviating effect would only set in later
showed no analgesic effect at this early test time-point but at the expected time
after 30 minutes. Such ‘external timing’ of placebo effect is noteworthy for sev-
eral reasons. Neuroimaging studies have shown that placebo effects are mediated
by top-down regulatory processes in the brain which alter responses to noxious
stimuli at various stages of the neuraxis including the spinal cord [186]. However,
very little is known about factors triggering this cascade. Our findings of an ‘ex-
ternal timing’ effect suggest that information reaching this top-down modulatory
circuit do not necessarily prompt an immediate response but also provide a ‘time
tag’ that determines when the effect is to be set in motion. Where and how
temporal aspects of treatment expectations interface with the pain system in the
brain needs to be explored using brain imaging technology. The timing effect
is also noteworthy from a clinical perspective as it could open up new ways to
enhance placebo effects (e.g., open-label placebo treatments [187]) but even more
importantly also the efficacy of active drug treatment [188]. Expectancy effects
have been shown to contribute substantially to the overall treatment outcome
of active drugs [189; 190]. Although most drugs develop their maximum effect
shortly after administration, some require days or weeks to become effective. For
example, the desired effect of some tricyclic antidepressants often only sets in
several weeks after start of treatment. Medication discontinuation is therefore a
frequent problem in the early weeks of such treatment [191; 192]. Importantly,
the lack of noticeable symptoms improvement can cause patients to abandon
their initially positive treatment expectations. This means that once the drug
has reached its critical concentration and the pharmacological effect unfolds, it
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may no longer be supported by positive expectations and even be counteracted
by the impression of ‘treatment failure’ which has been demonstrated to squelch
also unrelated subsequent treatment attempts [193]. Our observation of ‘external
timing’ of placebo effects suggests that explicitly informing patients about the
delayed onset could prevent the abandoning of treatment expectations and in-
stead trigger the supporting placebo effect when the pharmacological drug effect
sets in. Because our paradigm only tested whether the onset can be shifted by
thirty minutes, further studies are needed to explore more substantial delays.
We also confirmed that once placebo analgesia had been triggered, it was
maintained for the duration of the experiment (Figure 3.3). In the P5 group,
which expected and showed an early reduction in pain, analgesia was still present
after 30 minutes without a decrease in strength. Findings from experimental
studies indicate that placebo analgesia can at least be maintained for the duration
of a single experimental session [161; 194] and observations from a randomised
controlled trial suggest that placebo effects can even increase over time [195].
However, more systematic investigations are needed to explore the longevity of
placebo effects.
The current study extends our previous findings in one very important aspect.
While we previously showed an effect of temporal information on placebo anal-
gesia using short-lasting, low-intensity stimuli, we demonstrate here that similar
results can be achieved in an experimental model of high-intensity tonic pain.
Phasic pain models have been criticised for their lack of ecological validity as
their stimuli have little resemblance with chronic pain with respect to duration
and aversiveness [166]. In contrast, CPT-induced pain increases over time until
it reaches tolerance level and participants withdraw their hand. Although this
type of pain is still different from clinical pain, it is undoubtedly the better proxy.
Stimulus duration and intensity also play a key role for the degree to which ex-
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pectations can influence perception. Modern concepts of perception posit that
any sensation is determined not only by incoming sensory information but also
by the individual’s expectations. In this framework, expectations are assumed to
have a stronger effect if the afferent input is weak, noisy or ambiguous [168; 169]
leaving more room for expectations to “fill the gap” and bias the interpretation
of sensory information in the expected direction. It could therefore be speculated
that temporal expectations induced by verbal suggestions are more likely to im-
pact the onset of placebo analgesia in a model using short-lasting, low-intensity
stimuli (as in our previous study, [164]), than in a high-intensity and long-lasting
pain model (CPT). However, a direct comparison of the strength of placebo ef-
fects suggests the opposite. While an average placebo effect of r=0.47 was found
in our previous study, it was considerably stronger in the current trial (r=.71)(see
Section 3.6 for details).Of note, a similar result was found in a meta-analysis by
Vase et al (2009), who reported larger placebo effects for longer (> 20s, d=0.96)
than for shorter pain stimuli (< 20s, d=0.81). In addition to physical stimulus
features, differences in perceived controllability of the stimulation which is known
to dampen the perception and neural processing of pain [196; 197] might explain
the stronger placebo effects in the current study. In our CPT study, participants
had to decide for how long they could keep their hand in cold water. Exposure to
noxious input was therefore entirely controllable. In contrast, our previous study
used a passive stimulation with no element of control.
Using (self-determined) exposure time as the key outcome also allowed us to
quantify the effect of the temporal information in a way that is less prone to
report bias than the commonly used pain intensity ratings. Because participants
were instructed to reach tolerance level and analgesia was defined as increased
exposure time, (deliberate) overreporting, for instance due to social desirability
is unlikely because this would have required significantly longer exposure beyond
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the previous maximum tolerance level.
In pursuit of further changes in objective parameters, we also tested whether
the ‘external timing’ effect would be reflected in HR variations. However, HR
decreased over the course of the experiment in all three groups. So far, studies
exploring HR changes related to placebo analgesia have yielded inconsistent re-
sults. Studies using CPT-induced pain [194; 198] and electrical stimulation model
[199; 200] found no changes in HR associated with placebo analgesia. However,
other studies using ischemic arm pain [174] and thermal pain[173] reported a
reduction in HR during placebo analgesia.
Another aspect to take into account is that participants were provided with
a clock to help them keep track of time. It would be interesting to investigate
whether temporal suggestions have the same influence in shifting treatment onset
of action if participants were asked to internally monitor time passing, without
the help of an external tracker, like in our case the clock. The ability to perceive
time is a critical adaptive skill for individuals’ survival; from predicting the time
an object takes to reach us, either to catch it or to avoid it, to estimating the time
to perform tasks in our everyday life [201]. Since humans are good at perceiving
and predicting time, we could hypothesise that similar findings to ours would be
shown in the absence of the clock. Yet, time perception is a complex phenomenon
and further investigation of this aspect could give interesting outputs, especially
if looking into the clinical population, in which deficits in temporal processing
have been reported [202; 203].
A limitation of this study is that pain-related expectations were only assessed
retrospectively (instead of repeatedly during the experiment) to avoid drawing
attention to this variable and potentially disclosing the actual purpose of the ex-
periment. Our data do therefore not allow for any conclusions regarding changes
of temporal expectations over the course of the experiment. As expectations not
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only impact perception but are in turn also continuously updated to reflect past
(sensory) experiences, future studies could use trial-by-trial assessments of expec-
tations to explore the dynamics of analgesic experience and expectation updating
in more detail. Another aspect that warrants further investigation is the preci-
sion of temporal expectations. While in the present study, information about the
expected onset of the analgesic effect were very precise and a clock helped par-
ticipants to keep track of time such exact timing might be less feasible in clinical
practice. Insights into the robustness of ‘external timing’ effects against delayed
or premature onsets of treatment effects would therefore be desirable.
Taken together, our data confirm previous findings of ‘external timing’ of a
placebo analgesic effect and extend it to an experimental model of sustained pain
using pain tolerance as an observable outcome parameter. While these findings
hold promise for a systematic use of this effect in therapeutic contexts, further
research is required to investigate if and how it translates to clinical pain, active




3.6.1 Comparison of effect sizes of placebo responses
The present study and our previous one [164], both included two placebo groups
in which participants expected the analgesic effect to start after five (P5 group)
or thirty minutes (P30 group) from cream application. Both studies also included
a No Expectancy (NE) group that did not expect an analgesic effect.
Effect Size(r)
Test 10 : P5 vs NE .468
Test 35: P30 vs NE .465
Average r: .47
Table 3.9: Effect sizes (r) of the
placebo responses in Study 1, [164]
Effect Size(r)
Test 10 : P5 vs NE .743
Test 35: P30 vs NE .686
Average r: .71
Table 3.10: Effect sizes (r) of the
placebo responses in Study 1 [204]
We calculated effect sizes (r) of the placebo responses for our previous study
(Study 1, [164]) by comparing NRS scores at Test 10 between P5 and NE and at
Test 35 between P30 and NE. We then computed the average effect size (Table
3.9. We calculated the effect sizes (r) of the placebo response of the current study
(Study 2, [204] ) by comparing tolerance change at Test 10 between P5 and NE
and at Test 35 between P30 and NE. We then computed the average effect size
(Table 3.10).
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[160] P. M. Aslaksen, O. Åsli, M. Øvervoll, and E. Bjørkedal, “Nocebo hyperal-
gesia and the startle response,” Neuroscience, vol. 339, pp. 599–607, 2016.
83
[161] L. Colloca, M. Sigaudo, and F. Benedetti, “The role of learning in nocebo
and placebo effects,” Pain, vol. 136, no. 1-2, pp. 211–218, 2008. 83, 103
[162] A. I. van Laarhoven, M. L. Vogelaar, O. H. Wilder-Smith, P. L. van Riel,
P. C. van de Kerkhof, F. W. Kraaimaat, and A. W. Evers, “Induction of
nocebo and placebo effects on itch and pain by verbal suggestions,” PAIN®,
vol. 152, no. 7, pp. 1486–1494, 2011. 83
[163] A. Pollo, M. Amanzio, A. Arslanian, C. Casadio, G. Maggi, and
F. Benedetti, “Response expectancies in placebo analgesia and their clin-
ical relevance,” Pain, vol. 93, no. 1, pp. 77–84, 2001. 83
[164] E. M. Camerone, A. Piedimonte, M. Testa, K. Wiech, L. Vase, D. A.
Zamfira, F. Benedetti, and E. Carlino, “The effect of temporal information
on placebo analgesia and nocebo hyperalgesia,” Psychosomatic Medicine,
vol. 83, no. 1, pp. 43–50, 2021. viii, 83, 101, 104, 107
[165] J. L. Edens and K. M. Gil, “Experimental induction of pain: Utility in the




[166] P. Rainville, J. S. Feine, M. C. Bushnell, and G. H. Duncan, “A psychophys-
ical comparison of sensory and affective responses to four modalities of exper-
imental pain,” Somatosensory & motor research, vol. 9, no. 4, pp. 265–277,
1992. 84, 103
[167] K. Friston, “A theory of cortical responses,” Philosophical transactions of
the Royal Society B: Biological sciences, vol. 360, no. 1456, pp. 815–836,
2005. 84
[168] Y. Pinto, S. van Gaal, F. P. de Lange, V. A. Lamme, and A. K. Seth,
“Expectations accelerate entry of visual stimuli into awareness,” Journal of
Vision, vol. 15, no. 8, pp. 13–13, 2015. 84, 104
[169] F. P. De Lange, M. Heilbron, and P. Kok, “How do expectations shape
perception?” Trends in cognitive sciences, vol. 22, no. 9, pp. 764–779, 2018.
84, 104
[170] S. S. Cheung and H. A. Daanen, “Dynamic adaptation of the peripheral
circulation to cold exposure,” Microcirculation, vol. 19, no. 1, pp. 65–77,
2012. 85
[171] C. MacLachlan, E. A. Shipton, and J. E. Wells, “The cold pressor test as a
predictor of prolonged postoperative pain, a prospective cohort study,” Pain
and therapy, vol. 5, no. 2, pp. 203–213, 2016. 85
[172] L. A. Mitchell, R. A. MacDonald, and E. E. Brodie, “Temperature and the
cold pressor test,” The Journal of Pain, vol. 5, no. 4, pp. 233–237, 2004. 90
[173] P. M. Aslaksen and M. A. Flaten, “The roles of physiological and subjective
stress in the effectiveness of a placebo on experimentally induced pain,”
Psychosomatic medicine, vol. 70, no. 7, pp. 811–818, 2008. 91, 105
109
REFERENCES
[174] A. Pollo, S. Vighetti, I. Rainero, and F. Benedetti, “Placebo analgesia and
the heart,” Pain, vol. 102, no. 1-2, pp. 125–133, 2003. 91, 105
[175] R. K. Dishman, Y. Nakamura, E. M. Jackson, and C. A. Ray, “Blood
pressure and muscle sympathetic nerve activity during cold pressor stress:
fitness and gender,” Psychophysiology, vol. 40, no. 3, pp. 370–380, 2003. 91
[176] L. Mourot, M. Bouhaddi, and J. Regnard, “Effects of the cold pressor test
on cardiac autonomic control in normal subjects.” Physiological research,
vol. 58, no. 1, 2009. 91
[177] E. K. Broelz, P. Enck, A. M. Niess, P. Schneeweiss, S. Wolf, and K. Weimer,
“The neurobiology of placebo effects in sports: Eeg frontal alpha asymmetry
increases in response to a placebo ergogenic aid,” Scientific reports, vol. 9,
no. 1, pp. 1–10, 2019. 92
[178] N. Corsi and L. Colloca, “Placebo and nocebo effects: the advantage of
measuring expectations and psychological factors,” Frontiers in Psychology,
vol. 8, p. 308, 2017. 92
[179] P. S. Lyby, P. M. Aslaksen, and M. A. Flaten, “Is fear of pain related to
placebo analgesia?” Journal of psychosomatic research, vol. 68, no. 4, pp.
369–377, 2010. 92
[180] L. Zhou, H. Wei, H. Zhang, X. Li, C. Bo, L. Wan, X. Lu, and L. Hu, “The
influence of expectancy level and personal characteristics on placebo effects:
Psychological underpinnings,” Frontiers in psychiatry, vol. 10, p. 20, 2019.
92
[181] A. T. Beck, N. Epstein, G. Brown, and R. A. Steer, “An inventory for
measuring clinical anxiety: psychometric properties.” Journal of consulting
and clinical psychology, vol. 56, no. 6, p. 893, 1988. 92
110
REFERENCES
[182] C. S. Carver and T. L. White, “Behavioral inhibition, behavioral activation,
and affective responses to impending reward and punishment: the bis/bas
scales.” Journal of personality and social psychology, vol. 67, no. 2, p. 319,
1994. 92
[183] D. W. McNeil and A. J. Rainwater, “Development of the fear of pain
questionnaire-iii,” Journal of behavioral medicine, vol. 21, no. 4, pp. 389–
410, 1998. 92
[184] M. F. Scheier, C. S. Carver, and M. W. Bridges, “Distinguishing opti-
mism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a
reevaluation of the life orientation test.” Journal of personality and social
psychology, vol. 67, no. 6, p. 1063, 1994. 92
[185] R. Rosenthal, R. L. Rosnow, and D. B. Rubin, Contrasts and effect sizes in
behavioral research: A correlational approach. Cambridge University Press,
2000. 94
[186] T. D. Wager and L. Y. Atlas, “The neuroscience of placebo effects: con-
necting context, learning and health,” Nature Reviews Neuroscience, vol. 16,
no. 7, pp. 403–418, 2015. 102
[187] T. J. Kaptchuk and F. G. Miller, “Open label placebo: can honestly pre-
scribed placebos evoke meaningful therapeutic benefits?” Bmj, vol. 363,
2018. 102
[188] E. Carlino, A. Pollo, and F. Benedetti, “The placebo in practice: how to
use it in clinical routine,” Current opinion in supportive and palliative care,
vol. 6, no. 2, pp. 220–225, 2012. 102
[189] F. Benedetti, G. Maggi, L. Lopiano, M. Lanotte, I. Rainero, S. Vighetti,
and A. Pollo, “Open versus hidden medical treatments: The patient’s knowl-
111
REFERENCES
edge about a therapy affects the therapy outcome.” Prevention & Treatment,
vol. 6, no. 1, p. 1a, 2003. 102
[190] U. Bingel, V. Wanigasekera, K. Wiech, R. N. Mhuircheartaigh, M. C. Lee,
M. Ploner, and I. Tracey, “The effect of treatment expectation on drug ef-
ficacy: imaging the analgesic benefit of the opioid remifentanil,” Science
translational medicine, vol. 3, no. 70, pp. 70ra14–70ra14, 2011. 102
[191] K. Chakraborty, A. Avasthi, S. Kumar, and S. Grover, “Attitudes and
beliefs of patients of first episode depression towards antidepressants and
their adherence to treatment,” Social psychiatry and psychiatric epidemiol-
ogy, vol. 44, no. 6, pp. 482–488, 2009. 102
[192] F. Holvast, R. C. Oude Voshaar, H. Wouters, K. Hek, F. Schellevis,
H. Burger, and P. F. Verhaak, “Non-adherence to antidepressants among
older patients with depression: a longitudinal cohort study in primary care,”
Family practice, vol. 36, no. 1, pp. 12–20, 2019. 102
[193] M. Zunhammer, M. Ploner, C. Engelbrecht, J. Bock, S. S. Kessner, and
U. Bingel, “The effects of treatment failure generalize across different routes
of drug administration,” Science translational medicine, vol. 9, no. 393, 2017.
103
[194] A. L. Geers, S. L. Fowler, J. A. Wellman, S. G. Helfer, S. Close, and C. R.
France, “Prior experience with a pain stimulus as a predictor of placebo
analgesia,” Journal of behavioral medicine, vol. 38, no. 1, pp. 136–142, 2015.
103, 105
[195] S. N. Quessy and M. C. Rowbotham, “Placebo response in neuropathic
pain trials,” Pain, vol. 138, no. 3, pp. 479–483, 2008. 103
112
REFERENCES
[196] T. V. Salomons, T. Johnstone, M.-M. Backonja, and R. J. Davidson, “Per-
ceived controllability modulates the neural response to pain,” Journal of
Neuroscience, vol. 24, no. 32, pp. 7199–7203, 2004. 104
[197] K. Wiech, R. Kalisch, N. Weiskopf, B. Pleger, K. E. Stephan, and R. J.
Dolan, “Anterolateral prefrontal cortex mediates the analgesic effect of ex-
pected and perceived control over pain,” Journal of Neuroscience, vol. 26,
no. 44, pp. 11 501–11 509, 2006. 104
[198] K. Peerdeman, A. Van Laarhoven, D. Bartels, M. Peters, and A. Evers,
“Placebo-like analgesia via response imagery,” European journal of pain,
vol. 21, no. 8, pp. 1366–1377, 2017. 105
[199] L. Colloca and F. Benedetti, “Placebo analgesia induced by social observa-
tional learning,” PAIN®, vol. 144, no. 1-2, pp. 28–34, 2009. 105
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Background. Negative verbal suggestions enhance pain perception. How-
ever, the role of their temporal content remains largely unexplored. Here, we
investigate whether temporal suggestions modulate the timing of nocebo hyper-
algesia.
Methods. Fifty-one healthy participants were randomised across three groups.
Participants received an inert cream and were instructed that the agent had ei-
ther hyperalgesic properties that would manifest themselves in 5 (Nocebo 5, N5)
and 30 (Nocebo 30, N30) minutes from cream application, or hydrating properties
(No Expectation Group, NE). Pain was induced by the Cold Pressure Test (CPT)
which was repeated before cream application (baseline) and after 10 (Test10) and
35 (Test35) minutes.
Results. Changes in pain tolerance and in HR at each test point in re-
spect to baseline were compared between the three groups. Tolerance change at
Test10 was greater in N5 (MED=-36.8;IQR=20.9) compared to NE (MED=-
5.3;IQR=22.4;p < .001) and N30 (MED=0.0;IQR=23.1; p < .001), showing
that hyperalgesia was only present in the group that expected the effect of the
cream to set in early. Tolerance change at Test35 was greater in N5 (MED=-
36.3;IQR=35.3; p = .002) and in N30 (MED=-33.3;IQR=34.8; p = .009) com-
pared to NE, indicating delayed onset of hyperalgesia in N30, and sustained
hyperalgesia in N5. No group differences were found for HR.
Conclusions. Our study demonstrated that temporal expectations can shift
nocebo response onset in a tonic-pain model.
Trial registration. The trial has been registered at the ISRCTN register
(21/07/20; ISRCTN96623027).
Perspective. This study demonstrates that temporal suggestions modulate
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the timing of nocebo hyperalgesia on a model of sustained pain. Expectations
of pain increase can be anticipated or delayed and, once triggered, remain stable
over time. These findings could inform us on how to minimise the negative side
effects that are associated with patients’ negative expectations.
4.2 Introduction
Expectations of pain worsening can significantly increase one’s perception of pain
[205]. The impact of expectations on pain is evident in nocebo hyperalgesia,
where pain worsens following the administration of an inert treatment delivered
in association with negative verbal suggestions (i.e. suggestions of pain rise) [206;
207; 208]. Even though the nocebo effect is a widely studied phenomenon, little
is known about the influence of temporal expectations on nocebo hyperalgesia,
that is, when the effect is expected to set in and for how long it is meant to last.
In a recent experiment, we demonstrated that it is possible to shift the onset
of nocebo effects by modulating one’s temporal expectations in a phasic-pain
model, induced with short-lasting electrical pulses of medium-to-low intensity
[209]. Here, after the first pain test, an inert cream was administered along with
suggestions of pain increase. Yet, some participants were told that the cream
had a fast time of action (i.e. that the effect would set in five minutes after
its application), while others that the effect would be slower to set in (i.e. after
fifteen and thirty minutes from application). As expected, those who believed the
cream to have a fast time of action reported early onset of nocebo hyperalgesia,
while those that were instructed it would take longer showed delayed hyperalgesia
onsets.
From a clinical perspective, the use of a short-lasting, medium-to-low inten-
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sity pain model, induced with electrical pulses, restricts the results to a type of
painful experience that has limited resemblance with clinical pain, which is rarely
brief and precisely timed [210]. Furthermore, within the framework of contempo-
rary perception theories, the use of such pain model is significant to the outcome
of the study. According to these theories, pain perception is conceptualised as
the result of the interaction between one’s prior expectations and the incoming
noxious input [211]. Besides, there is evidence stemming from research on percep-
tual domains other than pain which demonstrates that prior expectations have
a greater influence on perception when the sensory stimulus is ambiguous (i.e.
low intensity, low precision) compared to when this is non-ambiguous (i.e. high
intensity, high precision) [212; 213; 214]. Although the greater influence played
by expectancy on ambiguous stimuli has not been tested in the context of pain
perception, a similar rule is likely to apply [211]. Accordingly, the ambiguous na-
ture of the noxious stimuli (i.e. short-lasting, medium-to-low intensity electrical
pulses) that we used in our previous experiment [209] might have made it easier
for verbal suggestions to bias pain perception.
If in our earlier experiment [209] we looked at the influence of temporal sug-
gestions on nocebo hyperalgesia on a phasic pain model with a high level of
ambiguity (i.e. short duration, medium-to-low intensity), here we aim to extend
the investigation to a tonic pain model characterised by a lower level of ambiguity
(i.e. long duration, high intensity). In this experiment, tonic pain was induced
by means of the Cold Pressor Test (CPT), which offers a good approximation of
clinical pain [215]. Pain tolerance, operationalised as the maximum time partic-
ipants could resist with their hand dipped in freezing-cold water (7C°), was the
primary outcome measure of this experiment. This design allowed us both to
explore whether unambiguous tonic pain is equally affected by temporal sugges-
tions as ambiguous phasic pain and to use a behavioural outcome (i.e. maximum
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pain tolerance) instead of relying solely on verbal pain reports (as done in [209]).
4.3 Methods
4.3.1 Trial Design
A randomised controlled trial with three parallel groups (No Expectations, No-
cebo 5 and Nocebo 30) is reported. This experiment is one of two studies ex-
amining the temporal onset of placebo and nocebo effects. The first experiment
investigated the placebo effect [216], while the second one, here reported, studied
the nocebo phenomenon. These two studies were conducted from June 2019 to
July 2020 and shared a common randomised control group (N=17). This decision
was made in line with an ethical approach that sought to avoid the induction of
pain in a larger sample size, since the two studies followed the same protocol for
the control group. Specifically, recruitment and testing for the two nocebo groups
took place between April and July, 2020, while for the control group this occurred
between June and July 2019. Here, the influence of temporal information on
the onset and duration of nocebo effects was tested using an established nocebo
manipulation [209; 217] combined with the Cold Pressure Test (CPT). All exper-
imental procedures followed the policies and ethical principles of the Declaration
of Helsinki. The study was reported in line with the Consolidated Standards of
Reporting Trials (CONSORT) [218]. The Ethics Committee of the Vrije Uni-
versiteit Brussel approved this study (18/03/20; BUN1432020000002/I/U). The




The study took place at the Experimental Anatomy Research Department at the
Vrije Universiteit Brussel (VUB), Belgium. Forty-four healthy volunteers were re-
cruited from the student population of the VUB, and from the general population
through different social media outlets. Participants between 18 and 45 years of
age were considered eligible to join the study. Participants that were in cure with
antidepressants or anxiolytics, had a history of cardiovascular disease, and that
suffered from psychiatric, neurological, chronic musculoskeletal and pain-related
disorders were not considered eligible to participate in the study. Moreover, we
instructed the participants not to consume alcohol, caffeine-based drinks, sup-
plements, and/or analgesic medications twelve hours before the experiment. We
informed participants that they would take part in a study investigating the time
of action of a newly developed hyperalgesic cream. We disclosed the actual pur-
pose of the study only after full data collection was completed (see Section 4.3.6
for details on debriefing). Participants provided written informed consent agree-
ing to be debriefed with all the study details at the end of the experiment. These
participants were recruited and randomised between two nocebo groups. For the
control group, on the other hand, we relied on data that was previously collected
(See Camerone et al., [216] for findings regarding placebo analgesia).
4.3.3 Intervention
An inert cream was applied to the participants’ dorsal and volar left hand. The
cream consisted of a water-based gel (KY-gel Johnson&Johnson) which was pre-
sented to participants in a transparent plastic tube. Participants received differ-
ent information regarding the given cream:
• No Expectation (NE): experimenter explained that the cream is inert,
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without any effects on pain perception;
• Nocebo 5 (N5): experimenter explained that the cream is a powerful
hyperalgesic that would have an effect after 5 minutes;
• Nocebo 30 (N30): experimenter explained that the cream is a powerful
hyperalgesic that would have an effect after 30 minutes.
After providing written informed consent, participants were asked to sit on
a chair positioned next to the CPT device. The investigator used a stopwatch
displayed on a computer screen in front of the participants as well as a customised
wall clock for participants’ temporal orientation. The wall clock with 5-minute
intervals (i.e., 5 to 55) showed an icon of a cream tube at the 12 o’clock position
to indicate the time-point of application of the cream (Figure 4.1).
The experiment started with a 4-minute heart rate measurement at rest, dur-
ing which participants were asked to relax and breathe naturally. After instruct-
ing participants on how to perform the CPT task, they completed a familiarisa-
tion trial. During the CPT, participants were asked to immerse their left hand
in seven litres of circulating cold water (7C°, ±.2C°; CPT device: Thermo Sci-
entific model Haake A 10B, Haake SC 100; Thermo Fisher Scientific, Waltham,
MA; procedure adapted from Mitchell et al., [219]). The experimenter drew a
red line from the participant’s ulnar to the radial styloid process (wrist level) to
indicate the level to which participants had to lower their hand. Before starting
the CPT, one minute of HR at rest was recorded. Ten seconds before the begin-
ning of the test, participants were prompted by the experimenter to get ready
(i.e. experimenter said ‘Get ready!’) and to place their hand above the CPT
device, showing readiness to immersion. Upon a verbal prompt from the exper-
imenter (“Go”), the participant lowered their hand into the CPT device. The
experimenter started the stopwatch to record the time between the beginning
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Figure 4.1: Experimental Setting.
of exposure and hand withdrawal. The stopwatch was displayed on a computer
screen located in front of the participant for temporal orientation. Participants
were instructed not to move their fingers or hand while in the water and to keep
their fingers spread with the palm parallel to the bottom of the device without
touching it. For safety reasons, 10 minutes were set as the maximum time partic-
ipants were allowed to spend with their hand in the water [220; 221], after which
the test was discontinued, and the experiment ended.
During CPT, subjective pain ratings were recorded every 15 seconds. The
experimenter asked participants to quantify the pain they were experiencing on a
scale from 0 (no pain) to 100 (unbearable pain). In order to facilitate participants’
self-reporting of pain, a poster depicting the rating scale was placed in front of
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them, which included verbal and numerical anchors (0= not painful at all, 25=
somewhat painful, 50= moderately painful, 75= very painful, 100= unbearable
pain) (Figure 4.1). Once pain became unbearable, participants’ removed their
hand from the water basin and rested it on a towel placed on their knees. The time
elapsed between hand immersion and withdrawal was recorded as CPT tolerance.
Despite verbal pain ratings were recorded every 15 seconds, the last pain score was
taken at the moment of hand withdrawal to ensure that the maximum tolerance
level was reached (i.e. this was the case for the two nocebo groups, but not for the
control group, in which the last pain rating was recorded at the last 15s interval
prior hand withdrawal).
After the CPT familiarisation trial, all participants underwent the CPT base-
line test, followed by participants’ randomisation to groups and cream application.
The cream was applied on the palmar and dorsal side of participants’ hand, and
it was massaged into the skin for approximately one minute to ensure full absorp-
tion. Along with cream administration, the experimenter provided participants
with information about the nature of the cream (hyperalgesic cream in both no-
cebo groups and inert cream in the control group), as well as about the expected
onset of the hyperalgesic effect (nocebo groups only). Simultaneously with the
application of the cream, the experimenter adjusted the customised wall-clock so
that the minute hand pointed at the noon position, indicating the time of cream
application (‘Time 0’). CPT was then repeated 10 (Test 10) and 35 minutes (Test
35) from the cream application (‘Time 0’) (Figure 4.2). Overall, the CPT was
repeated a total of four times (familiarisation, baseline, Test 10, Test 35) with
a break of 20 minutes between tests to restore the baseline hand temperature
(Figure 4.2). Note that the test was performed 10 and 35 minutes after cream
application and not after 5 and 30 minutes, which were the specific time points at
which participants expected the cream to set in, depending on group allocation.
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We allowed a 5-minute leeway to avoid participants doubting that the effect of
a cream could be so precisely timed (i.e., setting in exactly after 5 and 30 min-
utes). During the breaks between the test sessions, participants completed the
psychological questionnaires (see Section 4.3.4). Once finished, they were allowed
to read or study, but were asked not to use their phones.
Figure 4.2: Study Paradigm. After giving consent, participants’ heart rate at
rest was measured for 4 minutes. Participants completed the CPT familiarisation
run and filled in the psychological questionnaires. After the CPT Baseline test,
the cream was applied along with suggestions of hyperalgesia (N5, Bright red;
N30, Dark red) and neutral suggestions (NE), depending on group randomisation.
Application of the cream and the delivery of suggestions took approximately
2 minutes. The CPT was then repeated after 10 and 35 minutes from cream
application. Nocebo hyperalgesia, visualised as upper-facing arrows in the image,
was expected both at Test 10 and at Test 35 for N5, and only at Test 35 for N30.




Participants that were assigned to the control group were informed that they
would receive an inert cream (No Expectation, NE): “The agent you will receive is
an inert cream that only has hydrating properties but no effect on pain perception.
Therefore, your test performance after 10 and 35 minutes [experimenter points
at time 10 and 35 minute marks on a clock] may be similar to the performance
in the first test [CPT baseline], but it can also be longer or shorter than before”.
4.3.3.2 Nocebo groups
Participants in the two nocebo groups were instructed that the cream had hyper-
algesic properties that would augment the painful sensation induced during the
CPT. We provided both groups with specific details about the onset of action of
the hyperalgesic cream.
Participants allocated to the Nocebo 5 group (N5) were told that the hyper-
algesic effect would arise after 5 minutes from cream application, mimicking a
fast-acting drug. They received the following instructions: “The agent you will
receive is known to have a strong hyperalgesic effect which sets in after 5 minutes
from its application. You will, therefore, become more sensitive to pain and be
able to keep your hand in the cold water for a shorter time in the two test sessions
after 10 and 35 minutes [experimenter points at time 10 and 35 minute marks
on a clock] compared to the first test [CPT baseline].”
Participants allocated to the Nocebo 30 group (N30) were told that the hy-
peralgesic effect would set in 30 minutes from cream application. Specifically, the
following instructions were given: “The agent you will receive is known to have a
strong hyperalgesic effect which sets in after 30 minutes from its application. You
will, therefore, become more sensitive to pain and be able to keep your hand in the
cold water for a shorter time in the test session after 35 minutes [experimenter
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points at time 35 minute marks on a clock] compared to the first test [points at
CPT baseline] and the second test after 10 minutes [points at Test 10].”
4.3.4 Assessment of Retrospective Expectancy and Psy-
chological Traits
Participants were asked to complete multiple questionnaires that had previously
been shown to link nocebo responsiveness with given psychological traits [222;
223; 224; 225]. Specifically, participants completed the Beck Anxiety Inventory
(BAI) to test the level of trait anxiety [226], the Behavioural avoidance/inhibition
scale (BIS/BAS) to test individuals’ motivational systems [227], the Fear of Pain
Questionnaire (FPQ) to test fear of pain [228] and the Revised Life Oriented
Test (R-LOT) to test the degree of optimism [229]. Participants completed the
questionnaires during the breaks between CPT trials.
At the end of the experiment, participants were asked to rate retrospectively,
on a scale from 0 (= not at all) to 7 (= very much), how much they had expected
the cream to affect (i) their pain during the experiment (“When the cream was
applied on your hand, did you expect it to make you feel more pain during the
water task?”), and (ii) their ability to keep their hand in cold water (“When the
cream was applied to your hand, did you expect it to make you last less with your
hand in the water?”). Participants were also asked to rate the extent to which
they had believed the given information regarding the onset of the hyperalgesic
effect (“When the cream was applied on your hand, how much did you agree with
the following statement: The cream will start to become effective after 5 minutes”
(P5)/ The cream will start to become effective after 30 minutes (P30)”).
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4.3.5 Heart Rate Recording
In 2009, Colloca and Benedetti [230] showed that heart rate (HR) increases dur-
ing the anticipatory phase, before the onset of nocebo hyperalgesia. Accordingly,
we decided to include this physiological parameter to detect nocebo-related an-
ticipatory anxiety responses. Additionally, we investigated whether HR changes
characterised nocebo-modulated CPT trials compared to CPT trials without no-
cebo modulation.
The electrocardiogram (ECG) signal was measured using an HR monitor (Po-
lar V800, Polar Electro Oy, Kempele, Finland), connected to two standard surface
electrodes positioned on the participant’s sternum with a band. Data were col-
lected at a sampling rate of 700 Hz/sec. HR was recorded for four minutes during
a rest period in which participants were asked to sit comfortably and breathe nor-
mally. HR recording started one minute before each CPT and continued through
the test until two minutes after its completion. In order to limit the HR artefacts
that might arise from hyperventilation related to pain-response, participants were
instructed to maintain a regular and relaxed breath during each test session.
4.3.6 Debriefing
Participants were debriefed through an email sent once full data collection was
completed. Here, we explained the actual purpose of the study, and clarified why
deception had been necessary. Participants were invited to contact the exper-
imenter if they felt the need to discuss their participation in the study or any
other concerns. They were also reminded that they could withdraw their data if





Tolerance time during each CPT test is the primary outcome (Baseline, Test 10,
Test 35), along with the percentage of tolerance change from baseline to Test 10
(∆10 ) and Test 35 (∆35 ) as described below (see Section 4.3.10).
4.3.7.2 Secondary Outcomes
The secondary outcomes included participants’ HR, subjective pain ratings during
test sessions, psychological traits and retrospective nocebo expectations. See
specific sections above for further details on the secondary outcomes (see Sections
4.3.5, 4.3.4).
4.3.8 Sample Size
A priori analysis was run with G*Power 3.1 to calculate the sample size needed.
Based on ANOVA for repeated measure test, a sample of 42 participants was
determined to accept a power of 80%, a significant level of 0.05 and an effect size
of 0.41 [231]. By assuming a dropout rate of 20%, 50 participants were required
to run the study.
4.3.9 Randomisation
Participants eligible for the study were randomly assigned to the two nocebo
groups (allocation ratio 1:1) using computer-generated random numbers lists with
simple randomisation (www.random.org). The same experimenter was responsi-





A one-way ANOVA was run to test for baseline differences between the three
groups in demographic parameters, and psychological constructs were assessed
via the questionnaires. Data for CPT tolerance at baseline, after 10 (Test 10)
and 35 (Test 35) minutes did not follow a normal distribution (Shapiro-Wilk tests
p < .05), therefore non-parametric tests were used. Worth of mention is that,
since the noxious stimulus was not calibrated accordingly with each individual
pain threshold (water temperature was 7C° for everyone), individuals’ raw scores
were not directly comparable between participants. Therefore, the between-group
analysis required standardised tolerance scores. This was not necessary for the
within-group analysis, in which there was no need to account for differences in
individuals’ pain thresholds and tolerance raw scores were directly comparable
within the same individual.
4.3.10.1 Within-group analysis
Friedman Tests were performed to detect differences in tolerance time across CPT
trials at the three different time points (Baseline, Test 10 and Test 35) within each
group. Data are presented as median ±interquartile range and the significance
level was set at p < .05. Significant results were followed up using Wilcoxon
Signed-Rank Tests. Significance acceptance level for pairwise comparison was
adjusted for the number of comparisons (k) using the Dunn-Sidak Correction
(αnew = 1− (1− αo)1/k), resulting in a p=.017 [232].
4.3.10.2 Between-group analysis
Percentage change in pain tolerance from baseline to Test 10 (∆10) and Test 35
(∆35) was calculated as follow:
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∆10 = (Test 10*100)/Baseline - 100
∆35 = (Test 35*100)/Baseline - 100.
Percentage change (∆10,∆35) scores were used instead of raw scores in the
between-group analysis to rely on more standardised values. Kruskal-Wallis H-
Tests were used to compare percentage changes (∆10,∆35) in pain tolerance
between groups, allowing to check nocebo response magnitude differences directly.
Data are presented as median ±interquartile range and the significance level was
set at p < .05. Significant results were followed up using pairwise Mann-Whitney
U-Tests. Significance acceptance level for pairwise comparison was adjusted for
the number of comparisons (k) using the Dunn-Sidak Correction, (αnew = 1 −
(1−αo)1/k) resulting in a p=.017. Effect sizes were calculated as r = z/
√
N [233].
The effect size measures between the groups were used to assess the actual power
of the study in percentage, based on the data of the trial. A threshold > 80%
was set as satisfactory.
Pain rating analysis was performed only for the two nocebo groups. We
calculated the slope of pain ratings as a function of time; the steeper the slope,
the faster maximum pain tolerance was reached. Friedman Tests were performed
to detect differences in the slope across CPT trials at the three different time
points (Baseline, Test 10 and Test 35) within each nocebo group. We could not
perform pain rating analysis in the NE group because we did not record the pain
rating at the moment in which the participant removed their hand from the water.
Therefore, we could not safely assume any value at this point in time; instead,
the last pain rating for this group was recorded at the 15 seconds interval that
preceded hand-withdrawal. To address this limitation, we updated our protocol
when collecting the nocebo groups, adding pain rating recording at the time of
hand-withdrawal.
Correlation analysis was conducted to investigate the relationship between
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retrospective expectancy in nocebo groups and ∆10 and ∆35. Retrospective
expectations included participants’ expectations of (i) pain, (ii) tolerance, and
(iii) cream onset of action.
Further correlation analyses were performed to explore the relationship be-
tween participants’ psychological traits and nocebo effects. Specifically, corre-
lations between psychological traits in nocebo groups and ∆10 and ∆35 were
investigated.
Heart rate data followed a normal distribution (Shapiro-Wilk tests p > .05).
Therefore, parametric analysis was used. Firstly, mean HR was computed for the
10 seconds that preceded the beginning of the CPT, allowing us to assess HR
during the anticipatory phase before the test session (Anticipatory HR). Antici-
patory HR was calculated for each test, resulting in three mean indices for each
participant (Anticipatory HR Baseline; Anticipatory HR Test 10; Anticipatory
HR Test 35). A three-way mixed ANOVA was run, with the within factor TIME
(Anticipatory HR Baseline; Anticipatory HR Test 10; Anticipatory HR Test 35)
and the between factor GROUP (N5, N30, NE). Secondly, for each test session,
the mean HR value was calculated by averaging HR measurements over the first
10 seconds, resulting in three mean indices (HR Baseline; HR Test 10; HR Test
35). We selected the first 10 seconds because this was the shorter tolerance score
across participants, allowing us to have a parameter for all participants. A three-
way mixed ANOVA was run, with the within factor TIME (HR Baseline; HR
Test 10; HR Test 35) and the between factor GROUP (N5, N30, NE). Significant




We recruited 44 participants, 10 of which had to be excluded since they exceeded
the maximum exposure time allowed with their hand into freezing-cold water
(Figure 4.3). We relied on the same control group (N=17) recruited beforehand
for our study on placebo, resulting in a final sample size of 51 participants. One-
way ANOVA and Chi-Square tests showed no baseline groups differences (p > .05)
with respect to age, BMI, gender and key psychological traits (Table 4.1 - 4.2).
Kruskal-Wallis H-Test showed no significant baseline differences between groups
in CPT tolerance (p=.237).
Figure 4.3: CONSORT Flow-Diagram.
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Table 4.1: Participants’ descriptive analysis.
Demographics
Groups No Expectations Nocebo 5 Nocebo 30
N 17 17 17
Age in years
(Mean/SD)
28.3 ±3.4 24.3 ±3.9 27.2 ±4.6
BMI
(Mean/SD)
24.4 ±2.5 24.1 ±3.7 24.0 ±2.3
Sex (F(%);M(%)) 7(41.2); 10(58.8) 9(52.9); 8(47.1) 11(64.7); 6(35.3)
Handedness (R(%)) 13 (76.5) 17 (100.0) 17 (100.0)
Note: SD, Standard Deviation; BMI, Body Mass Index; M, Male; F, Female; R, Right.
Table 4.2: . Participants’ psychological traits.
Psychological Traits
Groups No Expectations Nocebo 5 Nocebo 30
BAI 10.4 ±4.9 14.8 ±11.9 14.0 ±9.2
BAS-Drive 8.8 ±2.3 8.8 ±2.1 9.0 ±1.7
BAS -Fun-Seeking 8.1 ±1.9 8.2 ±2.1 8.8 ±1.8
BAS-Reward 8.3 ±2.1 7.5 ±2.1 8.0 ±1.8
BIS 14.6 ±2.1 13.7 ±3.3 13.2 ±3.9
FPQ 72.4 ±12.9 71.3 ±18.1 78.9 ±14.2
RLoT 14.3 ±4.1 13.8 ±5.6 15.1 ±3.5
Abbreviations: BAI, Beck Anxiety Inventory; BAS, Behavioural Approach Scale;
BIS, Behavioural Inhibition Scale; FPQ, Fear of Pain Questionnaire;
RLoT, Life-Orientation Test-Revisited.
4.4.1 Nocebo Effects
Within-group analyses using Friedman Tests revealed, in both nocebo groups, a
statistically significant difference in CPT tolerance depending on the temporal ex-
ecution of the CPT test, either at baseline, after 10 (Test 10) or 35 (Test 35) min-
utes [Nocebo 5, χ2(2) = 15.394, p < .001; Nocebo 30, χ2(2) = 10.836, p = .004]
from cream application. Contrarily, no significant difference in CPT tolerance
across time-points was shown in the NE group, χ2(2) = 2.471, p = .291. Post-hoc
analyses were run using the Wilcoxon Signed Ranks tests (Table 4.3 - 4.4). N5
group showed a significant decrease in CPT tolerance at Test 10 (p = .001) and
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Table 4.3: Median and interquartile range of CPT pain toler-
ance of all groups at the three tests.
Baseline Test 10 Test 35
Median IQR Median IQR Median IQR
NE 72.0 262.5 65.0 250.5 69.0 284.5
N5 57.0 112.5 38.0 91.5 50.0 85
N30 53.0 37 50.0 64 38.0 49.5
Abbreviations: IQR, Interquartile Range.
Table 4.4: Within-group comparisons of CPT tolerance.
Groups Comparisons Wilcoxon Signed rank test Effect Size Power Analysis
NE No Post-hoc / / /
N5 T10 vs Baseline Z = -3.315, p=.001 r = .568 >80%
T35 vs Baseline Z = -2.912, p=.004 r = .499 >80%
T10 vs T35 Z =-.398, p=.691 r = .068 >80%
N30 T10 vs Baseline Z = -.700, p=.484 r = .120 >80%
T35 vs Baseline Z = -2.392, p=.017 r = .410 >80%
T10 vs T35 Z = 2.864, p=.004 r = .491 >80%
at Test 35 (p = .004) compared to baseline. No significant difference was shown
in CPT tolerance between Test 10 and Test 35 (p > .05). N30 group showed no
significant difference in CPT tolerance between Test 10 and baseline (p > .05).
However, CPT tolerance significantly decreased at Test 35 compared to both
baseline (p = .017) and Test 10 (p = .004).
Between-group analysis using Kruskal-Wallis H-Tests showed a statistically
significant difference in ∆10 between the different groups, χ2(2) = 18.1, p <
.001, Post-hoc Mann-Whitney U-tests (Table 4.5 - 4.6) showed that ∆10 did not
differ significantly between the NE group and N30 (p > .05). However, ∆10 was
significantly higher in N5 than in both NE (p < .001) and N30 (p < .001). For
∆35, Kruskal-Wallis H-Test showed a statistically significant difference between
groups, χ2(2) = 12.0, p = .002 (Table 4.6). Post-hoc Mann-Whitney U-tests
(Table 6) revealed that ∆35 was significantly higher in both N5 (p < .002) and
N30 (p < .009) compared to the NE group. No significant difference in ∆35
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was found between N5 and N30 (p > .05) (Table 4.6). Figure 4.4 summarises
between-group results employing bar graph representation.
Figure 4.4: Between-group Comparison: Percent change in CPT tolerance from
Baseline to Test 10 (∆10) and to Test 35 (∆35) for each group (NE, N5, N30).
Asterisks indicate significant differences in ∆s between groups (* p < .05; ∗ ∗ p <
.01; ∗ ∗ ∗p < .001). ∆10 was significantly lower in N5 than in both NE and N30.
∆35 was significantly lower in both N5 and N30 compared to the NE group.
The lowest and highest boundaries of the boxes indicate the 25th and the 75th
percentiles, respectively. The black line within each box indicates the median.
Whiskers above and below the boxes indicate the largest and the lowest data
points (excluding any outliers), respectively.
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Table 4.5: Median and interquartile range of
percent change in CPT pain tolerance (∆10,
∆35) in the three experimental groups.
∆10 ∆35
Median IQR Median IQR
NE -5.3 22.4 -4.6 26.8
N5 -36.8 20.9 -36.3 35.3
N30 0.0 23.1 -33.3 34.8
Abbreviations: IQR, Interquartile Range.





Mann-Whitney U-Test Effect Size Power Analysis
∆10
NE vs N5 U=43.0, p<.001 r = .599 >80%
NE vs N30 U=107.0, p=.196 r = .221 >80%
N5 vs N30 U=38.0, p<.001 r = .629 >80%
∆35
NE vs N5 U=53.0, p=.002 r = .541 >80%
NE vs N30 U=69.0, p=.009 r = .446 >80%
N5 vs N30 U=112, p=.263 r = .192 >80%
4.4.2 NRS Ratings
Within-group analyses using Friedman Tests did not show significant differences
in pain slope over time; this was the case for both the N5 [χ2(2) = 5.158, p = .076]
and the N30 [χ2(2) = 5.792, p = .055] groups. Yet, p-values show a tendency
towards significance.
4.4.3 Retrospective Expectancy and Psychological Tests
No significant correlations were shown, in either of the two nocebo groups, be-
tween retrospective expectations of (i) pain, (ii) tolerance, and (iii) cream onset
of action and ∆10 and ∆35. Also, none of the psychological measures for either




Mixed-methods ANOVA showed no significant main effect of TIME, GROUP, in-
teraction between factors (p values> 0.05) on anticipatory HR measures. Instead,
a significant main effect of TIME on HR test measures (HR Baseline; HR Test
10; HR Test 35) was shown (F(2,96)=6.601, p = 0.002), indicating that mean HR
differed significantly across the three-time points (BSL, Test 10, Test 35). Yet, no
significant main effect of GROUP nor interaction between both factors were ob-
served (both p values > 0.05). Post hoc pairwise comparison using the Bonferroni
correction revealed that HR decreased significantly between baseline (M =79.68,
SD=13.53) and Test 35 (M =75.84, SD=10.79) (p=0.006). Despite HR decreasing
at Test 10 (M =77.44, SD=11.62) compared to baseline (M =79.68, SD=13.53),
this difference did not reach significance (p > 0.05). Similarly, also the decrease
from Test 10 (M =77.44, SD=11.62) to Test 35 (M =75.84, SD=10.79) did not
reach significance (p > 0.05).
4.5 Discussion
Our previous study demonstrated that temporal suggestions modulate the onset
of nocebo hyperalgesia on a phasic pain model, induced by short-lasting, medium-
to-low intensity electrical pulses [209]. Here, these findings are extended to a
longer-lasting, high-intensity, tonic pain model while relying on a behavioural
outcome measure (i.e. maximum tolerance) instead of subjective pain ratings,
as done in Camerone et al., [216]. Experimental pain induced with mild and
short-lasting electrical pulses has limited resemblance with clinical pain, both in
terms of stimuli duration and their level of aversiveness [210; 215]. In the present
study, we induced tonic pain using the CPT, which, despite still being far from
clinical pain, has a longer duration and reaches higher intensity (i.e. maximum
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tolerance), leading to a sensation that is a better proxy to real-life pain [215].
Here, we replicated the main findings of our previous work, showing that the
onset of nocebo hyperalgesia is dependent on the temporal suggestions that par-
ticipants receive at the moment (inert-)treatment administration. Participants
that were told that the cream had a fast time of action (N5) showed a decrease
in tolerance level at the test session that took place soon after cream application
(Test 10), demonstrating that suggestions of a fast-acting cream lead to early no-
cebo hyperalgesia onset. Differently, participants who were told that the cream
would require a longer time before setting in (i.e. 30 minutes from application,
N30) did not show a reduction in tolerance level at the early test session (Test
10), instead tolerance reduction set in at the delayed test trial (Test 35), show-
ing that suggestions of delayed cream onset were responsible for postponing the
hyperalgesic effect. These results demonstrate that negative verbal suggestions
increase pain perception, and that they can modulate the timing of hyperalgesia.
The use of verbal cues to delay nocebo onsets can be particularly important
from a clinical standpoint. The acute phase of pain in several musculoskeletal
conditions (e.g. in acute low back pain) is characterised by the interaction be-
tween pain-intensity, the level of threat attributed to the pain, and pain-related
anxiety [234]. Following an injury, individuals with high anxiety sensitivity are
more likely to attribute a high level of threat to the traumatic event than those
with lower anxiety sensitivity (i.e. fear of not regaining full function after back in-
jury) [234; 235]. An increase in perceived pain threat level enhances pain-related
anxiety, which in turn increases pain perception (i.e. high anxiety increases pain
sensitivity, [236; 237; 238]), often resulting in pain avoidance behaviours (Turk
and Wilson [234] for a full review of a fear-avoidance model of pain). Pain in-
crease and pain avoidance strategies feed back into this negative, self-reinforcing
loop, which is often responsible for the passage from acute to chronic pain [239].
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Relieving the acute phase of pain, for instance by postponing the detrimental
effects of negative expectations, can represent a functional strategy that could
help preventing acute pain from turning into chronic.
Given what has been said, it is worth pointing out that although we measured
psychological factors that are central to pain modulation in the clinical setting
(i.e. pain catastrophising and anxiety sensitivity) [234], our analysis showed no
correlations between these traits and enhanced pain sensitivity. This can be
explained by the fact that, unlike patients, the participants knew that the pain
was limited to the duration of the experiment and that such pain would not
have consequences for their health. In further studies, it would be interesting to
explore temporal expectations while modulating the experimental-pain threat-
level, as done by Cimpean and David[240] and, most importantly, by extending
these results to a clinical sample.
A second important finding of this study is that, once triggered, nocebo hy-
peralgesia remains stable over time (i.e. no difference was shown between Test 10
and Test 30 in the N30 group). This result is partially in line with our previous
study which shows that once the nocebo response sets in, it increases over time
[209]. In both studies, the effect did not wear off over time. However, in one case
(present study) it remained stable, while in the other it continued to increase
[209]. This discrepancy could be due to the different nature of pain, phasic in
one case and tonic in the other, as well as to the different method of measur-
ing pain, with subjective ratings on the one hand and with maximum tolerance
threshold in the other. In line with the present findings, Rodriguez-Raecke et
al.[241] have shown that negative expectations induced by verbal suggestions at
day one, not only lead to pain worsening on that day, but also that this negative
effect remains stable over the next eight days. Accordingly, studies monitoring
patients’ recovery expectations from back pain onset during a 3-month [242] and
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a 2-week [243] period, have reported that expectations remained stable over time
for most of the patients, and that the direction of expectations (i.e. positive,
neutral, negative) was positively correlated with the therapeutic outcome. The
consistency across these studies in showing that negative expectations are likely
to endure over time underscores the importance of preventing the development
of negative expectations in clinical routine when patients start new therapies,
given that such expectations are likely to accompany the patient throughout the
intervention, thus limiting, or in the worse cases abolishing, its positive effects
[242; 243; 244].
A third outcome of this study is the comparison that can be made between
the magnitudes of the nocebo effects when using an ambiguous stimulus, as done
in our previous work [209], compared to when using an unambiguous one, as done
in this study. Research on perceptual domains other than pain has demonstrated
that one’s expectations have a greater influence upon perception when the in-
coming stimulus is ambiguous compared to when this is unambiguous [245; 246].
If the same principle applied to pain perception, then we might anticipate that
expectations would have a greater influence over the ambiguous pain model (i.e.
short-lasting and medium-to-low intensity) used in Camerone et al.,[209], than
over the unambiguous one (i.e. longer-lasting and high-intensity) used in the
present experiment, resulting in greater nocebo effects in the former, than in the
latter. Instead, the magnitude of nocebo effects was comparable between the
two experiments, with an average effect of r=.446 in Camerone et al., [209], and
r=.522 in this study (see Section 4.6 for details), suggesting that the level of
ambiguity of the incoming noxious stimulus does not interact with the extent
to which expectations influence perception. Yet, confounding factors could have
influenced the magnitude of such effect sizes, including specific characteristics
of each pain model (i.e. familiarity with the sensation of cold, as opposed to
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unfamiliarity with the sensation of electric shocks), differences in the pain test
modality (i.e. maximum tolerance versus non-maximum tolerance test), and par-
ticipants’ perceived controllability over the incoming noxious stimuli (i.e. partici-
pants controlled when to end the pain in the CPT, while they had no control over
electrical pulses onsets). In order to isolate the influence of stimulus ambiguity
on perception, future research should deliver the same type of pain (i.e. electrical
pulses) while modulating stimuli level of ambiguity, adjusting their duration and
intensity. Though this was not the purpose of the study, Van Laarhoven et al.,
[208] have done the first step in this direction by investigating nocebo effects on
electrical stimuli of either low (itch) or high intensity (pain), inducing more or
less ambiguous stimuli, respectively. In this case as well, the magnitude of no-
cebo effects on itch (r=0.39) and pain (r=0.36) was comparable, suggesting that
expectations have a similar degree of influence on sensory information, indepen-
dently from the ambiguines of the incoming sensory input. Further investigation
is required to properly assess this hypothesis, and it should rely on experimental
designs created specifically to address this issue.
To introduce an objective outcome that reflects the influence of temporal
expectations on pain, we looked at heart rate data. No differences in HR were
shown between groups, suggesting that nocebo hyperalgesia is not associated with
HR changes. However, in line with our previous data, HR during the pain test
decreased over time in all three groups, suggesting a physiological habituation
response to the cold pressor test [216]. Lack of HR sensitivity as a physiological
correlate of nocebo effects is in line with Daniali and Flaten [247] meta-analysis,
in which heart rate variability, but not HR, was demonstrated to be a good
physiological correlate of nocebo hyperalgesi. Also, anticipatory HR (i.e. HR
during the ten seconds that preceded hand immersion) did not differ between
groups, and it remained stable over time, failing to pick up on anticipatory anxiety
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responses that are associated with nocebo hyperalgesia onsets [248]. Our results
contrast with Colloca and Benedetti’s whose reported HR acceleration during the
anticipatory phase before nocebo-cued noxious stimulations. Yet, the different
type of noxious stimuli (electrical pulses in Colloca and Benedetti [248]) could
account for the diverse anticipatory anxiety reactions, as well as for the associated
HR responses.
The main limitation of this study is that participants’ expectations were only
measured retrospectively, instead of being recorded throughout the experiment.
On one hand, measuring expectancy retrospectively prevented participants’ from
questioning the true nature of the study. On the other hand, the lack of trial-
by-trial expectations recording prevents our data from giving us information on
the variation of temporal expectations over the course of the experiment. Since
expectations update accordingly with (sensory) experiences, further research is
needed to investigate the interplay between expectations updating and nocebo
hyperalgesia temporal modulation.
To conclude, we demonstrated that temporal suggestions modulate the onset
of nocebo hyperalgesia, extending our previous findings to a model of tonic pain,
relying on maximum pain tolerance as a behavioural outcome measure. Some-
times pain cannot be avoided but has to be tolerated (i.e. some chronic pain
cases). Therefore, understanding how to modulate one’s tolerance levels can be
particularly relevant in the clinical context [249]. These results are promising, and
further studies must build upon this evidence to better understand the influence





4.6.1 Comparison of effect sizes of nocebo responses
The present study and our previous one [209], both included two nocebo groups in
which participants expected the hyperalgesic effect to start after five (N5 group)
or thirty minutes (N30 group) from cream application. Both studies also included
a No Expectancy (NE) group that did not expect the cream to influence their
pain.
We calculated effect sizes (r) of the nocebo responses for our previous study
[209] by comparing NRS scores at Test 10 between N5 and NE and at Test 35
between N30 and NE. We then computed the average effect size (see Table 4.7).
We calculated the effect sizes (r) of the placebo response of the current study
by comparing tolerance change at Test 10 between N5 and NE and at Test 35
between N30 and NE. We then computed the average effect size (see Table 4.8).
Effect Size(r)
Test 10 : P5 vs NE .417
Test 35: P30 vs NE .475
Average r: .446
Table 4.7: Effect sizes (r) of the no-
cebo responses in Study [209].
Effect Size(r)
Test 10 : P5 vs NE .599
Test 35: P30 vs NE .446
Average r: 522
Table 4.8: Effect sizes (r) of the no-
cebo responses in the present study.
4.7 Acknowledgments
This work was developed within the framework of the DINOGMI Department of




[205] J. R. Keltner, A. Furst, C. Fan, R. Redfern, B. Inglis, and H. L. Fields,
“Isolating the modulatory effect of expectation on pain transmission: a func-
tional magnetic resonance imaging study,” Journal of Neuroscience, vol. 26,
no. 16, pp. 4437–4443, 2006. 118
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The first chapter of this thesis is an introduction to placebo and nocebo effects,
outlining the rationale behind the experiments conducted during this PhD. Specif-
ically, three experiments were conducted, each of which has a dedicated chapter in
this thesis (Chapter 2, 3 and 4). These studies investigated the influence of tem-
poral suggestions in placebo analgesia and nocebo hyperalgesia, both in phasic
and tonic pain models. In this last Chapter, the primary findings of this research
are summarised and discussed in relation to their clinical implications, and their
significance from a predictive coding standpoint. In addition, their strengths and
limitations are outlined, along with suggestions for future directions. Throughout
this discussion, I will refer to Study 1, 2 and 3 when mentioning the three studies
conducted during this PhD Doctoral Programme. In the interests of clarity:
• Study 1: Experiment described in Chapter 2, investigating both placebo
analgesia and nocebo hyperalgesia on a short-lasting , medium-to-low in-
tensity phasic pain model [250].
• Study 2: Experiment described in Chapter 3, investigating placebo anal-
gesia on a longer-lasting, high-intensity tonic pain model [251].
• Study 3: Experiment described in Chapter 4, investigating nocebo hyper-
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algesia on a longer-lasting, high-intensity tonic pain model [252].
5.1 Main Findings
The research projects presented in this Doctoral Thesis systematically investi-
gated if and how temporal expectancy directly influences the onset of action
of a given (inert-)intervention, exploring for the first time the causal relation-
ship between expected and perceived onset of action. In these studies, an inert
cream was administered along with suggestions of either analgesia (i.e. pain
reduction) or hyperalgesia (i.e. pain increase). To investigate the temporal com-
ponent of expectations, some participants were told that the effect of the given
(inert-)treatment would set in straight away, while others that it would take
a longer time. As expected, the onset of the effect was either anticipated or
delayed accordingly with the temporal information that participants received.
This demonstrates that placebo and nocebo onsets strictly follow temporal sug-
gestions, indicating that temporal expectancy influences the onset of action of
the given (inert-)intervention. More specifically, it was shown that once placebo
analgesia and nocebo hyperalgesia had set in they lasted for the duration of the
experiment, indicating that once triggered these effects are maintained over time.
Furthermore, it was demonstrated that when participants expected a slower time
of action, the onset of both placebo analgesia and nocebo hyperalgesia was de-
layed in time without these effects occurring before the expected time point. This
shows that expectations can be withheld over time, until it is their anticipated
time to set in. In other words, expectations do not expire over time. These find-
ings were consistent in both short-lasting phasic pain [250] (Study 1, see Chapter
2) and long-lasting tonic pain [251; 252] (Study 2 and 3, see Chapter 3 and 4,
respectively).
Before moving on to discussing the clinical implications of these results, it is
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useful to reflect on the magnitude of the effects that were shown in the present
research, giving a better sense of the impact that placebo and nocebo effects could
have on patients.
In the first experiment (Study 1), just by delivering positive verbal sugges-
tions, it was possible to decrease participants’ perception of pain of half a point
(mean=-0.6; sd=0.5; average across placebo groups at the time point of expected
onset of action) over a scale going from 0, no pain, to 10, unbearable pain. Im-
portantly, once the effect was triggered, it remained stable over time (i.e. within
group comparison over time was not significant, p > .05). Precisely, partici-
pants expecting the analgesic effect to set in after 5 minutes from its application,
reported pain reduction of 0.5 points at the test session after 10 minutes (mean=-
0.5, sd=0.6), and such decrease remained stable after 20 (mean=-0.6, sd=0.7) and
35 (mean=-0.7, sd=0.8) minutes. Similarly, those expecting the effect to set in
after 15 minutes, reported approximately half a point pain reduction after 15
(mean=-0.7, sd=0.5) and 35 (mean=-0.7, sd=0.6) minutes from cream applica-
tion, but not earlier.
On the contrary, the delivery of negative verbal suggestions was sufficient to
enhance participants’ perception of pain of 1 point (mean: 0.9; sd =0.6; average
across nocebo groups at the time point of expected onset of action). Interestingly,
nocebo hyperalgesia significantly increased over time (i.e. within group compar-
ison over time reached significance, p > 0.5). Those participants expecting the
hyperalgesic effects to set in after 5 minutes from cream application reported a
gradual increase of pain ratings over time (i.e. Test 10: mean= 0.7, sd=0.5; Test
20: mean=0.9, sd=0.6; Test 35: mean=1.1, sd=0.7). The same was reported
by participants expecting hyperalgesia to set in after 15 minutes (i.e. Test 20:
mean=0.9, sd=0.6; Test 35: mean=1.3, sd=0.9). Noteworthy is that these data
indicate a difference of almost 1.5 points in pain ratings between positive and neg-
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ative verbal suggestions, i.e. +0.9 in the case of negative verbal suggestions and
-0.6 in the case of positive verbal suggestions. The magnitudes of these effects,
both positive and negative, are in line with previous behavioural [253; 254; 255]
and neuroimaging studies [256].
The magnitude of these changes may not seem clinically relevant at first
glance, but on closer inspection their relevance becomes evident. First, such ef-
fects arise from verbal suggestions in the absence of any treatment, which means
that positive effects can easily be induced and negative effects avoided, simply
by modulating the information that the clinician gives to the patient. Second,
the magnitude of the effects of recognized treatments for musculoskeletal pain
are not on a much larger scale than the effects arising from placebo modulations.
For example, a recent RCT showed that after a week of manual therapy, lateral
epicondylitis pain decreased from an initial level of 4.47 to 4.03, over a scale from
0 to 10, resulting in an overall pain reduction of 0.44 [257]. In the same study,
acupuncture was shown to reduce pain of 1 point, from 4.00 to 3.00 [257]. In
a different study, manual therapy intervention was shown to reduce non-specific
neck pain of 1.3 points (i.e. 5.5 at baseline to 4.2, after three weeks of treat-
ment), while physical therapy reduced pain of 1.2 points (i.e. 5.8 at baseline to
4.6 after three weeks) [258]. This observation does not aim to undermine nor
question the effectiveness of the aforementioned interventions for musculoskeletal
pain, which were shown to significantly ameliorate pain compared to the control
group, but wants to highlight that gaining half a point of pain reduction due to
positive verbal suggestions is a clinically relevant change, given that recognised
interventions often lead to changes on the scale of 1 point. Indeed, the purpose of
positive verbal suggestions is not to be used in substitution to active therapies,
but instead, these are to accompany the treatment, boosting its effectiveness (i.e.
effect of the treatment + effect of verbal suggestions) [259; 260].
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In the second (Study 2) and third (Study 3) experiments of this Doctoral
Degree, maximum pain tolerance was the primary outcome measure, instead of
pain ratings as in the case of the first study. Unravelling strategies to maximise
patients’ tolerance to pain can be particularly important in those clinical cases
in which pain cannot be avoided, but has to be tolerated (i.e. some chronic pain
cases) [261]. Positive verbal suggestions (i.e. Study 2) led, on average, to a 33%
increase in maximum pain tolerance (i.e. at the time point of expected onset of
action), whereas negative verbal suggestions (i.e. Study 3) led, on average, to
a 35% decrease in maximum pain tolerance (i.e. at the time point of expected
onset of action). Also in this case, the positive effects of verbal suggestions
were maintained over time, as shown by those participants that expected early
analgesia onset and reported an increase of 29% in maximum tolerance after 10
minutes and of 27% after 35 minutes. The magnitude of these effects is in line
with data from Pollo et al [262] looking at the effect of positive expectations on
thoracotomized patients’ painkiller requests in the three consecutive days after
surgery. Despite all patients were receiving buprenorphine, those who were told
that they were receiving a potent painkiller requested 34% less buprenorphine
compared to those patients who were not informed of the analgesic effects of
the treatment (natural history). Interestingly, both groups reported similar pain
ratings over time, indicating that administering different doses of painkiller led
to a comparable analgesic effect. In line with Study 2 which reports an average
increase of 33% in pain tolerance due to positive verbal suggestions, patients
became more tolerant to pain (i.e. 34% decrease in painkiller requests) due to
positive expectations induced with positive verbal suggestions.
In Study 3, the negative effects of verbal suggestions were also maintained
over time, as demonstrated by a reduced maximum tolerance both after 10 (i.e.
37% decrease) and 35 (i.e. 36% decrease) minutes in those participants that
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expected early onset hyperalgesia. Once again, these data suggest that clini-
cians could increase and decrease patients’ tolerance to pain of a third simply by
delivering positive and negative verbal suggestions, respectively. Moreover, the
consequences of the verbal suggestions can be carried over time, highlighting the
importance of promoting positive effects, while avoiding negative ones.
5.1.1 Expectations are maintained over time: Clinical Con-
siderations
The finding that once triggered, placebo analgesia remains stable over time could
have important implications in the clinical setting. Symptoms improvement aris-
ing from patients’ positive expectations have been repeatedly demonstrated, both
in clinical trials in which expectations were directly manipulated [262; 263; 264;
265] and in observational studies of correlational nature [266; 267]. Indeed, the
results of correlational studies showing the association between positive expec-
tations at the beginning of the treatment and positive clinical outcomes at its
completion [266; 267] are supported by clinical trials data [262; 263; 264; 265],
attesting for the causal link between positive expectations and therapeutic bene-
fit. For instance, the previously mentioned study conducted by Pollo et al. [262]
and investigating the effect of positive expectations on thoracotomized patients’
painkiller requests showed that despite all patients had been given buprenor-
phine, those who were told that they would certainly be receiving a painkiller
(i.e. certain and strong positive expectations) showed a 16% reduction in drug
requests compared to those patients who were told that they would be receiving
either a painkiller or a placebo (i.e. uncertain and weaker positive expectations).
Patients’ pain ratings between the two groups were similar over the course of the
three days, indicating that the same analgesic effect was obtained, in spite of
the different doses of buprenorphine administered [262]. A different clinical trial
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showed that when patients were told (i.e. open administration) they were receiv-
ing a potent painkiller (i.e. morphine), post-operative pain decreased of 3.6 points
(on a scale from 0 to 10), compared to a decrease of 1.9 points when patients were
not aware of receiving the painkiller (i.e. hidden administration), indicating that
verbal suggestions of analgesia account for 1.7 points of pain decrease [263]. In-
terestingly, in the same study, on a different cohort of thoracotomized patients,
anxiety scores (STAI-I, [268]) variations before and after diazepam administra-
tion were also investigated. Note that STAI-I scores go from a minimum of 20 to
a maximum of 80 and they are commonly classified as ‘no or low anxiety’ (20-37),
‘moderate anxiety’ (38-44), and ‘high anxiety’ (45-80) [269]. Patients that were
aware of receiving an anxiolytic drug reported a significant decrease of 12 points
in anxiety scores, going from high anxiety (pre=49.7) to medium to low anxiety
(post=37.7). Differently, those patients who were not informed of receiving such
drug reported no significant changes in their anxiety level (i.e. anxiety scores post
anxiolytic administration increased of 2.1 points; pre=51.0; post=53.1), maintain-
ing a high anxiety score before and after anxiolytic administrations. These data
demonstrate that expectations accounted for the full effect of the anxiolytic drug.
Considering the important role of anxiety in musculoskeletal pain sufferers, these
findings are particularly relevant to this discussion [270; 271]. On these grounds,
if we combine existing evidence demonstrating the influence of positive expecta-
tions on clinical outcomes with evidence that placebo analgesia can remain stable
over time (i.e. as shown by the data of this Thesis), the importance of induc-
ing positive expectations at the beginning of the therapeutic treatment becomes
evident. Indeed, if positive expectations induced at session one are maintained
over time, these are likely to maximise treatment effectiveness throughout. Note
that according to the research presented in this Thesis, positive suggestions can




On the opposite hand, maintaining negative expectations over time is likely
to obstacle clinical amelioration. Observational clinical studies showed a correla-
tion between initial patients’ negative expectations and negative clinical outcomes
[266; 267]. Studies that experimentally induced pain also demonstrated that ad-
ministering inert treatments alongside negative verbal suggestions, worsens pain
[255; 272; 273; 274]. Pain changes due to negative suggestions tend to be of 1
point on a scale from 0 (no pain) to 10 (unbearable pain). This was the case for
Van Laarhoven et al.[255] study in which pain ratings varied of 1.2 points be-
tween those who received suggestions of pain increase (mean = 03.09; sd = 2.39)
and those who did not (mean = 1.89; sd = 1.34). Similarly, Colloca et al. [274]
reported a difference of 1.2 points in perceived pain between noxious stimulation
preceded by expectations of low pain versus expectations of high pain. Alike,
negative verbal suggestions induced in Study 2 also accounted for, on average, 1
point increase in pain ratings during nocebo trials compared to baseline. Further-
more, in a study investigating the influence of expectations on drug efficacy it was
demonstrated that the analgesic effect of remifentalin was completely abolished
once negative verbal suggestions were given. Precisely, participants were informed
that remifentalin administration was discontinued, even if in reality drug infusion
continued, and that this could lead to pain increase [259]. Therefore, consider-
ing the strong impact that negative expectations have on therapeutic outcome,
the longevity of negative expectations over time becomes particularly concerning
since these have the potential to reduce treatment effectiveness from the start,
limiting or even abolishing its overall effectiveness. Consequently, preventing
the development of negative expectations is a fundamental step that can have a
significant positive impact upon the overall treatment success rate.
The findings provided by this PhD research indicating that both placebo anal-
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gesia and nocebo hyperalgesia, once triggered, are maintained over time must be
considered carefully before generalising them to real-life scenarios. If on one
hand, the experimental nature of these studies allowed a controlled environment
in which the only factor that could have influenced one’s expectations of the re-
ceived (inert-)treatment effectiveness was one’s own experience of pain at each
test. On the other hand, this controlled environment prevents us from inferring
whether expectations would remain stable over time in real life, where multiple
uncontrolled factors interact with one’s expectations, potentially leading to their
update. In the clinical setting, for example, patients are likely to encounter situ-
ations that have the potential to change their expectations of a given treatment,
and of their chance of recovery. These include attending educational programs
about their pathology and about the intervention they are receiving, meeting pa-
tients suffering from a similar condition, meeting those who are undertaking the
same treatment and report positive/negative experiences and having a good/bad
quality relationship with their physician [275; 276]. In nowadays society the
internet is also an important source of information which is likely to influence pa-
tients’ expectations regarding their condition and regarding the treatment they
are undertaking [277].
Importantly, the data that emerged from this PhD suggesting that expecta-
tions remain stable over time, is supported by correlational research that moni-
tored patients’ expectations over time in real-life settings [266; 267]. For instance,
over a sample of 874 back pain sufferers, expectations were shown to remain sta-
ble over the course of three months for 80% of the patients. Notably, their
expectations, either negative, neutral or positive, correlated with the therapeutic
outcome [267]. Carstens et al., [266] also reported that the majority of the pa-
tients with low back pain (n=281) did not vary the direction of their expectations
over time (i.e. 2 weeks). However, both Kamper et al., [267] and Carstens et al.,
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[266] found a decrease in positive expectations in a subgroup of patients whom
did not experience positive treatment outcomes. This finding is in line with the
predictive coding framework of expectations [278], suggesting that expectations
update if there is a large enough mismatch between what one is expecting and
what one is receiving. Accordingly, a study looking at weight loss expectations
in obese patients reported that those patients with overly optimistic expectations
at the beginning of the treatment, were also the ones discontinuing the treatment
[279]. The correlation between excessive positive expectations at the beginning of
the treatment and treatment abandonment, is, arguably, a strong indicator that
such positive expectations were abandoned throughout the course of the medical
program, suggesting that expectation do not remain stable over time, if violated.
Yet, since these patients were not present at the follow up (i.e. after 12 months),
during which expectations were measured, it is not possible to draw conclusions
on if and how their expectations updated in light of the newly acquired incoming
data. It is important to notice that the aforementioned evidence is of correlational
nature, thus caution is encouraged before drawing definite conclusions from these
data.
Although sparse, there is explanatory research showing that once triggered,
placebo and nocebo effects remain stable over time. For instance, a review of
several randomised clinical trials in neuropathic pain reported that when present,
placebo response lasted over a period of> 12 weeks [280]. In addition, the findings
from Study 1 and Study 3, showing that once triggered nocebo hyperalgesia can
be maintained for 35 minutes, are supported by the findings of Rodriguez-Raecke
et al., [281] which showed that nocebo negative effects can endure for much longer,
specifically up to 8 days. However, the lack of direct measures of expectations
prevents us from concluding that the stability of these effects is to be attributed
to expectations stability. An additional interesting study in this context is the
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one from Benedetti et al. [263], in which the effects of patients’ knowing that
morphine administration was interrupted were investigated. Those patients who
were not told that morphine was discontinued, maintained analgesic effects in
the following hours (after 2h =2.2; after 4h = 2.6; after 6h=3.4), while those
patients who were informed of drug discontinuation reported an increase in pain
ratings (after 2h =3.5; after 4h = 4.1; after 6h=4.5). Pain scores between the
two groups were significantly different after 2h and 4h, but not after 6h. At
first glance, these results could be interpreted as suggesting that once triggered,
placebo-related analgesia can be maintained over time (i.e. maintained for 4
hours). However, it is not possible to infer from these data whether the differences
in pain scores between the two groups are to be attributed to an increase in
pain ratings due to a nocebo-related response associated with the information
of drug discontinuation, or to the maintenance of expectations of analgesia over
time. Further investigation directly measuring patients’ expectations is required
to better understand the nature of the pain changes.
In conclusion, the findings of this PhD research indicating that both placebo
analgesia and nocebo hyperalgesia, once triggered, are maintained over time, find
partial support in the available literature. Specifically, observation of patients’
expectations in real life settings, indicates that positive and negative expectations
are likely to remain stable over time, supporting positive and negative clinical
outcomes, respectively [266; 267; 280]. However, if evidence that contradicts
these expectations is accumulated, expectations seem to update accordingly [266;
267; 279]. Yet, further studies are required to systematically investigate patients’
expectations fluctuations and update over time.
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5.1.2 Expectations do not expire over time: Clinical Con-
siderations
One’s ability to withholding positive expectations until it is their time to set in
can be particularly interesting for those clinical conditions in which the treat-
ment requires a longer time before setting into action. A good example are some
tricyclic antidepressants which often need a few weeks to set in [282]. Over the
course of these weeks, after the patient began the treatment and before they start
perceiving any clinical benefit, they may feel discouraged and demotivated, and
may doubt the effectiveness of the intervention. This often results in medication
discontinuation during the early weeks of the treatment [283; 284]. Results from
this PhD research demonstrate that if one is made aware of when to expect the
treatment effect, expectations can be withheld over time. Therefore, informing
patients of delayed onset of treatment action, such as weeks in the case of tri-
cyclic antidepressants, may be sufficient to support the maintenance of positive
expectations over time. This could prevent the development of “treatment fail-
ure” beliefs, so that when the treatment sets in, its effectiveness is supported by
positive expectations. Another example is that of patients suffering from muscu-
loskeletal pain. Here, the treatment is rarely straight-forward and often requires a
combination of pharmacological, physiotherapeutic and psychological approaches
[285; 286]. Although it is not possible to provide a precise time course for when
different approaches will start to deliver their clinical benefits, it is often the case
that it does take time, from weeks to several months [287; 288; 289]. In those
patients in which acute pain has become chronic, expectations may be particu-
larly fragile due to the likelihood of having attempted previous treatments which
failed to alleviate their pain [290]. In this context, informing patients that clinical
amelioration might require time is particularly important to prevent them from
abandoning their positive expectations.
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One’s ability to withholding negative expectations until it is their time to set
in can be a valuable tool during one’s recovery path. Let us consider muscu-
loskeletal conditions such as back pain in which, the coping strategies that the
patient uses during the initial phase after a back injury are crucial in determining
pain recovery or transition to chronic pain [291]. During this acute phase, those
patients that are more susceptible to anxiety and more likely to feel overwhelmed
by catastrophising thoughts, are also more likely to engage in pain avoidance be-
haviours, which are known to worsen pain and increase recovery time [270; 271].
Since psychological traits such as anxiety sensitivity [292], pain catastrophising
[293] and pessimism [294] have been associated with enhanced nocebo responsive-
ness, and since these are common traits in patients with poor coping strategies,
these patients are likely to be greatly influenced by negative expectations (i.e.
greater nocebo responsiveness). Therefore, if it is the case that negative expec-
tations find a fertile ground in those patients with poor coping strategies, these
are likely to have a significant negative impact on the physical and mental state
of the patient, feeding into the pre-existing anxiogenic and fear-characterised re-
sponse to pain, and finally increasing the likelihood of acute pain transitioning
to chronic pain [291]. Therefore, using temporal suggestions to delay the onset of
patients’ negative expectations could allow us to lighten this initial acute phase,
facilitating recovery. For example, if a patient is about to receive a treatment
which is known to sometimes have side effects it may be possible to delay the
onset of such negative effects until the patient has more resources to face them.
However, it is important to point out that the research covered by this PhD fo-
cused on a reduced time window, investigating a maximum delay of thirty-five
minutes. Hence, it is not possible to draw conclusions on whether expectations
can be withheld over a longer period of time, such as weeks or months. Future
research is required to directly test the maximum time that expectations can be
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maintained for (i.e. weeks or months) on a clinical sample.
5.1.3 A Predictive Coding Perspective
The three studies of this PhD relied on a similar experimental design with the
main difference being the type of experimentally-induced pain. This allows us
to raise some interesting, but preliminary, considerations from a predictive cod-
ing perspective. Contemporary perception theories posit that perception arises
from the integration between incoming sensory information and one’s expecta-
tions about the incoming input [295]. The influence of expectations over visual
[296] and auditory [297] perception was found to be greater for more ambiguous
incoming stimuli. Indeed, if the stimulus is unclear, expectations are needed to
fill in the gaps and make sense of our sensory experience. Despite this never being
directly demonstrated on pain, it is likely that the same rule applies [298].
In this Doctoral Thesis, the two pain models that were used varied in terms
of their duration and intensity. Since these two features determine the level of
ambiguity of an incoming noxious stimulus, these two pain models differed from
each other in respect to their level of ambiguity. Precisely, gathering information
takes time, and therefore, a short-lasting stimulus (i.e. short duration) allows less
time to collect cues and decode the signal compared to a longer lasting one (i.e.
long duration) , making the former more ambiguous than the latter [299; 300].
Concerning stimulus intensity, a highly painful (i.e. high intensity) stimulus trig-
gers our alarm system and is recognised as a threat straight away, thus making
it unlikely for this stimulus to be perceived as ambiguous. Differently, the milder
the painful stimulus, the more ambiguous this becomes, to the point that it might
be difficult to classify the sensation as either pain, itch or touch. Accordingly,
the pain model used in Study 1, consisting of short-lasting electrical pulses with
a medium-to-low intensity, can be classified as having high ambiguity, while the
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pain model used in Study 2 and 3, consisting of longer lasting and high intensity
stimuli, as having low ambiguity. Perception theories (see Section 1.2.2.3) pos-
tulate that one’s expectations are more influential when the incoming stimulus
is ambiguous rather than non-ambiguous. Therefore, one would predict expec-
tations to be more influential in the high-ambiguity study (i.e. Study 1 using
a short-lasting, medium-to-low intensity pain model), than in the low-ambiguity
studies (i.e. Study 2 and 3 using a longer-lasting, high intensity pain model). This
would result in greater placebo and nocebo effects in Study 1 than in Studies 2
and 3. Comparison of effect sizes did not confirm such prediction. The model
with lower ambiguity (i.e. Study 2 and 3), reported greater placebo analgesia
than the model with greater ambiguity (i.e. Study 1). Differently, for nocebo
hyperalgesia the magnitude of the effect was similar across the two pain models
and the two levels of stimulus ambiguity. Such discrepancy between placebo and
nocebo could indicate that the influence of expectations on perception may vary
depending on whether such expectations predict pain increase, thus triggering
alertness, or pain decrease, thus downregulating anxiety. The magnitude of these
effects is not in line with what would have been predicted according to percep-
tion theories. This could be due to confounding factors that were not controlled
for including participants’ control over pain, which has been previously shown to
dampen pain perception [301; 302]. In fact, in Study 1 the experimenter, and
not participants themselves, decided when and for how long to deliver the nox-
ious stimuli, while in Studies 2 and 3, participants were able to control how long
they kept their hand in the water, deciding exactly when the pain was going to
end by withdrawing their hand. In the former case, participants had no control
over the incoming pain, while in the latter they did. Most importantly, com-
parison between the effect sizes of the three studies may be difficult due to fact
that the experiments were not purposely designed to systematically investigate
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the influence of expectations on stimuli that varied in their level of ambiguity.
For instance populations were different; Study 1 was conduced in Italy, recruit-
ing mostly Italian participants, while Study 2 and 3 were conducted in Belgium,
mainly recruiting Belgian participants. In addition, Study 3 was conducted after
the first Belgian national lockdown due to COVID-19 pandemic, whereas Study
1 and 2 were conducted before the pandemic outbreak. In the light of these con-
siderations, it is important not to draw strong conclusions from the comparison
between these studies. Indeed, the objective of such comparisons was not to pro-
vide with solid answers on the influence of stimulus ambiguity on pain perception,
but to provide preliminary data that could trigger the curiosity of the scientific
community to address these unanswered questions in future, purposely designed
experiments.
5.2 Strengths and Limitations
Novelty is the primary strength of this research project. Here, the influence
of temporal suggestions on placebo analgesia and nocebo hyperalgesia onsets
was investigated for the first time, paving the way for future studies. A second
important strength is the generalisability of the results to both phasic and tonic
pain, which was achieved by testing the same research question (i.e. the influence
of temporal suggestion on placebo analgesia and nocebo hyperalgesia) using the
two different pain models. Thirdly, the initial results that relied on subjective
pain reports (i.e. Study 1), were confirmed by follow up studies (i.e. Study 2 and
3) using maximum pain tolerance as a behavioural objective measure, showing
that it is unlikely that these effects are due to participants’ wanting to comply
with the experimenter’s demands. Overall, the consistency of the findings across
three experiments with a similar but not identical design attests for the strength
and reproducibility of the effects.
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Yet, these studies are not without limitations. First, the lack of neurophys-
iological outcomes prevents us from associating our behavioural findings with
neurophysiological responses. As outlined in section 1.2.2.1, neuroimaging evi-
dence has reported activity changes in pain-sensitive brain regions during placebo
analgesia and nocebo hyperalgesia [303; 304; 305; 306]. Therefore, placebo and
nocebo effects that arose in the studies included in this Doctoral Thesis are likely
to also be mirrored in such neurophysiological correlates, yet this requires direct
testing in future research. During the anticipation phase of placebo analgesia
and nocebo hyperalgesia, neuroimaging evidence has shown activation of cortical
regions of the descending pain modulatory system (see Section 1.2.2.2). Differ-
ently from previous research, the studies presented here added temporal details
to one’s expectations. Since there is compelling evidence for the involvement of
specific brain regions in formulating representations of time, the main candidate
being the basal ganglia [307; 308], there may be some differences in the brain
regions that are activated during the anticipatory phase of placebo and nocebo
effects when expectations have a specific time tag (as in the case of the stud-
ies presented in this Thesis) and when this is not the case, as done in previous
research [303; 304; 305; 306; 309]. Further research is required to explore the
neurophysiological correlates that underpin the temporal component of placebo
and nocebo effects.
A second limitation to consider is the lack of trial-by-trial expectations record-
ing. Expectations were only measured retrospectively to avoid making the par-
ticipants suspicious about the true purpose of the study. As shown by Jepma et
al., [310] the relationship between expectations and perception is bidirectional,
whereby one’s expectations influence the painful experience, and in turn, the
pain experience feeds back, updating expectations. Unfortunately, the lack of
trial-by-trial expectations recording prevents us from drawing any sort of con-
168
5.3 Future Directions
clusion regarding the interplay between expectations updating mechanisms and
placebo and nocebo effects, and their modulation over time.
5.3 Future Directions
The findings of this Doctoral Thesis are the starting point of an exciting stream
of research that could have great implications, both clinical and non-clinical.
For instance, a first line of investigation is to explore whether these findings
persist with patients suffering from acute and chronic pain. This line of research
is particularly pressing considering the numerous clinical implications that could
arise from modulating patients’ temporal expectations (See previous sections 5.1.2
5.1.1 for further discussion).
A second line of research must investigate the neurophysiological correlates
of placebo analgesia and nocebo hyperalgesia when shifted in time by temporal
expectations. On one hand, this would suggest once more that the shifts in time
of placebo and nocebo responses are not to be attributed to participants wanting
to comply with the experimenter, but to a physiological response to time-specific
expectancy. On the other hand, as mentioned in the previous section, this line
of investigation could provide valuable insight into the neurophysiological corre-
lates of time-specific expectancy. Altogether, supporting the behavioural results
presented in this Thesis with neuroimaging evidence, would give the appropri-
ate scientific credibility to the temporal phenomenon, so this knowledge can be
implemented in the clinical context to maximise clinical positive outcomes.
A third line of investigation is needed to extend these findings to active drugs.
It has been previously demonstrated that positive and negative expectations in-
fluence the analgesic effectiveness of remifentanil, boosting its effect in the first
case, and abolishing it in the second case [259]. Accordingly, a solid amount of
research using the open-hidden design (see Section 1.1) has demonstrated that
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treatment effect greatly depends on whether the patient is aware (i.e. open)
or not (i.e. hidden) of being administered the intervention, whereby the effec-
tiveness is significantly stronger in the first case, compared to the second one
[260; 263; 311]. Therefore, considering the impact of expectations upon active
treatment effectiveness, temporal expectations are likely to modulate the onset
of action for active treatments as they do with placebo and nocebo interventions.
Demonstrating that the offset of treatments can be shifted in time by temporal
suggestions would unlock multiple research paths investigating how to maximise
treatment outcomes, while minimising its negative side effects, therefore having
a strong clinical impact.
A fourth line of research is required to extend these findings to domains be-
yond pain, where expectations are known to be influential. Placebo responses
have been reported in patients suffering from Parkinson’s disorder [312; 313], de-
pression [314; 315], anxiety [316] and high-altitude headache [317]. In addition,
placebo responses are also present outside of the clinical context, for instance in
physical performance [318] and breath holding [319]. Exploring the influence of
temporal expectations in those domains known to be susceptible to expectancy
modulation, could give us insights into how to deliver time-specific expectations
to maximize intervention effectiveness in the clinical context and to boost perfor-
mance outside the clinical context.
5.4 Conclusions
The experiments within this Doctoral Thesis have shown that by delivering dif-
ferent timing information about the onset of action for a given (inert-)treatment,
it is possible to modulate the onset of its effect. This was the case both when
administering a placebo (i.e. inert treatment along with suggestions of pain de-
crease) and a nocebo (i.e. inert treatment along with suggestions of pain increase)
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treatment. Specifically, it has been shown that, once triggered, the effect lasts at
least for the period covered by the experiment (i.e. up to 35 minutes), suggesting
that, once induced, expectations persist over time. In addition, demonstrating
that the effect can be delayed indicates that expectations can be withheld over
time until it is their anticipated time-point of action.
Purposely modulating temporal expectations could have large implications in
the clinical setting. Yet, further research is needed to extend these beyond placebo
and nocebo interventions to patients and active treatments. Furthermore, these
behavioral findings need to be corroborated with objective neurophysiological pa-
rameters. Deepening our knowledge in this unexplored area could lead to impor-
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Carragee, P. M. Peloso, G. van der Velde, L. W. Holm, S. Hogg-Johnson
et al., “A new conceptual model of neck pain: linking onset, course, and
care: the bone and joint decade 2000–2010 task force on neck pain and its
associated disorders,” Journal of manipulative and physiological therapeutics,
vol. 32, no. 2, pp. S17–S28, 2009. 163
[289] M. Von Korff and K. Saunders, “The course of back pain in primary care,”
Spine, vol. 21, no. 24, pp. 2833–2837, 1996. 163
[290] M. E. Goossens, J. W. Vlaeyen, A. Hidding, A. Kole-Snijders, and S. M.
Evers, “Treatment expectancy affects the outcome of cognitive-behavioral
177
REFERENCES
interventions in chronic pain,” The Clinical journal of pain, vol. 21, no. 1,
pp. 18–26, 2005. 163
[291] E. L. Zale and J. W. Ditre, “Pain-related fear, disability, and the fear-
avoidance model of chronic pain,” Current opinion in psychology, vol. 5, pp.
24–30, 2015. 164
[292] N. Corsi and L. Colloca, “Placebo and nocebo effects: the advantage of
measuring expectations and psychological factors,” Frontiers in Psychology,
vol. 8, p. 308, 2017. 164
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6.1 Collateral Project 1
Title:
Effectiveness of a dance-physiotherapy combined intervention in
Parkinson’s disease: a randomized controlled pilot trial.
Published as:
Frisaldi, E., Bottino, P., Fabbri, M., Trucco, M., De Ceglia, A., Esposito, N.,
Barbiani, D., Camerone, E.M., Costa, F., Destefanis, C., Milano, E.,
Massazza, G., Zibetti, M., Lopiano, L. & Benedetti, F. (2021). Effectiveness of
a dance-physiotherapy combined intervention in Parkinson’s disease: a
randomized controlled pilot trial. Neurological Sciences, 1-9.
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Abstract:
Background: Physical therapies have been recommended as crucial compo-
nents in Parkinson’s disease (PD) rehabilitation.
Objective: The study aims to examine the effectiveness of a new dance -
physiotherapy combined intervention, called DArT method, in mild PD patients.
Methods: A prospective, randomized, single-blind, controlled pilot trial was
conducted on 38 mild PD patients under dopaminergic therapy. The intervention
consisted in an add-on protocol: the control group received 1 h of conventional
physiotherapy followed by 1 h of conventional physiotherapy each day, 3 times
a week, for 5 weeks. The experimental group received 1 h of conventional phys-
iotherapy followed by 1 h of dance class each day, 3 times a week, for 5 weeks.
The week before and after the training period, patients were assessed for motor,
cognitive, emotional, and sensory components of PD, with MDS-UPDRS-III as
primary outcome measure
Results: DArT method was associated with a 2.72-point reduction in the post-
treatment MDS-UPDRS-III total score compared to control group (95% CI 5.28,
0.16, p = 0.038, d = 0.71), and with a 2.16-point reduction in the post-treatment
MDS-UPDRSIII upper body subscore (95% CI 3.56, 0.76, p = 0.003, d = 1.02).
Conversely, conventional physiotherapy program was associated with a 2.95-point
reduction in the post-treatment trait anxiety compared to the experimental group
(95%CI 0.19, 5.71, p = 0.037, d = 0.70). Withdrawal and fall rates were equal
to 0% in both groups.
Conclusion: DArT method showed to be safe, well accepted, and more effec-
tive than an intensive program of conventional physiotherapy in improving motor
impairment in mild PD.
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6.2 Collateral Project 2
Title:
The impact of treatment expectations on clinical, physiological and
fatigue responses: a preliminary investigation in myasthenia gravis.
Submitted as:
Frisaldi, E., Ferrero, B., Di Liberto, A., Barbiani, D., Camerone, E.M.,
Piedimonte, A., Cavallo, R., Lopiano, L., Shaibani, A. & Benedetti, F.
Abstract:
Background: Expectations influence health outcomes in various conditions
and represent a major determinant of the placebo and nocebo effects.
Objective: Investigate treatment expectations in myasthenia gravis (MG)
within routine medical practice.
Methods: In this preliminary phase of the EMPAThy-EU (Expectations and
Myasthenic PATients- Europe) project, 17 patients were neutrally assessed for
their treatment expectations - Stanford Expectations of Treatment Scale and
Credibility Expectancy Questionnaire - before starting azathioprine, and after 3
and 6 months, and then clinically monitored over one-year follow-up (experimen-
tal group). Quantitative Myasthenia Gravis (QMG) score and pyridostigmine
daily dose were the primary outcomes used to compare treatment response be-
tween this group and a retrospective standard medical care (SMC) group of 17
patients. Disease-specific parameters and fatigue were used to assess the role of
expectation in the experimental group.
Results:The experimental group showed significantly higher improvement in
QMG score at 6 months compared with the retrospective SMC group (95% CI,
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-4.52 -0.77, p = 0.007, d = 1.02). Correlations of strong effect sizes (from r s =
0.608 to r s = 0.764) were found between treatment expectations and: clinical
(QMG p = 0.002, pyridostigmine p = 0.005), physiological (forced vital capacity
p = 0.002, single-fiber electromyography p = 0.0004), fatigue (Chalder Fatigue
Scale p = 0.009) responses.
Conclusion: These findings, to be confirmed on a larger sample size, revealed
that treatment expectations in MG finely modulate treatment response and are
able to predict clinical, physiological and fatigue responses, with important im-
plications for medical practice and clinical trials.
6.3 Collateral Project 3
Title:
What is the relative contribution of biological and psychosocial
factors to the generation of hypoxia headache?
Published as:
Barbiani, D., Camerone, E.M., & Benedetti, F. (2018).
Abstract:
Background: The biopsychosocial model claims that illness is generated by
both biological and psychosocial factors. Accordingly, several studies have shown
that both factors contribute to the generation of pain.
Aims: The aim of the present study is to manipulate biological, psychological,
and social factors in hypobaric hypoxia headache in order to understand their
relative contribution to the generation of headache pain.
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Methods: Healthy subjects were subdivided into three groups and brought
to our high-altitude labs for the assessment of hypoxia-induced headache, blood
oxygen saturation (SO2), prostaglandins, and cortisol during the first 24 h after
arrival. The first group did not undergo any manipulation. The second group
(negative expectation) was told that severe headache would occur if SO2 dropped
to less than 80% and their oximeters were set to display a saturation of 75%, even
though real SO2 was much higher. The third group (negative expectation and
social interaction) underwent the same manipulation as the second group, but
these subjects spent the night together with people experiencing headache and
insomnia.
Results: Although none of the three groups differed significantly for SO2,
the second group, compared to the first, experienced more severe headache and
showed an increase in prostaglandins and cortisol. The third group, compared to
the second group, showed a further increase of headache as well as of prostaglandin
(PG) E2 and cortisol.
Conclusions: These findings indicate that biological, psychological, and so-
cial factors are additive not only in the generation of headache but also for the
biochemical changes related to hypoxia.
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